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Abstract
Skeletal muscle plays a crucial role in the insulin-mediated post-prandial disposal of 
blood glucose. Insulin resistance, that is a reduction in insulin’s ability to stimulate 
glucose uptake, is of major pathogenic importance in several prevalent human disorders, 
including type 2 diabetes, hypertension and obesity. Interestingly, there is good evidence 
to suggest that in insulin-resistant individuals exercise-stimulated glucose uptake is 
unaffected. In an effort to explore these two mechanisms, I have examined insulin- and 
5-aminoimidazole-4-carboxamide I-(3-D-ribonucleoside (AICAR)-stimulated glucose 
uptake in isolated skeletal muscle from the insulin-resistant stroke-prone spontaneously 
hypertensive rat (SHRSP) and the obese Zucker diabetic fatty rat (ZDF), a model of type 
2 diabetes.
The data presented here will show that while the stroke-prone spontaneously hypertensive 
rat (SHRSP) and Zucker diabetic fatty rat display reduced insulin-stimulated gmcose 
transport, their response to AICAR is unimpaired with respect to their insulin-sensiti/e 
controls, the Wistar Kyoto (WKY) and lean Zucker rats, respectively. Importantly, the 
observed insulin-resistance is also maintained in skeletal muscle cells cultured from 
SHRSP and ZDF rats, implying that the defect does not arise as a consequence of the 
tissue environment, but rather is a genetic characteristic of the muscle cells.
The expression and function of key molecules in the insulin-signalling cascade was also 
examined in these strains. Intriguingly, the total cellular expression levels of caveolin and 
flotillin, key proteins implicated in insulin signal transduction and compartmentalisation, 
are increased in the skeletal muscle from SHRSP compared to WKY but are unchanged 
between ZDF and lean Zucker rats. On the other hand the insulin-dependent activation of 
protein kinase B is markedly impaired in ZDF skeletal muscle with respect to lean Zucker 
rats, but is not different between SHRSP and WKY.
Taken together these results indicate that an inherent defect, at the level of skeletal 
muscle, is responsible for the observed insulin resistance. Moreover, this defect is 
confined to an insulin-specific step in the activation of glucose transport and is not a 
consequence of generalised resistance in the mechanism(s) of glucose transport. In 
addition, this underlying defect may be different between SHRSP and ZDF rats.
Finally, the molecular mechanism by which hyperglycaemia impairs insulin action was 
investigated in ZDF rats. Hyperglycaemia impairs insulin-stimulated glucose transport in 
lean Zucker muscle cells but does not lead to further impairment in the ZDF rat. The 
anti-diabetic drug, Rosiglitazone, was found to increase the basal glucose uptake by 
approximately two-fold but had no effect on insulin-stimulated glucose transport in lean 
or ZDF muscle cells cultured under normoglycaemic or hyperglycaemic conditions. 
These data are discussed within the context of present theories on the aetiology of insulin 
resistance.
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Chapter 1 
Introduction
1.1 Glucose homeostasis
Sugar metabolism describes the physical and chemical processes required for the 
transformation of carbohydrate into energy, vital for the various activities and survival of 
the cell (Banks et al., 1976). Metabolism of circulating dietary sugar is also essential for 
glucose homeostasis, i.e. the maintenance of blood glucose at normal levels (Banks et al., 
1976); (Shulman and Rothman, 2001). In the post-prandial state, utilisation of the 
circulating glucose by the peripheral tissues of skeletal muscle and fat has to overcome 
some key constraints. These can be summarised as the physiological limitations of 
getting glucose from the blood into the interstitial space surrounding the muscle, and the 
cellular control in moving glucose from the interstitium across the plasma membrane into 
the cell (Vock et al., 1996). Finally, once inside the cell the utilisation of glucose is 
important in maintaining cellular function.
Movement of glucose from blood to interstitium.
The capillai'y bed that vascularises skeletal muscle is not a barrier to the glucose molecule 
since evidence suggests that glucose can freely move through the junctions between the 
capillary endothelial cells (Perry, 1980); (Vock et al., 1996). However, the amount of 
glucose moving into the interstitium and subsequently into the muscle cell is dependent 
on blood glucose concentration, blood flow and the degree of vascularisation of the 
muscle (Vock et al., 1996).
Skeletal muscle vascularisation influences the amount of interstitial glucose and distance 
between substrate (glucose) and target (skeletal muscle cell). The red in pigment type-1 
muscle fibres are highly vascularised and have a higher oxidative capacity and more 
mitochondria (Wasserman and Halseth, 1998). In contrast, the white in pigment type-2b 
muscle fibres are poorly vascularised, have a low oxidative capacity with very few 
mitochondria and rely primarily upon the glycolytic pathway for energy production 
(Wasserman and Halseth, 1998). The above characteristics of type-1 muscle fibres give 
them the ability to work at a sustained level of output for longer periods, and therefore are 
refeired to as slow-twitch fibres. Type-2b, are more suited to short powerful bursts of 
output and are referred to as fast-twitch fibres (Wasserman and Halseth, 1998). Studies 
have correlated insulin action with a greater increase in glucose uptake in the highly 
vascularised type-1 fibres in contrast to a negligible increase in the poorly vascularised
type-2b fibres (ODoherty et a l, 1998). Together with the extent of vascularisation, 
perfusion of the vasculature also determines extracellular glucose availability 
(Wasserman and Halseth, 1998). Both muscle contraction and exercise increase perfusion 
of skeletal muscle by as much as twenty-fold (Wasserman and Halseth, 1998). In 
addition, insulin through a haemodynamic effect is believed to increase skeletal muscle 
perfusion, thereby leading to an increase in extracellular substrate availability (Baron, 
1994).
In summary, vascularisation and perfusion of skeletal muscle are important factors which 
influence the availability of extracellular glucose to the muscle cell and may in part 
explain the decreased rates of glucose disposal seen in poorly vascularised type-2b 
muscle in contrast to highly vascularised type-1 muscle.
Movement of glucose from interstitium across sarcolemma into the muscle cell.
The sarcolemma of the muscle cell/fibre is an effective bam er to the polar glucose 
molecule (Rea and James, 1997). As a consequence, glucose transfer across the 
sarcolemma requires a facilitative transport system (Gould and Seatter, 1997). Insulin 
maintains glucose homeostasis not only by facilitating the uptake of glucose molecules by 
the cells, but also by stimulating the conversion and storage of glucose in the form of 
glycogen (Yeaman et a l, 2001). In the next few pages the signalling pathways by which 
insulin facilitates glucose transport and glycogen synthesis will be discussed.
1.2 Insulin-stimulated glucose transport
1.2.1 Insulin and the insulin receptor
Insulin is a polypeptide hormone that is synthesised and processed into the active form by 
the pancreatic p cells in the Islets of Langerhans. It was insulin’s ability to reduce high 
levels of blood glucose in diabetics that attracted scientific interest after its discovery in 
1922. This lead to the belief that lack of insulin was the primary defect in all patients 
with diabetes. Work by Himsworth in 1936 proved that lack of insulin was not the only 
form of the disease, indeed the more common form still prevailed in spite of insulin 
administration (Himsworth, 1936). He pointed to two forms of diabetes, the first he 
termed ‘insulin sensitive’ due to the ability of insulin to ameliorate the disease and the 
second ‘insulin insensitive’ or insulin resistant where insulin treatment was ineffective 
(Himsworth, 1936). Research since has been occupied with the challenging task of 
understanding the molecular events which insulin elicits in cells.
The unique ability of insulin to regulate glucose metabolism is brought about by its 
binding to the insulin receptor (Kasuga et al., 1982b). The insulin receptor belongs to the 
tyrosine kinase family of receptors and is widely expressed in many tissues including 
brain, liver, pancreas, cardiac muscle, skeletal muscle and fat (Siddle et al., 2001). 
Tyrosine kinase receptors are capable of phosphorylating intracellulai' substrates on 
tyrosine residues thus communicating an external signal into the cell (Siddle et al., 2001).
The insulin receptor (Figure 1.1) consists of two extracellular a-subunits and two 
membrane-spanning g-subunits that aie held together by extracellular disulphide bonds to 
give a p - a - a - p  subunit structure (Van Obberghen et al., 1981); (Kasuga et al., 1982a). 
Thus the insulin receptor is referred to as a heterotetrameric receptor. The a-subunits 
contain the ligand binding domains made up of two P helices and a cysteine rich region 
(Siddle et al., 2001). The p-subunits contain an extracellular domain, which also 
possesses ligand contact sites, a transmembrane domain and an intracellular domain 
(Siddle et al., 2001). This intracellular domain can be further subdivided into 3 
functionally distinct regions: the juxta-membrane domain, the tyrosine kinase domain and 
the carboxyl terminal (C-terminal) domain (Siddle et al., 2001). The juxta-membrane
domain contains an internalisation NPXY motif that can be phosphorylated on the 
tyrosine residue and participates in insulin receptor substrate binding (White et ah, 
1988a). Site-directed mutagenesis of this tyrosine prevents receptor interaction with and 
phosphorylation of receptor substrates (White et al., 1988a). The tyrosine kinase domain 
contains binding sites for ATP and receptor substrates (Cheatham and Kahn, 1995). 
However, under basal conditions these sites are not available for ATP or receptor 
substrate binding (Hubbard et al., 1994). Insulin binding stimulates each p-subunit to 
phosphorylate the other on several residues. The subsequent autophosphorylation of three 
tyrosines in the tyrosine kinase domain is associated with the active form of the receptor 
(Kasuga et al., 1982c); (White et al., 1988b). This tris-autophosphorylation of the insulin 
receptor kinase domain reveals ATP and insulin receptor substrate binding sites (Hubbard 
et al., 1994); (Hubbard, 1997). Site-directed mutagenesis of the ATP-binding site within 
the kinase domain of human insulin receptors, abolishes subsequent tyrosine kinase 
activity toward insulin receptor substrates (Ebina et al., 1987); (Chou et al., 1987). In 
summary, the consequences of this tyrosine phosphorylation are twofold; it reveals 
recognition sites for and signals increased kinase activity toward cellular substrates.
As the insulin receptor is the first point of transmission and amplification of the insulin 
signal, any alteration in insulin binding, receptor expression, location, phosphorylation or 
kinase activity will drastically affect propagation of the insulin signal into the cell (Taira 
et al., 1989); (Williams et al., 1990); (Krook and ORahilly, 1996). Such alterations in the 
insulin receptor lead to severe insulin resistance as seen in Rabson-Mendenhall syndrome, 
in which a genetic deficiency of insulin receptors expression is observed (Rabson and 
Mendenhall, 1956); (Moncada et al., 1986). Such syndromes are rare in the general 
population and do not account for the majority of the insulin resistance seen, thus events 
downstream of the insulin receptor are suspected.
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Figure 1.1 Structure and activation of the insulin receptor.
The insulin receptor is a hete rote tramer composed o f  two identical a-subunits 
and two p-subunits. The a-subunits are disulphide linked to each other and to 
the p-subunits. The insulin receptor is activated by intramolecular trans- 
phosphorylation o f  the p-subunits upon binding o f  monomeric insulin ligand. 
Three tyrosine residues in the kinase domain become phosphorylated (indicated 
by circled letter P) and are associated with activated insulin receptor tyrosine 
kinase activity toward intracellular substrates.
1.2.2 Insulin receptor substrates and downstream events that lead to glucose 
transport.
The kinase domain of the insulin receptor was first shown to specifically phosphorylate a 
185 KDa protein named IRS-1 (White et ak, 1985); (Rothenberg et ah, 1991); (Sun et al., 
1992). Three other genetically and structurally homologous proteins, which are 
phosphorylated by the insulin receptor, have since been characterised: the 190 KDa IRS-2 
(Sun et al., 1995), the 60 KDa IRS-3 (Lavan et al., 1997b) and the 160 KDa IRS-4 (Lavan 
et al., 1997a). Mutations in the insulin receptor juxtamembrane domain that disrupt 
insulin receptor-IRS-I binding result in decreased insulin signalling (White et al., 1988a), 
whereas over expression of functional 1RS-1 with these mutant insulin receptors restores 
the insulin response (Chen et al., 1995). Genetic ablation of either IRS-1 or IRS-2 in 
mice has deleterious effects on glucose transport (Araki et al., 1994); (Tamemoto et al,,
1994); (Withers et al., 1998). Specifically, IRS-2 gene knock-out (KO) results in a 
diabetic phenotype whereas IRS-1 gene KO mice are insulin resistant (Araki et al., 1994); 
(Tamemoto et al., 1994); (Withers et al., 1998). The less severe insulin resistant 
phenotype seen in IRS-1 gene KO animals is attributed to the presence of other 1RS 
isoforms (IRS-2 and -3), which are able to compensate for the lack of IRS-1 (Araki et al.,
1994); (Tamemoto et al., 1994).
Each 1RS isoform possesses an amino terminal (N-terminal) pleckstrin homology (PH) 
domain, capable of localising the protein toward charged phosphoinositide lipids in 
cellular membranes (White, 1998). Adjacent to the PH domain lies a phospho-tyrosine- 
binding domain (PTB domain), which binds the NPXpY motif present in the juxta- 
membrane domain of the insulin receptor p-subunit (White, 1998). The PH and PTB 
domains specifically target the substrates toward the insulin receptor where the activated 
insulin receptor tyrosine kinase domain phosphorylates multiple tyrosine residues C- 
terminal of the PH and PTB domains (Figure 1.2). Specifically, IRS-1 is phosphorylated 
on multiple tyrosine residues, which lie in YMxM or YxxM motifs (White, 1998). These 
tyrosine residues act as ‘multiple docking sites’ for proteins that contain PTB domains or 
Src homology-2 (SH-2) domains (White, 1997). SH-2 domains display great homology
to the 60KDa viral sarcoma oncogene protein, ppbo'^ that was first shown to have 
activity toward tyrosine residues.
In summary, the insulin receptor transduces its signal by recruitment and phosphorylation 
o f IRS-1, -2, -3 and -4 (White, 1998). This permits multiple downstream events 
dependent on the recognition of pY motifs by SH2 or PTB containing effector proteins 
and on the repertoire of effector proteins present in the cell (White, 1998). The use of 
‘multiple docking proteins’ like IRS’s allows the insulin receptor to escape the 
stoichiometric constraints faced in ligand-receptor activation (one insulin molecule 
activating one insulin receptor) therefore amplifying the receptor signal (White, 1998).
Insulin
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Figure 1.2 Protein-protein interaction domains involved in insulin signal 
transduction .
The amino-terminal PH domain is involved in the targeting o f a typical 1RS 
protein to the plasma membrane. The PTB domain is critical for the recognition 
of the juxta-membrane NPXpY sequence o f the insulin receptor. Therefore both 
the PH and PTB domain contribute to the interaction o f 1RS with the insulin 
receptor. During interaction with the activated insulin receptor, the 1RS proteins 
are phosphorylated on several tyrosine residues by the insulin receptor kinase 
domain. Reproduced from Virkamaki, Ueki and Kahn, 1999
Under insulin-stimulated conditions lRS-1 is found to co-immunoprecipitate with a 
heterodimeric protein consisting of an 85 KDa (p85) and a 110 KDa (pi 10) subunit 
(Shepherd et al., 1998). The p85 subunit acts as an adapter protein and interacts with 
phosphorylated tyrosine residues of 1RS-1 via two SH2 domains (Rordorf-Nikolic et al..
1995), and recruits the p llO  subunit via a SH3 domain (Shepherd et al., 1998). The pllO  
subunit phosphorylates the D3 position of the inositol ring in phosphatidyl inositol-4,5- 
bisphosphate (PIP2) lipids, thereby leading to an accumulation of phosphatidyl inositol- 
3,4,5-trisphosphate (PIP3) lipids (Whitman et al., 1988); (Shepherd et al., 1998). Due to 
this specific activity it was named Phospho Inositide 3-Kinase (PI3K) (Figure 1.3). PI3K 
belongs to a large family of kinases categorised in four classes according to their function, 
structure and substrate specificity (Vanhaesebroeck et al., 1997). These enzymes are sub­
classified in respect to the adapter and catalytic subunit isoforms they possess (Shepherd 
et al., 1998). Currently, the only PI3K form known to be implicated in insulin-stimulated 
glucose uptake is the Class I heterodimeric p 8 5 a / pllO P PI3K (Wang et al., 1998; Wang 
et al., 1999).
Studies using a mutant adapter subunit (Ap85) in Chinese Hamster Ovary (CHO) and 
adipocyte cells showed that insulin-stimulated PI3K activity and glucose transport were 
impaired without affecting insulin receptor tyrosine kinase activity and IRS-1 
phosphorylation (Hara et al., 1994); (Sharma et al., 1998). The PI3K inhibitor, 
wortmannin, inhibits insulin stimulation of glucose transport in skeletal muscle and fat 
cells (Cheatham et al., 1994); (Clarke et al., 1994); (Okada et al., 1994); (Kaliman et al.,
1995); (Tsakiridis et al., 1995). Interestingly, the yeast PI3K homologue, vps34, is also 
involved in membrane trafficking events (Schu et al., 1993). In agreement, data regarding 
PI3K inhibition in mammalian systems found that treatment of cells with wortmannin 
prevented the sorting of proteins out of endosomes into a recycling or exocytic pathway 
and lead to their accumulation in large vacuolar-like bodies (Reaves et al., 1996). This 
suggested that PI3K activity facilitates vesicle budding from internal compartments and 
or vesicle fusion with target membranes, with possible implications for the insulin- 
sensitive glucose transporter, (Glut-4). Glut-4, as discussed in detail in the following 
sections (1.2.3 - 1.2.4.1), under basal conditions is sequestered intracellularly in a 
vesicular compartment and moves to the plasma membrane in response to insulin 
stimulation (Rea and James, 1997). In adipocytes, insulin-stimulation results in the 
specific targeting of 1RS-I along with recruited PI3K, from a cytosolic location to an 
intracellular protein matrix believed to be a cytoskeletal structure, which is distinct from 
but co-sediments with microsomal membranes (Yang et al., 1996); (Clark et al., 1998). 
Recent observations in myocytes, demonstrate that insulin stimulates a rapid re-
organisation of the actin cytoskeleton near the plasma membrane (Khayat et al., 2000). 
These actin cytoskeletal structures rapidly concentrate PI3K and subsequently recruit 
Glut-4 (Khayat et al., 2000).
In summary, these data suggest that PI3K activation is a point of convergence of insulin 
signalling and Glut-4 trafficking pathways, thus implying a necessity for PI3K activity in 
insulin-stimulated glucose transport (Shepherd et al., 1998). Therefore, the possibility 
exists that mutations in the PI3K gene could contribute to insulin resistance. Indeed, the 
mutation M3261, on the p85a coding sequence has been associated with glucose 
intolerance in humans (Hansen et al., 1997).
Recent investigations of downstream targets suggests that the product of PI3K activity, 
PI-3 ,4 ,5-P3 (PIP3) is necessary for glucose uptake (Jiang et al., 1998). This is borne out 
by overexpression experiments utilising PTEN (phosphatase and tensin homologue 
deleted on chromosome 10), which results in decreased PIP3 levels in conjunction with an 
inhibition of insulin-stimulated glucose transport (Nakashima et al., 2000); (Ono et al., 
2001). It has been proposed that localised production of phosphoinositides could promote 
budding and subsequent fusion of Glut4-containing vesicles with the plasma membrane 
(Heller-Harrison et al., 1996) (Glut4-containing vesicles are described in detail in
1.2.4.1).
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Figure 1.3 Schematic illustration of insulin signal transduction via IRS-1 
and FI3K. .
The insulin receptor uses the 1RS proteins to activate PI3K. The activated 
insulin receptor transiently binds and phosphorylates IRS-1 proteins. 
Phosphorylated tyrosine residues of IRS-1 interact with the p85a regulatory 
subunit o f PI3K via two SH2 domains, which results in the activation of PI3K 
and increased glucose transport. The activated PI3K catalyses the 
phosphorylation of phosphoinositides on the 3-position to produce 
phosphatidylinositol-3-phosphate, especially PI(3 ,4 ,5)P3. The fungal metabolite, 
wortmannin, specifically inhibits PI3K activity and insulin-stimulated glucose 
transport.
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1.2.3 The glucose transporter family.
The family of glucose transporters (Gluts) consists of 12 members (Gluts 1-12) (Table
1.1). The Gluts consist of 12 transmembrane spanning a-helices, which are arranged to 
form a central pore through which the bi-directional transport of monosaccharides can 
take place (Barrett et al., 1999). Studies indicate that regions of the transporters exposed 
to the extracellular or intracellular space have binding sites for monosaccharides (Barrett 
et al., 1999). Monosaccharide binding induces conformational changes in the transporter 
that results in the movement of the sugar molecule through the central pore and 
subsequent release on the other side of the membrane (Barrett et al., 1999). All the 
glucose transporters are post-translationally glycosylated on an asparagine residue of the 
exofacial loop between helices 1 and 2. The glucose transporters have a varied tissue 
distribution with Glut-1 being expressed in nearly all tissues. Skeletal muscle variably 
expresses Gluts-1, -3, -4, -5  and -11, all having marked differences in monosaccharide 
specificity (Table 1.1).
1 2
Protein alias Tissue distribution in humans Hexose specificity
Glut 1 Erythrocytes, blood-tissue bamers, 
brain, low expression in all other 
tissues
Glucose
Glut 2 Liver, pancreatic p-cells, intestinal 
epithelia, kidney tubules
Low affinity but high 
capacity for glucose 
transport
Glut 3 Brain and neuronal tissues, placenta, 
liver, heart and skeletal muscle
High affinity for 
glucose
Glut 4 Fat cells, skeletal muscle, cardiac 
muscle, low expression in brain
High affinity for 
glucose
G lu ts Small intestine epithelia, kidney, 
testis, spermatozoa, skeletal muscle
Fructose
Glut 6 Glut 9 Spleen, leukocytes, brain Glucose
G lut? Uncharacterised Unknown at present
G lu ts GlutXl Testis, blastocyst, brain High affinity for 
glucose, can be 
specifically inhibited 
with fructose
Glut 9 GlutX Liver, kidney Unknown at present
Glut 10 Liver, pancreas Unknown at present
Glut 11 GlutlO Cardiac and skeletal muscle Low affinity for 
glucose, can be 
specifically inhibited 
with fructose (possible 
fructose transporter)
Glut 12 Gluts Cardiac muscle and prostate Unknown at present
Table 1.1 The facllitative glucose transporter isoforms. Adapted from (Joost and 
Thorens, 2001).
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1.2.4 The muscle specific Gluts
Glut-1
Originally discovered as the abundant glucose transporter in erythrocyte membranes, this 
ubiquitous glucose transporter resides predominantly at the plasma membrane of most 
cells where it is responsible for the basal transport of glucose into the cell (Kasahara and 
Hinkle, 1977); (Baldwin et ah, 1979); (Gorga et al., 1979). Glut-1 is highly expressed in 
brain, endothelial cells and erythrocytes, and is expressed (in vitro) in neo-natal and 
developing myoblasts but this expression is diminished in mature muscle and myotubes 
(in vitro) (Guillet-Deniau et al., 1994).
Glut-3
Glut-3 is expressed in nerves, pancreatic p-cells and embryonic tissues where it has a high 
affinity for glucose transport (Kayano et al., 1988); (Colville et al., 1993). Glut-3 is 
highly expressed during development of embryonic myoblasts and is restricted to 
intracellular compartments. However, during the early stages of myoblast alignment and 
fusion, Glut-3 is exclusively found at the plasma membrane. By three to four days post 
differentiation no Glut-3 (in vitro) is expressed in the mature myotube (Guillet-Deniau et 
al., 1994).
Glut-5
Glut-5 has a wide tissue distribution and can be found in the small intestine, skeletal 
muscle, adipose tissue, kidney, brain and spermatozoa (Kayano et al., 1990); (Mantych et 
al., 1993). Detailed functional characterisation showed Glut-5 to be a fructose specific 
transporter (Rand et al., 1993). Isolation of membrane fractions and 
immunocytochemistry revealed that Glut-5 localisation in skeletal muscle is restricted to 
the sarcolemma and is completely absent from internal membranes (Hundal et al., 1992); 
(Darakhshan et al., 1997); (Kristiansen et al., 1997). Glut-5 provides skeletal muscle with 
the ability to utilise fructose as a possible substrate.
Glut-4
The unique characteristic of Glut-4 is its high responsiveness to insulin. This transporter 
is predominantly expressed in cardiac muscle, skeletal muscle and fat (Fukumoto et al., 
1989); (James et al., 1989); (Bimbaum, 1989). It is expressed late in the differentiation of
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myoblasts but is the dominant glucose transporter isoform in mature myotubes (Guillet- 
Deniau et al., 1994). Glut-4 is unique among other glucose transporters in that under 
basal conditions it is sequestered intracellularly and localises to perinuclear compartments 
and large tubulo-vesicular aggregates within the centre of the muscle and fat cell 
(Friedman et al., 1991); (Slot et al., 1991b). This distribution of Glut-4 is also seen in 
whole skeletal muscle fibres and cultured differentiated skeletal muscle cells (Ploug et al.,
1998), (Ralston and Ploug, 1996). In skeletal muscle fibres, contraction or insulin 
stimulation results in a redistribution of Glut-4 from these intracellular compartments to 
the sarcolemma and T-tubules and is concomitant with an increase in glucose uptake 
(Fushiki et ah, 1989); (Roy and Marette, 1996); (Zorzano et ah, 1996).
1.2.4.1 Subcellular localisation and translocation of Glut-4
Cushman and Suzuki were the first to show that insulin stimulated the recruitment of 
glucose transporters from an intracellular storage site to the cell surface (Cushman and 
Wardzala, 1980); (Suzuki and Kono, 1980); (Holman and Cushman, 1994). It has been 
the purpose of much research to define this intracellular storage site and thus discover 
how Glut-4 trafficking is regulated in response to insulin or contraction (Czech and 
Corvera, 1999); (Holman and Sandoval, 2001); (Ryder et ah, 2001). Such information 
could aid in the rational design of drugs able to mimic the insulin and contraction 
responsiveness of this Glut-4 compartment. However, recent analyses have found that 
Glut-4 colocalises with numerous compartments of the cellular recycling system. These 
compartments include clathrin coated vesicles, endosomes, the trans-Golgi network and 
vesicles collectively refeiTed to as Glut-4 storage vesicles (GSVs) that are enriched with 
Glut-4 and other insulin responsive proteins such as the insulin responsive amino 
peptidase (IRAP) and the vesicle associated membrane protein 2 (VAMP2) (Tanner and 
Lienhard, 1989); (Slot et ah, 1991a); (Slot et ah, 1991b); (Holman and Cushman, 1994); 
(Holman and Sandoval, 2001). Taken together these results indicate that Glut-4 utilises 
the endosomal-recycling pathway along with other integral membrane proteins (Figure 
1,4). An example of one such protein is the transferrin receptor (TfR) that binds iron- 
loaded transfenin on the exofacial side of the plasma membrane and is internalised via 
clathrin-coated vesicles (Ponka and Lok, 1999). After disassembly of the clathrin coat 
these vesicles fuse with the early endosomes, where under an acidic environment iron 
dissociates from the receptor bound transferrin, which rapidly recycles back to the plasma
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membrane (Ponka and Lok, 1999). In the absence of insulin the exocytic rate of Glut-4 is 
lower that TfR whereas in insulin-stimulated conditions the exocytic rate of Glut-4 is 
increased some 10-20 fold compared with TfR (Holman et al., 1994); (Yang and Holman, 
1993). This data implies that Glut-4 is actively withdrawn from the recycling system in a 
compartment highly sensitive to insulin (Holman and Sandoval, 2001). (Livingstone et 
al., 1996) and (Martin et al., 1996), exploiting TfR’s exclusive localisation to the 
endosomal recycling system and capacity to bind transferrin, chemically ablated the 
endosomal system using horseradish peroxidase (HRP)-conjugated transferrin, 3,3- 
diaminobenzidine and hydrogen peroxide. Under these conditions HRP-conjugated 
transferrin forms a highly reactive cross-linker. They demonstrated that 60% of the Glut- 
4 , which exists in a compartment devoid of transferrin receptors, was resistant to ablation 
(Livingstone et al., 1996). This data suggests that the unablatable Glut-4 is not part of the 
endosomal recycling system but is withdrawn into a specialised storage compartment 
referred to as the Glut-4 storage vesicles (GSVs) (Holman and Cushman, 1994); (Rea and 
James, 1997). Immunofluorescent confocal microscopy studies found that Glut-4 
containing structures colocalised with VAMP2, however no overlap was observed with 
the TfR (Malide et al., 1997), a result consistent with data from TfR-HRP ablation studies 
by (Livingstone et al., 1996) and (Martin et al., 1996). Recent experiments, using low- 
density membrane fractions from adipocytes, efficiently separated GSVs from endosomal 
fractions based on their differential densities in iodixanol gradient material (Hashiramoto 
and James, 2000). These findings indicated that insulin stimulation leads to a decrease in 
GSV Glut-4 content as opposed to endosomal Glut-4 content.
In summary, these findings suggest that the majority of the Glut4-containing vesicles are 
sequestered from the plasma membrane under basal conditions in a sub-compartment that 
is distinct from the endosomal system and the trans-Golgi network (TGN). 
Morphological analyses show that this sub-compartment consists of tubulo-vesicular 
aggregates and is enriched in other insulin-responsive proteins like IRAP and VAMP2. 
On insulin stimulation, Glut4-containing vesicles preferentially move from this 
compartment and fuse with the plasma membrane. This compartment has therefore been 
aptly named ‘Glut-4 storage vesicles’ (GSVs) (Rea and James, 1997); (Simpson et al., 
2001).
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Figure 1.4 Trafficking o f Glut-4
Under basal conditions Glut-4 is sequestered within the cell by  efficient
internalisation (1 ) from the plasma membrane and by  intracellular retention in the
Glut-4 storage compartment (GSVs) subsequent to sorting (S) out o f  the
endosomes. Insulin stimulates the exocytosis (E) o f  the endosom al recycling
conpartm ent and the unique Glut-4 storage conpartm ent. A dapted  from  Holman, 
2001 .
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The insulin-stimulated movement and fusion of the GSVs with the plasma membrane is 
analogous to the mechanism of neurotransmitter release at the nerve synapse (Sudhof,
1995). In that system a specialised pool of small synaptic vesicles (SSVs) stimulated by 
the resultant Ca^ "^  influx due to nerve cell depolarisation, rapidly fuse with the presynaptic 
membrane releasing neurotransmitter into the nerve synapse (Sudhof, 1995); (Rothman 
and Warren, 1994). This membrane is rapidly recycled and refilled with neurotransmitter 
ready for another round of activity. Work by Rothman and colleagues identified several 
molecules mediating the targeting, docking and fusion of SSVs with the plasma 
membrane (Rothman and Warren, 1994). From their observations it was evident that a N- 
ethylmaleimide Sensitive Fusion protein (NSF) and its interaction with Soluble NSF 
Attachment Proteins (SNAPs) was central to the ATP-requiring fusion event (Sollner et 
al., 1993). However, the specificity of membrane fusion events is mediated by the pairing 
of the transport vesicle located SNAP receptor (vSNARE) with the target membrane 
SNAP receptor (tSNARE) (Sollner et al., 1993) (figure 1.5). This paradigm of membrane 
fusion known as the SNARE hypothesis prompted the search for homologues of v- and t- 
SNAREs in other systems in which membrane fusion occurred. Homologues of these 
SNARE proteins have been found in both myocytes and adipocytes suggesting that 
membrane fusion events analogous to those seen in neurones occur in these cell types 
(Cain et al., 1992); (Volchuk et a l, 1994); (Volchuk et a l, 1996).
18
VAMP
SNAP 25
Syntaxin ,
0 - m
Figure 1.5 Model for SNARE complex formation.
Schematic showing the assembly o f  the neuronal SNARE complex during 
vesicle/plasma membrane fusioa (a) VAMP (blue) on the incoming vesicle 
interacts with syntaxin (red) and SNAP-25 (green) at the plasm a membrane to 
form a four-helical bundle that ‘zips’ together pulling the two membranes 
together thus allowing membrane fusion to occur, (b) The left hand panel shows 
the four-helix bundle SNARE complex, the local helical axes (gray), the 
hydrophobic interaction layers (black boxes) and the middle layer (red box) 
containing a glutamine from SNAP-25. Cross-sectional views o f  the indicated 
positions are given on the right. Reproduced from Chen & Scheller, 2001.
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In adipocytes and myocytes two vSNARES, vesicle associated membrane protein 
(VAMP2) and cellubrevin, were found to colocalise with Glut-4 vesicles (Cain et al., 
1992). Further analysis found that VAMP2 localised with the unablated GSV pool 
(Martin et al., 1996) while cellubrevin localised to the ablated endosomal pool (McMahon 
et al., 1993). In agreement with these findings synthetic VAMP2 peptides prevented 
insulin-stimulated Glut-4 exocytosis in permeabilised fat cells whereas cellubrevin 
peptides did not inhibit Glut-4 translocation (Martin et al., 1996). As suggested by the 
SNARE hypothesis, these observations highlighted the suspected level of specificity of 
membrane fusion events afforded by the differential expression and localisation of the 
SNAREs. In this case a clear demarcation between the insulin-sensitive movement of 
GSVs to the plasma membrane was afforded by the vesicular localisation of the vSNARE 
VAMP2 in contrast to the endosomal trafficking of Glut-4 specified by cellubrevin.
Subsequently, the cognate target membrane SNARE (tSNARE) syntaxin-4 was found in 
fat and muscle cells (Volchuk et al., 1996). Syntaxin-4 bound VAMP2 with high affinity 
and was found to be highly expressed in and predominantly localised to the plasma 
membrane of muscle and fat cells (Volchuk et al., 1996). Further evidence of this 
interaction was obtained using synthetic peptides developed from the cytoplasmic tail of 
syntaxin-4 and antibodies raised to syntaxin-4. In both circumstances insulin-stimulated 
Glut-4 translocation to the plasma membrane in adipocytes was inhibited (Volchuk et al.,
1996); (Tellam et al., 1997). This is convincing evidence that SNARE interaction is 
decisive in the regulation of Glut-4 vesicle fusion.
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1.3 Insulin-stimulated glucose storage (glycogen synthesis)
After glucose is transported into the cell, the next step in glucose metabolism in skeletal 
muscle and fat is its phosphorylation by hexokinase II to produce glucose-6-phosphate 
(G6P) (Salway, 1994). The benefits of this action are twofold; it maintains a low 
intracellular glucose concentration essential in driving further transport, and traps the 
substrate inside the cell where it is utilised further in metabolism via the glycolytic or 
glycogenesis pathways. The choice of which pathways are used is dependent on the 
cellular energy demands. However, under insulin-stimulated conditions the storage of 
glucose, as glycogen is favoured (Salway, 1994).
Glycogen synthesis involves the incorporation of uridine diphosphate (UDP)-glucose, 
into the growing glycogen chain by the rate-limiting enzyme glycogen synthase (GS) 
(Salway, 1994). Interestingly, glycogen synthesis is found to be impaired in non-insulin- 
dependent diabetes mellitus (Shulman et al., 1990); (Rothman et al., 1995). This may 
come as no surprise as the tetrameric 85KDa protein GS, is regulated by an insulin- 
stimulated pathway involving kinase/ phosphatase activities (Cohen, 1999); (Yeaman et 
a l, 2001). GS exists in an active (de-phosphorylated) and an inactive (phosphorylated) 
form. Inactivation of GS is catalysed by, among other enzymes, glycogen synthase 
kinase-3 (GSK-3) which phosphorylates key serine residues of the GS carboxyl terminal 
domain (Cohen, 1999). A consensus of opinion on the mechanism by which insulin 
brings about the de-phosphorylation and thus activation of GS during glycogen synthesis 
is described as follows (see also Figure 1.6). Recent studies have shown that wortmannin 
and LY294002 both block the insulin-stimulated activation of GS and PKB, and also 
prevents the inhibition of GSK3 (Burgering and Coffer, 1995); (Shepherd et a l, 1995), 
(Yamamoto-Honda et a l, 1995); (Cross et a l, 1995). This evidence indicates that 
insulin-mediated inhibition of GSK-3 occurs via PKB phosphorylation through a PI3K- 
dependent pathway. PKB, also known as Akt, belongs to the AGC (cAMP-dependent 
protein kinase/protein kinase G/protein kinase Ç) extended family of protein kinases and 
exists as three isoforms, named PKB a , P and y (Figure 1.7) (Hajduch et a l, 2001). PKB 
contains an N-terminal pleckstrin homology (PH) domain followed by a catalytic kinase 
domain, and a C-terminal tail (Cohen, 1999). The PI3K phosphorylated membrane lipid 
products, PIP2 and PIP3 are believed to promote the recruitment of PKB to the cell
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membrane through the interaction with the N-terminal PH domain (Freeh et ah, 1997). At 
the cell membrane a 63kDa monomeric kinase known as 3-phosphoinositide-dependent 
kinase-1 (PDKl) phosphorylates PKB (Alessi, 2001). PD K l is expressed ubiquitously in 
human tissues and consists of an N-terminal catalytic domain similar to that of PKA, PKB 
and PKC, and has a C-terminal PH domain (Alessi et ah, 1997a); (Stephens et ah, 1998). 
PDKl activates PKB by phosphorylation of a threonine residue specific to each of the 
three PKB isoforms (Alessi et ah, 1997b); (Walker et ah, 1998). It is in fact suggested 
that PIP3 not only recruits PKB to the membrane but also alters the conformation of PKB 
such that the relevant threonine residue becomes accessible to PDKl (Cohen, 1999) 
(Figure 1.8). As a consequence the activated PKB phosphorylates and inactivates GSK3, 
leading to the promotion of glycogenesis (Cohen, 1999). It should be noted that while 
this pathway explains much of insulin’s effects on glycogen synthesis, other growth 
factors and stimuli such as glucose and amino acids are also able to stimulate glycogen 
synthesis via alternative and as yet not fully characterised pathways (Yeaman et ah, 
2001).
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Figure 1.6 The regulation of glycogen synthesis by insulin
Insulin stim ulates glycogen accum ulation through a coordinated increase in 
glucose transport and glycogen synthesis. Insulin activates glycogen synthase 
(GS) by prom oting its dephosphorylation, through the inhibition o f  kinases such 
as GSK-3 and activation o f  the glycogen associated protein phosphatase-1 (P P l- 
G). Upon its activation dow nstream  o f  PI3K, PKB phosphorylates and 
inactivates GSK-3, decreasing the rate o f  phosphorylation o f  glycogen synthase, 
therefore increasing its activity state. Insulin also specifically activates discrete 
pools o f  phosphatase, primarily increasing protein phosphatase - 1 activity 
localised at the glycogen particle (PPl-G ). Taken together insulin decreases the 
rate o f  phosphorylation o f  GS, increasing its activity state, w hich results in the 
increased incorporation o f  UDP-glucose into the growing glycogen molecule.
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Figure 1.7 Structure of PKB isoforms
Schematic representation o f  the structure o f the three PKB isoforms with the 
am ino-terminal PH domain and kinase domain shown. The equivalent PDKl 
threonine phosphorylation site and putative PDK2 serine phosphorylation site 
are indicated.
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Figure 1.8 The mechanism of activation of PKB. .
The stimulation o f  cells with insulin activates PI3K and elevates the level o f  
PI(3,4,5)Pg at the plasma membrane. PIP3 and or its intermediate breakdown 
product PI(3 ,4 )P2 then interacts with the PH domain o f  PKB, which has two 
effects. First it alters the conformation o f  PKB in such a way that Thr308 and 
(perhaps) Ser473 become accessible for phosphorylation by PDKl and PDK2, 
respectively. Second, PKB is recruited from the cytosol to the plasma membrane 
where PD K l and PDK2 are located. The phosphorylation o f  PKB at Thr308 and 
Ser473 (indicated by the circled letters Ps) activates PKB. Reproduced from Cohen, 
1999
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1.4 Alternative cascade events in insulin-stimulated glucose 
transport
Additional molecules that are potentially implicated in insulin-mediated glucose transport 
are the atypical Protein Kinase Cs (PKCs), PKB, the lipid raft-associated c-Cbl and the c- 
Cbl-associated protein (CAP) (Czech and Corvera, 1999). More specifically, the p 
isoform of PKB has been reported to be recruited to Glut4-containing vesicles upon 
stimulation by insulin (Calera et al., 1998). A number of studies have shown that 
overexpression of constitutiveiy active PKCÇ, PKCÀ or membrane directed PKBcx/p 
stimulates Glut-4 translocation in a number of insulin-sensitive cell culture models and 
tissues (Standaert et al., 1997); (Bandyopadhyay et al., 2000); (Kohn et al., 1996a); (Ueki 
et al., 1998); (Hajduch et al., 1998). In addition, overexpression of dominant negative 
PKCÇ, PKCX or PKB lead to a partial inhibition of Glut-4 translocation (Bandyopadhyay 
et al., 1997); (Kotani et al., 1998). The activation of PKCÇ / X and PKB in response to 
insulin is wortmannin sensitive, suggesting a PI3K-dependent mechanism (Standaert et 
al., 1997); (Nakanishi et al., 1993). Although these data support the involvement of PI3K 
activity, PKCÇ / X and PKBP in insulin-stimulated Glut-4 transloeation, evidence is 
emerging which raise important questions as to whether these molecules aie sufficient or 
necessary for insulin-stimulated Glut-4 translocation and glucose transport (Baumann et 
al., 2000).
Recent studies have demonstrated that cell permeable PIP3 esters were unable to stimulate 
glucose transport in the absence of insulin (Jiang et al., 1998). In contrast PIP3 esters 
were able to overcome wortmannin inhibition of insulin-stimulated glucose transport 
(Jiang et al., 1998). In addition, p-integrin receptor clustering, platelet derived growth 
factor and interleukin-4 have been demonstrated to stimulate PI3K activity without 
increasing glucose transport (Guilherme and Czech, 1998); (Isakoff et al., 1995); (Wiese 
et al., 1995). These results suggest that at least one additional insulin-dependent but 
PI3K-independent pathway is necessary for insulin-stimulated glucose transport. Recent 
studies aimed at examining this wisely focused on a reassessment of other insulin receptor 
substrates that may be responsible for glucose transport (Ribon and Saltiel, 1997); 
(Baumann et al., 2000); (Watson et al., 2001); (Watson and Pessin, 2001). They found 
that insulin could tyrosine phosphorylate the proto-oncoprotein c-Cbl (Ribon and Saltiel,
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1997). The c-Cbl proto-oncogene was first identified in haematopoietic tumours of mice 
infected with Casitas Br-M retrovirus (Thien and Langdon, 2001). The isolated retrovirus 
was able to induce pre- and pro-B lymphomas through the expression of the truncated 
viral protein product of the v-Cbl oncogene (Thien and Langdon, 2001). Therefore the 
name c-Cbl stands for çellular-Çasitas B-lineage lymphoma. Cbl proteins are 
ubiquitously expressed and have been found to interact with a number of activated 
tyrosine kinases, targeting them for down regulation (Thien and Langdon, 2001). 
However, in insulin-responsive cells the c-Cbl protein was tyrosine phosphorylated by the 
insulin receptor through the interaction with the adapter protein with pleckstrin homology 
and src homology domains (APS) (Ahmed et al., 2000). Tyrosine phosphorylated c-Cbl 
is subsequently localised to plasma membrane lipid raft domains through the interaction 
with the SH3 domain of Cbl-associated protein (CAP) (Baumann et al., 2000). CAP 
specifically localises with caveolae through the interaction with the caveolae / lipid raft 
associated protein flotillin (Baumann et al., 2000). Moreover, this localisation is 
functionally important as a dominant interfering CAP mutant (CAPASH3), unable to 
interact with c-Cbl but able to bind flotillin, interfered with c-Cbl localisation to lipid raft 
domains and blocked insulin-stimulated Glut-4 transloeation and glucose transport 
without any effect on PI3K activity (Baumann et al., 2000). The search for downstream 
molecules in the CAP/c-Cbl pathway has found that tyrosine phosphorylated c-Cbl 
recruits a small adapter protein c-Crkll that in turn binds the guanyl nucleotide exchange 
factor C3G, known to activate a number of small guanosine triphosphate (GTP) binding 
proteins (Ribon et al., 1996); (Reedquist et al., 1996). Interestingly, the small GTP 
binding Ras homologue (Rho) family member, TCIO was activated by C3G in an insulin- 
dependent but PI3K-independent manner (Chiang et al., 2001). Once activated TCIO was 
found to co-localise with CAP and c-Cbl in caveolae (Chiang et al., 2001). Disruption of 
TCIO activation inhibited insulin-stimulated glucose transport and Glut-4 transloeation 
(Chiang et al., 2001).
The downstream effectors of TCIO are still unknown but their discovery may hold further 
clues to the mechanism by which insulin stimulates Glut-4 transloeation (Figure 1.9). 
Intriguingly, the insulin receptor is also found localised to caveolae / lipid raft domains, 
suggesting that these domains may indicate a mechanism of compartmentalisation of the 
insulin signal (Gustavsson et al., 1999); (Nystrom et al., 1999). Lipid rafts are small
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membranous microdomains that are preferentially enriched in cholesterol and 
sphingolipids (Smart et ah, 1999); (Galbiati et ah, 2001). This preferential lipid 
enrichment makes for a less fluid membrane that is resistant to non-ionic detergents as 
opposed to the bulk of the plasma membrane (Galbiati et ah, 2001). These properties have 
aided in the isolation and characterisation of these lipid microdomains. Intriguingly, 
certain molecules such as glycosylphosphatidylinositiol-anchored and acylated proteins 
dynamically associate with rafts (Galbiati et ah, 2001). As a consequence these lipid rafts 
concentrate molecules and act as platforms for conducting a variety of cellular functions 
such as signal transduction and membrane trafficking (Smart et ah, 1999). Interestingly, a 
structural protein known as caveolin-1 directly binds cholesterol, a key component of 
lipid rafts, and promotes the invagination of the lipid raft to form caveolae (Smart et ah, 
1999); (Galbiati et ah, 2001).
In summary, these data demonstrate that Glut-4 transloeation and glucose transport, in 
adipocytes, require the inputs of both the insulin receptor■=>PI3K and insulin 
receptor/APS/c-Cbl/CAP"=>TC 10 signalling pathways (Chiang et ah, 2001). These 
pathways must at some point converge on the trafficking and membrane fusion machinery 
involved in Glut-4 vesicle transloeation and plasma membrane localisation (Figure 1.9).
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Figure 1.9 Insulin-stimulated pathways leading to Glut-4 
transloeation and glucose transport.
Insulin receptor autophosphorylation catalyses the phosphorylation o f  cellular 
proteins such as members o f  the 1RS femily and cCbL U pon tyrosine 
phosphorylation (circled letter P), these proteins interact with signalling 
molecules through their SH2 domains resulting in the activation o f  a diverse 
series o f  signalling pathways including activation o f  PI3K and TCIO. TCIO 
activation comes about by the tyrosine phosphorylation and subsequent 
recruitment o f  c-C bl to the lipid raft through the adaptor protein CAP. 
Activated c-Cbl also recruits the CrkII/C3G co n p lex  into the lipid raft 
environment, where C3G can stimulate guanylnucleotide exchange on TCIO. 
These pathways act in a concerted fashion to coordinate the regulation o f  
Glut-4 vesicle trafficking, which results in increased glucose transport. 29
1.5 Exercise-stimulated glucose transport
It is currently widely believed that in addition to insulin, exercise promotes transloeation 
of glucose transporters and glucose uptake ((Douen et al., 1990); reviewed in (Goodyear 
and Kahn, 1998)). However, the pathway through which exercise achieves this effect is 
believed to be different from that utilised by insulin (reviewed in (Hayashi et al., 1997); 
(Ryder et al., 2001)).
(Coderre et al., 1995) identified and characterised an exercise-sensitive pool of glucose 
transporters in rat skeletal muscle. By sucrose density gradient centrifugation, they 
isolated an insulin-sensitive Glut-4 pool (in the 32% fraction) and an exercise-stimulated 
pool (in the 36% fraction). No obvious differences in the protein composition between 
the two pools were found but further analysis by velocity gradient centrifugation revealed 
that the insulin-sensitive Glut-4 vesicles had a larger sedimentation coefficient (Coderre 
et al., 1995). In the same year, (Lund et al., 1995) provided supportive evidence on the 
contraction-stimulated transloeation of Glut-4. By using the sensitive exofacial labelling 
technique with the impermeant photoaffinity reagent ATB-BMPA (2-N-[4-(l-azi-2,2,2- 
trifluoroethyl)benzoyl]-l,3-bis-(D-mannose-4-xyloxy)-2-propylamine), they
demonstrated that contraction stimulates exocytosis of Glut-4. Furthermore, the 
combined effect of contraction and insulin on glucose uptake or Glut-4 transloeation was 
greater than either stimulation alone (Lund et al., 1995); (Ploug et al., 1998). In contrast 
to the insulin-mediated pathway, contraction-mediated glucose uptake does not involve 
PI3-K, suggesting different signalling networks (Lund et al., 1995); (Yeh et al., 1995). 
Moreover, subcellular fractionation and immunofluorescence microscopy experiments 
suggest that insulin primarily recruits Glut-4 from a VAMP2 positive TfR-negative 
compartment whereas exercise/contractions primarily recruit Glut-4 from a TfR-positive 
compartment (Ploug et al., 1998); (Randhawa et al., 2000). This differential pattern of 
expression suggests that contraction mobilises an endosomal like pool of Glut-4 whilst 
insulin mobilises the GSV pool. A further level of distinction between exercise and 
insulin responsive Glut-4 vesicle fusion may come from a differential regulation of 
SNARE associated proteins which may have a preferential sensitivity to insulin or 
exercise stimulus. Examples of such proteins are munc-18c and syndet which interact 
closely with syntaxin-4 (Khan et al., 2001).
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1.5.1 Signalling mechanisms involved in exercise-stimulated glucose transport
Although much progress has been made in elucidating the signal transduction mechanism 
for insulin-stimulated glucose uptake via Glut-4, little is known about the molecular 
signals that regulate Glut-4 recruitment during exercise. A molecule currently emerging 
as an important candidate component of exercise-mediated glucose transport in skeletal 
muscle is the AMP-activated protein kinase (Hardie and Carling, 1997).
1.5.1.1 AMPK - Role in exercise-stimulated glucose transport
AMP-activated protein kinase (AMPK) is a trimeric protein consisting of the catalytic 
subunit a , and the regulatory subunits p and y. The kinase-containing subunit a , transfers 
a phosphate from the ATP to the target substrate (Hardie and Carling, 1997). Each 
subunit exists as two or three isoforms designated a l ,  a2  and p i , p2 and y l, y2 and y3. 
The isoforms display differences in abundance, muscle type distribution and also 
sensitivity to AMP (Salt et al., 1998).
AMPK is considered to have a role in the maintenance of stable high-energy phosphate 
concentrations (ATP) and thus energy in muscle cells by promoting catabolic processes 
such as fatty acid oxidation and glucose transport, and inhibiting anabolic processes such 
as fatty acid and cholesterol synthesis (Hardie and Carling, 1997). During contraction 
and exercise the muscle utilises ATP as an energy source at increased rates. Depletion of 
ATP causes the elevation of the AMP: ATP ratio by displacement of the adenylate kinase 
(myokinase) reaction, and this activates AMPK via direct allosteric activation (Carling et 
al., 1989) and by multiple mechanisms which promote phosphorylation of AMPK by an 
upstream protein kinase, AMPK kinase (AMPELK) (Hawley et al., 1995) (Figure 1.10 & 
1 .1 1 ).
AMPK activity in the red region of rat quadriceps muscle has been found to be two- to 
three-fold increased during exercise, in a manner dependent on work rate (Winder and 
Hardie, 1996), (Rasmussen and Winder, 1997). Similarly, AMPK activity has been 
demonstrated to increase in rat epitrochlearis muscles stimulated with 5-aminoimidazole- 
4-carboxamide 1-p-D-ribonucleoside (AICAR), a molecule which after phosphorylation 
forms an AMP analogue called 5-aminoimidazole-4-carboxamide ribonucleotide (ZMP)
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and can therefore activate AMPK and AMPKK (Hayashi et ah, 1998) (Figure 1.11). In a 
study by (Hutber et ah, 1997), contraction of rat gastrocnemius muscles was followed by 
a significant increase in AMPK levels and activity, as well as by a decline in creatine 
phosphate levels. These results taken together indicate a link between exercise-induced 
muscle contraction/AICAR treatment and elevation of AMPK activity in skeletal muscle. 
Similarly, studies on humans have also shown a direct response of AMPK to contraction 
(Chen et ah, 2000); (Wojtaszewski et ah, 2000b), More specifically, (Chen et ah, 2000) 
have reported an increase in the activity of AMPK isoforms a l  and a2  and 
(Wojtaszewski et ah, 2000b) found a three- to four- fold increase in the a2  isoform in the 
vastus lateralis muscle from ‘healthy’ humans under a high intensity exercise protocol.
A role of AMPK in glucose uptake was initially observed when AICAR was used in 
resting perfused muscle of rats, in an attempt to identify a potential role of AMPK in the 
regulation of muscle fatty acid oxidation (Merrill et ah, 1997). In that particular study by 
Merrill and colleagues, it was found that AMPK activity after AICAR stimulation not 
only increased fatty acid oxidation but also resulted in increased glucose uptake (Merrill 
et ah, 1997). In an attempt to throw light on the yet obscured contraction-mediated 
glucose uptake pathway, several teams have studied the effect of AICAR on glucose 
uptake by Glut-4, in the absence of insulin in situ and in vivo (Kurth-Kraczek et ah,
1999); (Bergeron et ah, 1999). Their results have provided evidence of a role for AMPK 
in contraction-stimulated glucose transport.
Not all effects of AMPK on glucose transported should be attributed to Glut-4. (Abbud et 
ah, 2000) observed a two- to three- fold increase in glucose uptake in C2C12 cells treated 
with AICAR. This glucose uptake was said to be facilitated by Glut-1, the predominant 
Glut isoform in those cells (Abbud et ah, 2000).
In summary, AMPK is implicated in Glut-4 mediated glucose uptake during exercise and 
contraction. However, the exact mechanism by which AMPK stimulates Glut-4 
transloeation is not known. In a review by Winder it has been suggested that AMPK 
could activate transcription factors that target the control elements of the Glut-4 gene 
favouring its expression (Winder, 2001). Indeed, (Zheng et ah, 2001) using transgenic 
mice containing different segments of the human Glut-4 gene promoter linked to the
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bacterial chloramphenicol acetyltransferase (CAT) reporter gene, showed that the region 
between 730 to 895 base pairs from the Glut-4 transcription start contains an element 
essential for induction of Glut-4 mRNA synthesis by AMPK, after AICAR stimulation.
Role of AMPK in type II diabetes and obesity.
An elevation in the activity of the AMPK a2 isoform in Type 2 diabetic patients 
subjected to exercise has been reported (Musi et al., 2001). Other studies have also 
suggested that some forms of type 2 diabetes are in fact due to abnormalities in signalling 
pathways that involve AMPK (Winder and Hardie, 1999). Taking into account the 
evidence for a role of AMPK in Glut-4 transloeation and glucose transport during 
contraction and exercise, as well as the role of AMPK in muscle fatty acid oxidation 
(Merrill et al., 1997), it is natural to speculate that a deficiency in AMPK or a decrease in 
AMPK activity could lead to obesity and insulin resistance, and that exercise-stimulated 
AMPK activity could be significant in prevention of type 2 diabetes.
1.5.1.2 Nitric Oxide - Role in exercise signalling and muscle metabolism
It has been suggested that nitric oxide (NO) may regulate muscle metabolism, with most 
studies supporting a contribution of NO in glucose uptake, glycolysis, creatine kinase 
activity and mitochondrial oxygen consumption (Reid, 1998). Nitric oxide is produced in 
cells from L-arginine via the action of nitric oxide synthetase (NOS) (Palmer et al., 1988); 
(Marietta, 1994). One of the first studies to provide evidence on the existence of NOS in 
skeletal muscle was carried out by Balon and Nadler (Balon and Nadler, 1994). Using a 
chemiluminescent detection system, they monitored a 50-200% increase in NO efflux in 
rat extensor digitorum longus (EDL) muscle cultures incubated with L-arginine. 
Moreover, the NOS inhibitor NG-monomethyl-L-arginine monoacetate (L-NMMA) 
decreased NO efflux and the basal 2-deoxy-D-glucose (deGlc) transport, providing 
evidence for the existence of NOS in that tissue and a potential role of NO in 
carbohydrate metabolism (Balon and Nadler, 1994). In 1996, Balon and Nadler further 
extended their hypothesis of NO-induced glucose transport in skeletal muscle with 
additional data, which showed that NOS inhibition selectively inhibits contraction- 
stimulated glucose transport (Balon and Nadler, 1996). In agreement with this, EDL- 
muscles co-stimulated with maximal or sub-maximal concentrations of insulin and the 
NO donor sodium nitroprusside (SNP), showed an additive and dose-dependent increase
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in glucose uptake (Balon and Nadler, 1997). Intriguingly, animals that underwent acute 
exercise showed increased NOS activity in skeletal muscle (Roberts et al., 1999). These 
findings suggested that NO may be a potential mediator of contraction induced glucose 
transport. Roberts and colleagues showed in rat sarcolemmal membrane preparations, 
that exercise- but not insulin-stimulated glucose transport was sensitive to another NOS 
inhibitor, N^-nitro-L-arginine-methyl-ester (L-NAME) (Roberts et al., 1997). These 
results further implicated NOS activity in exercise-stimulated glucose transport.
Young et al studying the in vitro effects of the nitric oxide donors, SNP and spermine 
NONOate, on glucose transport and utilisation in rat soleus muscle, suggested that nitric 
oxide may be able to specifically inhibit insulin-stimulated glycogen synthesis, or that 
glycogen synthase may be inactivated by a mechanism involving the NO-cGMP 
signalling pathway (Young et al., 1997). Finally, soleus muscle preparations incubated 
with SNP showed an eighty-fold increase in the cGMP content as well as an elevation in 
glucose transport and oxidation. This cGMP elevation was significantly decreased by 
LY-83583, a guanyl ate cyclase inhibitor (Young et al., 1997). These results suggest that 
NO increases glucose uptake and oxidation through a pathway that involves stimulation 
of guanylate cyclase and generation of cGMP.
In 1998, Young and Leighton investigated the effects of zaprinast on cGMP levels in 
soleus muscles isolated from lean, insulin-sensitive and obese, insulin-resistant rats 
(Young and Leighton, 1998). Zaprinast is a selective inhibitor of cGMP type V 
phosphodiesterase. The use of zaprinast results in the elevation of cGMP due to the 
inhibition of its hydrolysis by the cGMP type V phosphodiesterase. The results from this 
study showed that the cGMP content was significantly increased in lean rat muscles 
incubated with zaprinast, but not in the muscles of obese, insulin-resistant rats. (Young 
and Leighton, 1998) suggested that the lack of cGMP increase in zaprinast treated obese 
rat muscles could be due to a defect in NOS or due to a lack of stimulation of guanylate 
cyclase by NO. In both cases the result would be a decrease in cGMP generation, such 
that the inhibition of the cGMP phosphodiesterase would have little effect on the levels of 
intracellular cGMP. In fact, direct measurements illustrated impaired NOS activity in 
soleus, diaphragm, gastrocnemius and EDL muscles from obese rats (Young and 
Leighton, 1998). This finding indicates the presence of an endogenous cGMP
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phosphodiesterase and an intrinsic guanylate cyclase activated by NO and that the 
sensitivity o f this cyclase to NO and/or the function o f  NOS m ay be impaired in insulin- 
resistant muscle.
In summary, taken collectively the above data suggest that NO potentially mediates 
exercise-induced glucose transport through a pathway involving stimulation o f guanylate 
cyclase and cGMP (Figure 1.11).
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Figure 1.10 Maintenance of ATP levels during contraction.
Creatine phosphate (CP) decreases, creatine (C) increases and AMP increases
in muscle during exercise/contraction as a result o f  actions o f  creatine
phosphokinase (CPK) and myokinase (adenylate kinase). R eproduced from  
Winder, 2001.
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Figure 1.11 Signalling mechanisms involved in exercise-stimula ted glucose 
transport.
The mechanisms by which exercise increases skeletal muscle glucose transport 
has not been precisely identified, however roles for nitric oxide (NO) and AMPK 
have been demonstrated. Exercise increases NO production, cGMP levels and 
AMPK activity in skeletal muscle. AMPK is activated allosterically in skeletal 
muscle by increases in the creatine-to-phosphocreatine and AMP-to-ATP ratios 
and is also activated by phosphorylation by an upstream kinase (AMPK-kinase). 
5 - amino im idazo le-4- carboxamid e 1-p-D-ribonucleoside (AICAR), a conpound 
which is converted to 5-aminoimidazole-4-carboxamide ribonucleotide (ZMP) 
within muscle, mimics the effect o f  AMP to increase AMPK activity and results 
in an increase in glucose transport.
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1.6 Diabetes
1.6.1 Insulin-dependent diabetes mellitus (type 1 diabetes)
Insulin-dependent diabetes mellitus (IDDM), also known as type 1 diabetes, is the result 
of an abrupt cessation of insulin secretion from the pancreatic P-cells (Atkinson and 
Eisenbarth, 2001). This is usually caused by an autoimmune response of genetic or 
environmental origin that leads to the destruction of these cells (Atkinson and Eisenbarth, 
2001). Consequently, the inability to regulate hepatic production of glucose together with 
reduced peripheral tissue glucose uptake due to the lack of insulin results in an abnormal 
accumulation of glucose in the blood (Zimmet et al., 2001). This abnormal accumulation 
of blood glucose or hyperglycaemia is the classical symptom of IDDM that accompanies 
excessive thirst, hunger, rapid weight loss, fatigue and polyuria (Atkinson and Eisenbarth, 
2001). Long-term complications include retinopathy, nephropathy, neuropathy and 
peripheral vascular and coronary heart disease (Atkinson and Eisenbarth, 2001); (Zimmet 
et al., 2001). Variable combinations of the above complications are the main cause of 
morbidity and premature mortality in the IDDM population, which constitutes 10% of the 
total diabetic population (Zimmet et al., 2001). Daily insulin injections and dietary 
measures are employed in the management of this disease (Atkinson and Eisenbarth, 
2001).
1.6.2 Non-Insulin-dependent diabetes mellitus (type 2 diabetes)
Non-insulin-dependent diabetes mellitus (NEDDM), alias type 2 diabetes comprises the 
remaining 90% of the total diabetes incidence and as in the case of IDDM, is also of 
environmental and genetic origin (Zimmet et al., 2001). NIDDM is particularly 
associated with obese individuals and it differs from IDDM in that patients do not suffer 
from the absence of insulin production. Instead, the insulin present, even when at highly 
elevated levels is unable to stimulate the utilisation of the accumulating blood glucose, 
either due to dysfunction of the insulin receptor/ insulin responsive cell or due to a 
blockade in the insulin-signalling pathway. NIDDM is characterised by insulin resistance 
in the liver, |3-cells and peripheral tissues and is manifested as hyperglycaemia (Figure 
1.12). As in the case of IDDM the long-term clinical complications of type 2 diabetes 
include heart disease, neuropathy, kidney failure and blindness. Type 2 diabetes
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constitutes the majority of diabetes cases and as the number of affected individuals in the 
western cultures are increasing, pharmaceutical companies and health care systems are 
being urged to find a preventative measure for the onset of NIDDM. Cunently, a low 
sugar/fat diet, exercise and anti-diabetic drugs are used to manage type 2 diabetes 
(Zimmet et ah, 2001).
1.6.2.1 Therapeutic treatments for type 2 diabetes
There are three main classes of drugs aimed at maintaining normoglycaemia in NIDDM. 
These are the sulphonylureas, biguanides and the thaizolidinediones;
Sulphonylureas aim at enhancing P-cell insulin secretion. They do so by binding to a 13- 
cell receptor causing closure of an ATP-dependent channel that results in membrane 
depolarisation. In response to membrane depolarisation, Ca^ "^  influx occurs and 
stimulates the exocytosis of insulin-containing vesicles. The biguanides act via an as yet 
undefined molecular target however their site of action is believed to be liver and skeletal 
muscle (Moller, 2001). The thiazolidinediones are oral hypoglycaemic drugs typified by 
rosiglitazone, pioglitazone, ciglitazone and troglitazone (Murphy and Holder, 2000). 
They promote peripheral glucose uptake and lower hepatic glucose output by increasing 
the sensitivity of these tissues to the action of insulin (Murphy and Holder, 2000). 
Indeed, it has been documented that administration of rosiglitazone to adipocytes 
provokes increase in insulin receptor expression along with enhancement of Glut-4 
expression and translocation thus leading to an improvement in glucose metabolism 
(Young et al., 1995). The thiazolidinediones act as synthetic agonist of the peroxisome 
proliferator activated receptor gamma (PPARy), a nuclear receptor involved in the 
formation of fat cells (adipogenesis) (Spiegelman, 1998). PPARy belongs to a family of 
three nuclear receptors known as PPARot, y and Ô (Murphy and Holder, 2000). The 
family took their names from studies on mice that showed proliferation of fatty-acid 
oxidising peroxisomes when treated with fibrates (Murphy and Holder, 2000), a class of 
hypolipidaemic drugs that bind PPARa, the first receptor to be cloned (Murphy and 
Holder, 2000). When activated, the PPARs are capable of influencing transcription of a 
target gene by binding to a specific peroxisomal proliferator response element (PPRE) 
(Murphy and Holder, 2000). More specifically, PPARy that exists as two isoforms 1 and
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2 is expressed predominantly in adipose tissue and promotes differentiation of fibroblasts 
into adipocytes via the activation of adipogénie genes and also insulin receptor, IRS-1 and 
Glut-4. PPARy is also expressed in liver and skeletal muscle but its predominant 
expression in fat cells is understandable as adipose tissue plays an important role in 
metabolic homeostasis and therefore activation of the above genes leads to an increased 
insulin sensitivity and glucose uptake.
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Figure 1.12 The development of type 2 diabetes
The contribution o f  insulin resistance in liver, muscle, fat and pancreatic P-cells to the 
development o f  type 2 diabetes. 1. Potential causative Actors in early stages o f  the 
disease. 2. Peripheral insulin resistance in insulin-sens it ve target tissues o f  skeletal 
muscle, adipose tissue and liver result in impaired glucose tolerance and is associated 
with increased insulin secretion by pancreatic P-cells. 3. Resultant blood anomalies 
o f type 2 diabetes due to the persistent peripheral insulin resistance and the decreased 
insulin secretion by pancreatic P-cells. 4. Late stages o f  type 2 diabetes, with little or 
no insulin secretion and persistent peripheral insulin resistance.
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1.7 Insulin resistance in relation to hypertension
Studies such as the one by Mitchel et al (1990) showing that lean, non-diabetic 
hypertensives are hyperinsulinaemic compared with normotensive controls have now 
established an association between insulin resistance, hypertension and associated 
conditions such as obesity. It has been commonly observed that hypertension is 
approximately twice as frequent in patients with diabetes compared with patients without 
the disease (Morris et a l, 1994). Nevertheless a debate still exists on whether 
hypertension constitutes a clinical manifestation of insulin resistance and diabetes or 
whether it is hyperinsulinaemia that predisposes the organism to the development of 
diabetes. Currently there is available evidence in favour of both theories. (Julius et a l,
1991) suggested that hypertension may precede the development of insulin resistance and 
hyperinsulinaemia and may in fact be the cause. They proposed that insulin resistance is 
secondary to the inability of blood glucose to be transported in the cells due to the 
reduced muscle blood flow and microvascular disease as occurs in hypertension and 
obesity. In contrast, studies have shown that insulin resistance is prevalent only in 
subjects with primary and not secondary hypertension (Donnelly and Connell, 1992). 
The lack of association between secondary hypertension and insulin resistance therefore 
suggests that elevated blood pressure does not lead to insulin resistance. Finally, it has 
been demonstrated that the spontaneously hypertensive rat (SHR), a genetic model of 
hypertension, develops insulin resistance (Reaven et a l, 1989). This observation is of 
significance since the insulin resistance characterised by defective glucose transport into 
SHR adipocytes, develops long before any elevations in blood pressure are apparent 
(Reaven et a l, 1989). Taken together these data suggest that hypertension is more likely 
to constitute a clinical manifestation secondary to the pre-existing condition of insulin 
resistance.
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1.8 General aims of this thesis
It has been shown that glucose uptake can be mediated not only by insulin but also by a 
distinct mechanism regulated by exercise. Yet the individual steps that render the 
exercise-mediated pathway distinct from that mediated by insulin are not fully identified.
Aiming at better understanding the differences between the two pathways I compared and 
contrasted the deGlc transport under insulin and exercise-like conditions using the 
insulin-resistant SHRSP (stroke-prone spontaneously hypertensive rat), the type 2 
diabetes rat model ZDF and their equivalent normal phenotypes. The results from these 
comparisons compose chapters 3 and 5 respectively while the work in chapter 4 aimed at 
identifying the origin of the insulin resistance observed in SHRSP animals. Is this defect 
secondary to a pathophysiological factor or is it due to a primary genetic defect? In order 
to answer this question, a model for the study of insulin resistance was developed in the 
form of skeletal muscle culture. The methodological development and characterisation of 
the skeletal muscle cell cultures along with the novel findings are detailed in chapter 4.
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Chapter 2 
Materials & Methods
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2.1 Materials.
2.1.1 Animals
Male Wistar Kyoto (WKY) rats and Stroke Prone Spontaneously Hypertensive rats 
(SHRSP) were reared in house in the Joint Animal Facility at the University of Glasgow. 
Male Zucker (fa/fa) diabetic fatty (ZDF) rats and lean controls f/a/+) were purchased 
from Genetic Models Inc., USA.
2.1.2 Antibodies
Professor K. Siddle (University of Cambridge) supplied anti-1RS-1 antibodies. Anti- 
syntaxin-4 was a gift from Professor D.E. James (University of Queensland, Australia). 
Anti-AM PKal and a2  were provided by Professor D.G. Hardie (University of Dundee, 
UK). Anti-PKB (PH domain) was a gift from Professor P. Cohen (University of Dundee, 
UK). Dr. S.A Baldwin (University of Leeds, UK) donated anti-Glut-1 antibody. Anti- 
Glut-4 antibody raised against the C-terminal 14 amino acids of human Glut-4 was 
produced in house. Anti-caveolin-1 and Anti-flotillin antibodies were purchased from 
Becton Dickinson (Oxford, UK). Anti-Myogenin and anti-MyoD were purchased from 
Pharmingen (Oxford, UK). Anti-IRS-1 raised to carboxy terminus, Anti-IRS-2, and anti- 
p85a antibodies were from Upstate Biotechnology (TCS Biologicals, Bucks, UK). Anti- 
eNOS antibodies were from Sigma (Poole, Dorset, UK). Anti-VAMP-2 antibody was 
purchased from Synaptic Systems (Gottingen, Geimany). Horse-radish peroxidase 
(HRP)-conjugated donkey anti-rabbit IgG and HRP-conjugated anti-mouse IgG 
antibodies were purchased from Amersham International pic, (Aylesbury, 
Buckinghamshire, UK).
2.1.2 Cells
L6 skeletal muscle cell line from American tissue culture collection was a gift from Dr 
E.M. Gibbs (Pfizer Central Research Groton, CT)
2.1.3 Cell Culture
Pederson Fetuin was supplied by Sigma (Poole, Dorset, UK). a-MEM, Chick embryo 
extract 60Â filtrate, Hams-FlO, foetal bovine serum, lOOOOU/ml Penicillin, lOOOOU/ml 
streptomycin and trypsin/EDTA were from Gibco/Life Technologies, Inc (Paisley, UK).
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13.5ml and 50ml centrifuge tubes and 1, 5, 10, 25ml sterile pipettes were supplied by 
Bibby Sterilin Ltd, (Stone, Staffordshire, UK). 25cm^ Falcon Primaria flasks, 6-well 
Collagen type I BioCoat™ plates, 75cm^ and 175 cm^. Collagen type I BioCoat™ flasks 
were purchased from Becton & Dickinson (Franklin Lakes, NJ, USA).
2.1.4 General chemicals and reagents
ECL Western Blotting Detection Kit was purchased from Amersham International pic, 
(Aylesbury, Buckinghamshire, UK). Extra-thick filter paper, N, N, N', N’, - 
tetramethylenediamine (TEMED) and non-fat blocking grade powdered milk were 
purchased from Bio-Rad Laboratories ltd, (Hemel Hempstead, Hertfordshire, UK). 
Bovine serum albumin-Fraction V (Low Hormone), Complete^^ Protease Inhibitor 
Cocktail tablets and Tris were purchased from Boehringer Mannheim (GmbH, Germany). 
10% Brij-35 solution, Hepes, MES, MOPS, NP-40 and 10% Tx-lOO solution were 
obtained from Calbiochem (Nottingham, UK). 30% Acryl/Bis-acrylamide (35.7/1) 
solution was purchased from Fisons, (Loughborough, Leicestershire, UK). PIP3 (1-0- 
stearoyl-2-0 -arachidonoyl-5'rt-glycer-3 -yl-D-myo-inositol-3 ,4 ,5-triphosphate.tetrasodium 
salt and MicrocystinLR were purchased from Alexis, (San Diego, California, USA). L-a- 
phosphatidylcholine and L-a-phosphatidylserine were purchased from Avanti Polar 
Lipids (Alabaster, Alabama, USA). Sterile Acrodisc® 0.2jLim filters were purchased from 
Gelman Sciences Ltd, (Northampton, UK). RP X-Omat liquid fixer and developer and X- 
Omat AR film were purchased from Kodak Ltd, (Hemel Hempstead, Hertfordshire, UK). 
BCA protein assay reagent was purchased from Peribio (Cheshire, UK). Nitrocellulose 
membrane (0.45pm pore size) was supplied by Schleicher and Scheull, (Dassel, 
Germany). AICAR, collagenase type lA, cytochalasin B, dexamethasone and 
wortmannin were supplied by Sigma (Poole, Dorset, UK). P-81 phosphocellulose paper 
was purchased from Whatman International Ltd. (Maidstone, UK). All other laboratory 
chemicals were of analytical reagent grade and purchased from either Sigma Chemical 
Company (Poole, Dorset, UK) or BDH (Loughborough, Leicestershire, UK).
2.1.5 Peptides
Dr G. Danielson (Novo Nordisk, Denmark) provided porcine insulin. PKB substrate 
peptide (RPRAATF) was from Dr. R. Plevin, (University of Strathclyde, U.K.). Protein 
Kinase A Inhibitor peptide (PKI) (TTYADFIASGRTGRRNAIHD) was purchased from 
Bachem (Merseyside, UK).
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2.1.6 Radioactive chemicals
[Y^^P]-ATP, [^"^CJ-D-glucose, [^"^CJsucrose, 2-deoxy-D-[2,6-^H]glucose were purchased 
from NEN Dupont Ltd (Hertfordshire, UK)
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2.2 Buffers
2.2.1 General Buffers
Hepes EDTA Sucrose Buffer (HES),
20mM Hepes (pH 7.4), ImM EDTA, 225mM Sucrose
Immunoprécipitation buffer (IP buffer),
150mM NaCl, 50mM NaF, ImM EDTA, ImM EOT A, lOmM Na4P20y, 1.5mM MgCE, 
1% (v/v) Glycerol, 50mM Hepes (pH 7.2), (ImM  Activated NaV0 4 , ImM DTT, 1 
Complete™ Protease Inhibitor Cocktail tablet and 2pM  MicrocystinLR) added 
immediately prior to use.
Krebs Heinsleit Buffer (KH),
118mM NaCl, 4.7mM KCl, 1.2mM KH2PO4, 1.2mM MgS0 4 , 25mM NaHCOs gassed 
with 95%02 /5%C02  prior to addition of 2.5mM CaCE. Buffer will be pH 7.4.
Krebs Ringers HEPES buffer (KRH),
118mM NaCl, 5mM NaHCOs, 4.7mM KCl, 1.2mM KH2PO4, 1.2mM MgS04 , 25mM 
Hepes (pH 7.4), 2.5mM CaCE
Kinase Assay Buffer (KAB),
50mM Hepes (pH 7.4), ImM  DTT
2x Kinase Assay Buffer + Mg "^^  (2x KAB+Mg)
lOOmM Hepes (pH 7.4), 2mM DTT, 40mM MgCE, 2pM MicrocystinLR
Mes Buffered Saline (MBS),
25mM MES (pH6.5), 150mM NaCl
Phosphate buffered saline (PBS),
137mM NaCl, 2.6mM KCl, lOmM Na2HP04 ,1.7mM KH2PO4 (pH7.4)
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2.2.2 SDS-PAGE Buffers
Electrode buffer,
25mM Tris base; (pH 8 .6) ,  192mM glycine, 0.1%(w/v) SDS 
Sample buffer,
93mM Tris.HCl; (pH 6 .8), ImM EDTA, 10% (v/v) glycerol, 2% (w/v) SDS, 0.002% 
(w/v) bromophenol blue and (20mM dithiothreitol added immediately prior to use).
2.2.3 Western Blotting Buffers
PBS-T,
PBS; (pH 7.4), 0.1% (v/v)Tween-20 
Towbin buffer,
25mM Tris base; (pH 8 .6), 192mM glycine, 20% (v/v) methanol
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2.3 Methods
2.3.1 Growth and maintenance of WKY, SHRSP, lean Zuckers and ZDF rats.
Male Wistar Kyoto (WKY) rats, Stroke Prone Spontaneously Hypertensive rats, Zucker 
diabetic fatty rats and lean Zucker rats were housed under controlled conditions of 
temperature (21+ 2°C) and light (12hr light-dark cycle) and fed on normal rat chow (rat 
and mouse no.l maintenance diet. Special Diet Services, Waltham, Essex, UK) and water 
ad libitum. SHRSP and WKY blood pressure measurements were made by insertion of 
telemetry probes and by tail cuff measurements, according to standardised techniques 
(Jeffs et ah, 1997). Glucose was measured by the glucose oxidase technique. 
Characteristics of the animals are presented in Table 3.1 and Table 5.1.
2.3.2 2-Deoxy-D-glucose (deGlc) transport assays in intact muscle.
Flexor digitorum brevis (FDB) muscles were dissected and cleaned of connective tissue 
without stretching and with tendons intact. Muscles were placed in KH buffer and were 
allowed to recover for 30 minutes at 37°C with continuous gassing with 95%02 /5%C0 2 . 
Muscles were pinned at resting length and incubated for 30 minutes in the presence or 
absence of IpM  insulin or 500pM AICAR after which time the muscles were rapidly 
washed three times with glucose-free KH buffer. Muscles were incubated for a further 10 
minutes at 37°C in uptake buffer (KH buffer containing IpM  insulin, lOpM deGlc 
(IpCi/m l) and [^'^Cj-Sucrose (0.2pCi/ml; used as an extracellular marker) (in the presence 
or absence of lOOnM wortmannin as indicated in the figure legends). Muscles were 
washed three times with ice-cold saline, blotted on filter paper, weighed and solubilised in 
1ml of 0.5N NaOH at 60°C for 45 minutes and tissue associated radioactivity determined 
by scintillation spectrophotometry.
2.3.3 Preparation of muscle extracts.
Freshly dissected muscles were placed in a 50 ml Coming tube and homogenised in ice- 
cold immunoprécipitation buffer pH7.4, 1% NP40 using a Polytron (setting 5), followed 
by 20 strokes in a Dounce homogeniser. The homogenate was centrifuged at 14,000xg for 
5 min at 4°C to remove unsolubilised material. The supernatant containing solubilised
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protein was collected and assayed for protein as outlined in 2.3.5 prior to 
immunoprécipitation or immunoblot analysis as described below in 2.3.7 through to 
2.3.10. The remainder of solubilised protein was aliquoted and stored at -80°C.
2.3.4 Fractionation of skeletal muscle.
Muscles were quickly dissected and snap frozen in liquid nitrogen. Frozen tissue was 
powdered using a mortar and pestle on dry-ice and resuspended in HES buffer 
supplemented with Complete™ protease inhibitor cocktail tablets prior to 
homogenisation. The homogenate was centrifuged at 12,000xg for 20 min at 4°C and the 
pellet collected (heavy membrane fraction). The supernatant was further centrifuged at 
140,000xg for 1 hour at 4^ ’C and the pellet (light membrane fraction) and supernatant 
(soluble protein fraction) collected. These fractions were assayed for protein and 
resuspended in SDS-PAGE sample buffer prior to immunoblot analysis.
2.3.5 Protein estimation using the Bichiconic Acid protocol
Protocol was carried out essentially as directed by manufacturer’s instructions. A 
standard curve (ranging from 0 to Img/ml) was prepared from a 2mg/ml BSA solution. 
The standard curve was prepared in the same buffer as unknown sample to account for 
any interference from buffer constituents. Triplicate lOpl aliquots of each sample was 
then added to a 96 well plate, followed by 200pl of diluted BCA reagent (prepared by 
diluting 1 part of reagent A with 50 parts of reagent B). The plate was incubated at 37°C 
for 60 minutes, after this time the absorbance of the samples was read in an automated 
plate counter at 565nm. Using Microsoft Excel5.0 values of absorbance were plotted 
against their respective known standard BSA concentrations. A linear line of best fit was 
drawn, equation of line y = mx + c, intercept of x-axis set to zero. Unknown protein 
concentrations were interpolated from the linear fitted line.
2.3.6 In-vitro stimulation of extensor digitorum longus muscle
EDL muscles were isolated by dissection with tendons intact and were placed in KH 
buffer supplemented with 25 mM D-glucose and were allowed to recover for 30 minutes 
at 37°C with continuous gassing with 95%02 /5%C0 2 . Muscles were incubated under a
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constant tension for 30 minutes in the presence or absence of 1 pM insulin after which 
time the muscles were rapidly washed three times with glucose-free KH Buffer and snap 
frozen.
2.3.7 Immunoprécipitation and assay of Protein kinase B.
Frozen tissue was powdered using a mortar and pestle on dry-ice and resuspended in 
immunoprécipitation buffer supplemented with 1% Tx-100. Muscle lysates were spun in 
a microfuge at 14,000 xg for 10 minutes to remove insoluble material. A 25% Protein G- 
Sepharose slurry was washed 3 times with 1ml of immunoprécipitation buffer 
supplemented with 1% Tx-100. Ipg of anti-PKB (PH domain) antibody was added to 
every 20pl of 25% Protein G-Sepharose (5pi packed volume) and incubated in a total 
volume of 300-500pl on a rotating mixer for 2 hours at 4°C. After this time antibody- 
Protein G-Sepharose complex was pelleted by a pulse spin at 14000 xg, 4°C. Any 
unbound antibody was aspirated off and the antibody-bead complex was washed 3 times 
with 1ml of immunoprécipitation buffer supplemented with l%Tx-100. 20pl of 25% 
Protein G-Sepharose-antibody conjugate was used per immunoprécipitation. 50-100pg of 
lysate was added to 20pi of 25% Protein G-Sepharose-antibody complex and the volume 
was made up to 300pl with IP buffer supplemented with 1% Tx-100 and mixed for 2 
hours at 4°C on a rotating mixer. The mixture was centrifuged at 14,000 xg, 30 seconds, 
4°C, and the pellet was washed three times with 1ml lysis buffer supplemented with IM 
NaCl followed by two times with 1ml Kinase Assay buffer (KAB) at 4°C. Pellets were 
resuspended in 20pl KAB and assayed as follows. Reaction mixtures, with a total volume 
of 20pl, containing lOpl of KAB, 5pi of 150pM RPRAATF substrate peptide in KAB 
and 5pi of immunoprecipitate were prepared on ice and the reaction initiated by the 
addition of 5pi of [y-^^PJATP solution (250pM [y-^^P]ATP with a specific activity in the 
range of 250,000 to 500,000 cpm/nmol (0.5 to 1 pCi [y-^^P]ATP/reaction), 50mM 
MgCE). Blank reactions were prepared by substituting KAB for substrate peptide. After 
incubation with shaking at 30°C for 15 minutes, 15pi of the reaction mixture was 
removed and spotted onto Icm^ pieces of Whatman P-81 phosphocellulose paper and the 
paper dropped into 1% (v/v) phosphoric acid. The P-81 paper squares were washed for 
10 minutes through three changes of 1% (v/v) phosphoric acid and then rinsed with water.
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Rinsed squares were air dried and the incorporation of [y-^^PJATP into the substrate 
peptide determined by liquid scintillation counting.
2.3.8 SDS-PAGE
SDS/Polyacryiamide gel electrophoresis was canied out using Bio-Rad mini-PROTEAN 
II. The Bio-Rad mini-PROTEAN II slab gels had a stacking gel of 2cm composed of 5% 
acrylamide/0.136% bisacrylamide (v/v) in 125mM Tris-HCl (pH 6 .8), 0,1% (w/v) SDS, 
polymerised with 0.1% (w/v) ammonium persulphate and 0.05% (v/v) TEMED. The 
resolving gel consisted of 6.5-10% acrylamide/0.18-0.28% bisacrylamide in 0.383mM 
Tris-HCl (pH 8 .8), 0.1% (w/v) SDS, polymerised with 0.1% (w/v) ammonium 
persulphate and 0.01% (v/v) TEMED. Protein samples were solubilised in sample buffer 
and heated at 80°C in water bath for 3minutes. Samples were loaded into the wells in the 
stacking gel. lOpl of broad range pre-stained molecular weight markers were loaded into 
at least one well. Gels were immersed in electrode buffer and electrophorised until the 
dye front had reached the desired position or until adequate separation of pre-stained 
molecular weight markers. A constant voltage of 70 volts was applied through the 
stacking gel, which was increased to 120 volts through the resolving gel.
2.3.9 Western blotting
After separation of the proteins as described earlier, gels were removed from the plates 
and equilibrated in Towbin’s buffer for 10 minutes. A sandwiched aiTangement of 
components, individually soaked in Towbin’s buffer, were made as follows from bottom 
to top: brillo pad, two pieces of Whatmann 3MM filter paper, nitrocellulose paper, 
equilibrated polyacrylamide gel, two pieces of Whatmann 3MM filter paper, brillo pad. 
The sandwich was placed in a cassette and slotted, bottom nearest to cathode, into a Bio- 
Rad mini trans-blot tank filled with Towbin’s buffer. Transfer of proteins was performed 
at room temperature for 3 hours at a constant current of 250mA. Efficiency of transfer 
was determined by staining the nitrocellulose membrane with Ponceau S solution.
Membrane was incubated with 5% (w/v) non-fat milk (BioRad) made up in PBS-T for 1 
hour to block non-specific binding sites. Primary antibodies were diluted in 1% (w/v) 
non-fat milk/PBS-T. Blots were incubated with primary antibody of interest overnight on 
a shaking platform at 4°C. The blot was washed three times over 15 minutes with PBS-T
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and incubated for 1 hour with l|Lig/ml of an HRP-linked secondary antibody raised to the 
(tail) Fc-region of primary antibody IgG molecule. The blot was washed for 15 minutes 
with PBS-T supplemented with 1 Molar NaCl, followed by 3 changes over 15 minutes 
with PBS-T.
2.3.10 Immunoblot analysis.
Immuno-labelled proteins were visualised using HRP-conjugated secondary antibody and 
the ECL system (Amersham, UK). Bands were quantified by densitometry using Tina 
Image software. In order to quantify the relative levels of expression, increasing loads of 
protein were loaded into adjacent lanes and the linearity of the immunoblot signal 
determined by densitometric analysis of blots developed using ECL. Multiple exposures 
of X-ray film were performed in order to insure linearity of response to film to signal. All 
immunoblot signals were quantified from linear regions of the protein titration curve.
2.3.11 Growth and Maintenance of L6 cultures.
L6 cells were seeded into 175cm^ flasks and maintained at 37°C/5% CO2 in a humidified
incubator. On average the L6 cells from one 175cm^ flask were seeded onto ten 10cm 
plates or six dwell plates. Cells were fed 24 hours after seeding and then every two days 
with a-modification Minimum Essential Medium (a-MEM) supplemented with 8% FBS 
and lOOU/ml penicillin/streptomycin until 30% confluence.
2.3.12 Passage of skeletal muscle cultures
Rat skeletal muscle cultures and L6 cultures were passaged at 50% and 30% confluence, 
respectively, on the fourth day since seeding or last passage. Medium was aspirated from
cells in a 75cm^ flask and the cells then washed for 20 seconds with 5ml pre-warmed 
sterile trypsin EDTA. This trypsin was removed and replaced with 2ml of fresh trypsin. 
Cells were returned to the incubator and left for around 2-4 minutes to allow cells to 
detach. The trypsin was neutralised by the addition of 10ml of growth medium (defined 
in chapter4) or in the case of L6 cells, a-M EM  supplemented with 8%FBS and cells 
seeded as desired.
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2.3.13 Freezing down cultures
Three to four 75cm^ flasks of rat skeletal muscle cultures or one to two 175cm^ flasks of 
L6 cells were trypsinised as previously described. Cells were pelleted and resuspended to 
1x10^ cells per ml in 100%FBS-10%DMSO. 0.5ml aliquots of cell suspension were 
placed into cryovials. Cryovials were wrapped in blue roll and placed in a polystyrene 
box at -80°C overnight, after which vials were placed in the vapour phase of liquid 
nitrogen for long term storage.
2.3.14 Whole cell indirect immunofluorescence
Skeletal muscle cells were cultured on collagen coated coverslips placed in a 6 well 
culture dish. Cells were then transferred onto ice and washed three times with ice cold 
PBS and fixed using 3mis of para-formaldehyde per well. Cells were washed three times 
with PBS, followed by three washes in PBS/5% goat serum over a time period of 15 
minutes, in order to block non-specific binding sites. Cells were incubated with primary 
antibody diluted in PBS/1 % goat serum for 1 hour. After this time, cells were washed 
three times with PBS/0.1% (w/v) BSA and incubated with FITC-conjugated secondary 
antibodies diluted in PBS/1% goat serum. Finally, cells were washed with five changes 
of PBS over a 15-minute period and mounted on glass slides using Vector Laboratories 
mounting medium. Slides were visualised using a Zeiss fluorescent microscope.
2.3.15 2-Deoxy-D-glucose (deGlc) transport assays in cultured myotubes.
Cultured myotubes serum starved for 16 hours, were washed two times in 3 ml of Ki*ebs 
Ringer Hepes buffer pH7.4 and incubated for 30 min at 37°C in the presence or absence 
of InM  to IjLiM insulin or 500pM AICAR (in the presence or absence of lOOnM 
wortmannin as indicated in the figure legends). Uptake was initiated by addition of 
lOpM 2-deGlc (IjaCi/ml) for 10 min. Specific earner mediated deGlc uptake was 
determined by calculating the cell associated radioactivity in the presence of lOjaM 
Cytochalasin B. Plates were washed rapidly by three changes in ice cold PBS. Cells 
were lysed in 1ml of 1% Tx-100. The lysate was transferred to scintillation tubes and cell 
associated radioactivity was determined by liquid scintillation spectrophotometry.
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2.3.16 Recombinant protein kinase B (PKB) phosphorylation and activity microtitre 
plate assay
This is a two-step reaction. First, S473D-PKBa was combined with its allosteric 
activator, PIP3 and/or the test compound, in the presence of its constitutive!y active 
upstream kinase, 3-phosphoinositide-dependent kinase-1 (PDK l) and unlabelled ATP. 
Phosphorylation/activation of S473D-PKB was then allowed to proceed for 30 min at 
30°C. Secondly, radiolabelled ATP and a peptide substrate specific for S473D-PKB was 
added, and the incubation continued for a further 30 min. The reaction was then 
terminated by the addition of 20 mM EDTA and the extent of peptide phosphorylation (an 
index of PKB activation) measured upon capture of the peptide by p81 paper.
(i) Preparation of lipid vesicles 
The following lipid stock solutions were made up and stored at -20°C in glass vials under 
N2.
• Img/ml (0.837 mM) stearoyl, arachidonyl PIP3 in distilled water (in opaque 
polypropylene tube).
• 25 mg/ml (32.89 mM) phosphatidycholine in chloroform/methanol (2:1)
• 10 mg/ml (12.31 mM) phosphatidylserine in chlorofoim/methanol (2:1)
For 2.2 ml of vesicles, 66.9 pi phosphatidylcholine and 178.2 pi of phosphatidylserine 
were mixed in a polypropylene tuhe. Solvent was removed under vacuum in a centrifugal 
evaporator (Howe GyroVap) for as short a time as possible. 26.5 pi PIP3 was added to 
the dried lipids and the evaporation process repeated. When all the water was removed
2.2 ml 10 mM Hepes/NaOH pH 7.0 was added to the dried lipids, minimising exposure of 
the dried lipid to air (which can lead to oxidation). The mixture was incubated on ice for 
1 hour with occasional brief vortexing (protected from light). Once the lipid has 
rehydrated and no longer adheres to the wall of the polypropylene tube it should appear to 
be an opaque, homogeneous suspension. This lipid suspension was sonicated for 20 min 
in a bath sonicator at 4°C. The prepared vesicles contain 1 mM phosphatidyl choline 
(PC), 1 mM phosphatidyl serine (PS) and 0.01 mM PIP3. Once diluted 10-fold in the 
assay, the final lipid concentrations is 100 pM (PC/PS) and 1 pM PIP3 (determined within 
GlaxoSmithkline as the optimal concentration for stimulation of recombinant PKB). The 
lipid vesicles from now on will be referred to as ‘PIP3 vesicles’ and were stored at 4°C 
until use. Vesicles were aliquoted, snap-frozen under liquid nitrogen and stored at -80°C,
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for storage periods longer than a week. They are good for 2-3 freeze-thaw cycles and 
were, prior to use, vortexed vigorously and sonicated briefly on thawing.
(ii) Assav
Activation reactions, with a total volume of 20 pi, containing 10 pi 2x KAB+Mg, 1 pi 
recombinant PKB (0.5 pg/pl), 4pl of unlabelled ATP (0.25 mM), 2 pi PIP3 vesicles or 
compound (100 pM) and 2 pi water were prepared at room temperature. Activating 
reactions were initiated by addition of 1 pi recombinant PDKl (0.02 pg/pl) and incubated 
at 30°C for 20 min. Blank reactions were prepared by prior addition of 5 pi EDTA (20 
mM). Subsequently 10 pi of [y^^P]-ATP (50 pM, 1 pCi/reaction) and RPRAATF 
substrate peptide (30 pM final) in Ix KAB+Mg was incubated at 30°C for 20 min. The 
reaction was terminated by addition of 5 pi EDTA (20mM). 17.5 pi of the reaction
mixture was spotted onto P81 paper. The paper was dropped into 1% (v/v) phosphoric 
acid. The P-81 paper squares were washed for 10 min through three changes of 1% (v/v) 
phosphoric acid and then rinsed with water. Rinsed squares were air-dried and the 
incorporation of [y^^P]-ATP into the substrate peptide was determined by liquid 
scintillation counting.
2.3.17 Statistical analysis.
Statistical analysis was performed using Student’s t-test (2-tailed independent samples) 
with S tat View software (Abacus Software, CA). A p  value < 0.05 was taken as a 
significant difference between groups.
It should be noted that for clarity and conciseness of data, quantification of 
immunoreactivity from immunoblots in chapters three and five are presented as fold 
increase in protein expression in SHRSP/ZDF relative to WKY/lean Zucker.
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Chapter 3.
A comparative analysis of glucose transport in 
skeletal muscle of WKY and SHRSP rat.
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3.1 Introduction
Reduced insulin-stimulated glucose uptake (insulin resistance) by skeletal muscle and 
adipose tissue is of major pathogenic importance in several common human disorders 
including type 2 diabetes, hypertension, obesity and combined hyperlipidaemia, but the 
underlying mechanisms are unknown (Reaven, 1988). The primary nature of the link 
between insulin resistance and cardiovascular disorders is reinforced by the 
demonstration that the abnormality is also found in genetic models of hypertension. For 
example, Reaven and colleagues showed that the Spontaneously Hypertensive Rat (SHR) 
exhibited blunted insulin-stimulated glucose transport in adipose tissue compared to 
control normotensive animals (Reaven et al., 1989), while more recent studies have 
demonstrated grossly defective insulin inhibition of lipolysis (Aitman, 2001). These 
findings have been recently extended to a close relative of the SHR, the stroke-prone 
spontaneously hypertensive rat (SHRSP). The stroke-prone SHR represents a derivative 
of SHR that displays even higher blood pressures than the SHR and, as the name 
suggests, is more prone to cerebrovascular lesions resulting in stroke (Yamori et al., 
1974). Studies on this sub-group have shown that adipocytes from these animals exhibit 
blunted insulin-stimulated glucose transport and a reduced ability of insulin to suppress 
isoproterenol-stimulated lipolysis (Collison et al., 2000). However, although such data 
clearly show that both SHR and SHRSP exhibit insulin resistance at the cellular level in 
adipocytes, they provide no information on whether this insulin resistance is also manifest 
in skeletal muscle, the major site of post-prandial glucose disposal (James et al., 1986).
3.1.1 Exercise-stimulated glucose transport
Exercise, like insulin, stimulates glucose disposal via glucose transporter-4 (Glut-4) 
translocation in skeletal muscle (introduction, section 1.5). However, insulin and exercise 
appear to promote Glut-4 translocation through distinct intracellulai’ signalling cascades. 
Thus, in response to insulin, Glut-4 translocation is dependent upon the activation of 
phosphatidylinositol 3 -kinase (PI3K) and is sensitive to the PI3K inhibitor, wortmannin 
(Yeh et al., 1995). By contrast, exercise-stimulated Glut-4 translocation is wortmannin- 
resistant (Yeh et al., 1995) and appears to involve the activation of AMP-activated protein 
Idnase (AMPK) (Hayashi et al., 1998); (Kurth-Kraczek et al., 1999). Moreover, these two
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stimuli appear to act upon distinct intracellular pools of Glut4-containing vesicles (Ploug 
et al., 1998); (Aledo et al., 1997). Several studies have demonstrated defective insulin- 
stimulated Glut-4 translocation in patients with type 2 diabetes (Kahn, 1992), (Kahn et al.,
1992); (Garvey et al., 1992); (Garvey et al., 1998). By contrast, it is noteworthy that 
several studies have suggested that normal exercise-stimulated Glut-4 translocation can 
often be observed in the face of insulin resistance in human type 2 diabetic populations 
(Goodyear et al., 1991); (Hughes et al., 1993); (Kennedy et al., 1999); (Wojtaszewski et 
al., 2000a).
3.1.2 Aims and objectives
The stroke prone spontaneously hypertensive rat (SHRSP) is a model of human insulin 
resistance and is characterised by reduced insulin-mediated glucose disposal and 
defective fatty acid metabolism in isolated adipocytes (Collison et al., 2000).
The aims of this study were:
(i) The assessment of insulin- and AICAR-stimulated glucose transport in isolated 
skeletal muscle from male SHRSP and WKY rats.
(ii) The quantification of total cellular expression and/or subcellular localisation of 
key proteins involved in insulin-signal transduction and glucose uptake namely 
(1RS-1/2, PI3K, caveolin, flotillin, SNAREs and Glut-4).
(iii) The measurement of the activity of PKB in SHRSP and WKY skeletal muscle.
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3.2 Results.
3.2.1 The effect of insulin and AICAR on deGIc uptake by flexor digitorum brevis 
muscles.
The characteristics of the animals used in this study are shown in Table 3.1. Blood 
pressure was higher in the SHRSP compared to the WKY animals. (Collison et al., 2000) 
have previously shown that adipocytes from SHRSP animals exhibit reduced insulin- 
stimulated glucose transport in isolated adipocytes, and a blunted ability of insulin to 
suppress isoproterenol-stimulated lipolysis compared to the WKY strain. To further 
extend these findings, the ability of insulin to stimulate 2-deoxy-D-glucose (deGlc) 
uptake in isolated flexor digitorum brevis (FDB) muscles from these animals was 
examined. Figure 3.1 compares the effect of IfxM insulin and 500 pM AICAR (5- 
aminoimidazole-4-carboxamide ribonucleoside), an activator of AMPK, on deGlc 
transport into FDB muscle. As shown, muscles from SHRSP exhibit decreased insulin- 
stimulated deGlc uptake compared to WKY muscles, but the response to AICAR is 
essentially identical between the two groups.
3.2.2 Total cellular expression of Glut-4 in skeletal muscle from WKY and SHRSP 
animals.
The Glut-4 glucose transporter mediates the insulin-stimulated glucose transport in 
skeletal muscle (Ploug et al., 1998). I therefore determined the total cellular levels of 
Glut-4 in skeletal muscle membranes from SHRSP and WKY animals by quantitative 
immunoblotting. Figure 3.2 demonstrates that Glut-4 levels are similar in different 
muscles from SHRSP and WKY animals. These data indicate that reduced Glut-4 
expression cannot explain the reduced ability of insulin to stimulate deGlc uptake in 
SHRSP muscle.
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Table 3.1 Characteristics of the animal groups.
Blood pressure Blood pressure Serum glucose Weight
systolic(mm Hg) diastolic(mm Hg) (mmol/L) (g)
WKY(n=16) 126 ±11 94 ± 10  8.3 ±0 .5  283.8 ±26.5
SHRSP(n=16) 174 ±12^ 128 ±10* 8.0 ±0 .6  227.6 ±13.5*
Shown are the mean body weight, serum glucose and systolic and diastolic blood 
pressures of the 12 week old animals used in this study. * Indicates a statistical difference 
between the groups, p<0.02. Performed in collaboration with Dr. D. Graham, Dept. 
Medicine and Therapeutics, University of Glasgow.
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Figure 3.1 The effect of insulin and AICAR on deGlc uptake in FDB muscle from
SHRSP and WKY rats.
Flexor digitorum brevis muscles were incubated in Krebs Hensliet buffer for 30 min in 
the presence or absence of 1 pM insulin or 500 pM AICAR in 95 % air/5 % CO2 prior to 
assay of deGlc uptake as described. The results are expressed as a fold stimulation over 
basal (typically between 0.6 - 0.9 pmol/min/mg wet weight muscle). Basal rates were not 
significantly different between the two strains. The results shown are the mean + S.E.M. 
for three experiments. * indicates a statistically significant increase in response to insulin, 
/7=0 .02 .** indicates a significant increase in response to AICAR, p=0.05. t  indicates a 
significant increase in response to insulin compared to SHRSP basal (p<0.05) and also 
that the magnitude of the insulin response is lower in SHRSP compared to WKY muscles 
(p=0.02). t t  indicates a statistically significant increase in response to AICAR (p=0.03) 
and also refers to no significant difference in the magnitude of the AICAR effects 
between the two strains.
Figure 3.1 The effect of insulin and AICAR on deGlc uptake in FDB muscle from
SHRSP and WKY rats.
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Figure 3.2 Immunoblot analysis of Glut4 levels in muscle from SHRSP and WKY 
animals.
Shown is a representative immunoblot for Glut4 levels in either tibialis or EDL muscles 
from SHRSP or WKY animals in which 20 |rg of muscle lysate was loaded per lane. 
Shown are samples from two different animals. Quantification of Glut4 protein levels in 
these muscles from six different animals revealed no significant differences between the 
two strains.
Figure 3.2 Immunoblot analysis of Glut-4 levels in muscle from SHRSP and 
WKY animals.
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3.2.3 Immunoblot analysis of molecules involved in insulin-stimulated glucose 
transport.
In an attempt to identify differences between the SHRSP and WKY muscle that could 
account for the observed insulin resistance, the cellular content and distributions of 
proteins involved in insulin signalling and Glut-4 trafficking in muscles of these animals 
was assessed. Figure 3.3A shows an immunoblot analysis of the levels and distribution of 
IRS-1, IRS-2 and the p85a subunit of PI3K in muscle fractions. Expression levels of 
these proteins were examined in three crude subcellular fractions of muscle, specifically a 
heavy membrane fraction, a light membrane fraction (enriched in intracellular 
membranes, as evidenced by the majority of cellular Glut-4 being present in this fraction) 
and a soluble protein fraction (figure 3.3A and quantified in 3.3B). As has been reported 
in adipocytes (Clark et ah, 1998); (Clark et al., 2000); (Whitehead et al., 2000), these key 
insulin-signalling molecules were found localised predominantly in the light membrane 
and soluble protein fractions of skeletal muscle. Neither the absolute level nor the 
distribution among these fractions was significantly different between SHRSP and WKY 
animals (Figure 3.3B). Hence, it would seem unlikely that defective expression of IRS-1, 
IRS-2 or PI3K can explain the insulin resistance observed in SHRSP muscles.
3.2.4 PKB Activity in EDL and soleus skeletal muscle from WKY and SHRSP 
animals.
In order to evaluate possible signalling defects associated with insulin action in these 
muscles, the ability of insulin to stimulate protein kinase B activity was examined. PKB 
has been suggested to be involved in the insulin-stimulated translocation of Glut-4 to the 
plasma membrane of both adipocytes and muscle (Alessi et al., 1996); (Coffer et al.,
1998); (Foran et al., 1999); (Hill et al., 1999); (Wang et al., 1999). Figure 3,4 shows that 
no differences in the basal or insulin-stimulated PKB activity were observed in soleus or 
EDL muscles isolated from SHRSP and WKY animals. In addition, no differences in 
levels of serine phosphorylation of PKB at position 473 were observed between insulin- 
stimulated EDL muscles from WKY and SHRSP animals (Figure 3.5). Phosphorylation 
of the serine residues has been suggested to be required for PKB activation (Cohen,
1999). Thus, it appears that SHRSP muscles exhibit normal insulin-stimulation of PKB 
activity.
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Figure 3.3 Immunoblot analysis of insulin signalling proteins in skeletal muscle 
from SHRSP and WKY rats.
The distribution of IRS-1, IRS-2 and the p85a subunit of PI3K in skeletal muscle 
fractions from SHRSP and WKY animals were analysed by quantitative immunoblotting 
(A). The light membrane (LM) fraction contains the majority of the intracellular 
membranes, as evidenced by the majority of the cellular Glut4 being present in this 
fraction. HM = heavy membranes, Cyt = soluble protein fraction. The data presented is 
representative of three separate experiments involving different rats in which 20 ug of 
each fraction was loaded on each lane of the gel. No significant differences in either 
expression level or subcellular distribution were observed for any of the proteins studied. 
B shows quantification of four experiments of this type, in which the distribution of these 
molecules among the different fractions is presented, expressed as a % of total 
immunoreactivity (mean value presented). Experiments were performed in collaboration 
with F. Cairns, Dept. Biochemistry and Molecular Biology, University of Glasgow
Figure 3.3 Immunoblot analysis of insulin signalling proteins in skeletal muscle 
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Figure 3.4 Protein kinase B activity in muscles from WKY and SHRSP rats.
EDL or soleus muscles were incubated with or without 1 p,M insulin for 30 min and PKB 
activity determined as outlined methods. Shown is data from three experiments from six 
different animals (mean ± S.E.M.) with each condition performed in triplicate in each 
experiment. No significant differences were observed between the strains. Experiments 
were performed in collaboration with F. Cairns, Dept. Biochemistry and Molecular 
Biology, University of Glasgow
Figure 3.4 Protein kinase B activity in muscles from WKY and SHRSP rats.
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Figure 3.5 Immunoblot analysis of PKB serine-473 phosphorylation in EDL 
muscle lysates from WKY and SHRSP rats.
EDL muscles were incubated with or without 1 |LtM insulin for 30 min and whole muscle 
lysates were made as outlined in methods. Shown is a representative immunoblot for 
PKB-PH domain and phosphorylated serine-473 PKB levels in EDL muscles from 
SHRSP or WKY animals in which 10 ug of muscle lysate was loaded per lane. PKB-PH 
domain is shown to illustrate that the observed changes in PKB serine-473 
phosphorylation is not a consequence of global changes in PKB expression. The 
experiment was repeated three times with similar results. No significant differences in 
PKB serine-473 phosphorylation were observed between the strains.
Figure 3.5 Immunoblot analysis of PKB serine-473 phosphorylation in EDL 
muscle lysates from WKY and SHRSP rats.
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3.2.5 Immunoblot analysis of SNARE proteins in skeletal muscle from SHRSP and 
WKY rats.
To further elucidate the defects leading to insulin resistance in SHRSP muscle, I 
compared the total cellular content of VAMP2, VAMP3/cellubrevin and syntaxin 4, the 
SNARE proteins that mediate Glut-4 translocation (see (Rea and James, 1997) for review) 
in total muscle extracts. Quantification of this data revealed that VAMP2 expression was 
elevated 2.9 ± 0.2-fold in EDL and 2.7 ±  0.3-fold in tibialis muscles from the insulin 
resistant SHRSP strain compared to WKY animals (p=0.02 for both). 
VAMP3/cellubrevin levels was statistically significant only in the tibialis muscle (2.5 + 
0.13-fold in tibialis, /?<0.05). Syntaxin 4 levels were also increased in EDL muscles from 
SHRSP animals (2.08 + 0.2-fold, p=0.03) and tibialis (2.8 + 0.05-fold, p=0.02). By 
contrast, cellular levels of AMPKa2, PKB/cAKT and eNOS did not differ significantly 
between strains in either muscle (Figure 3.6). A M PK al was barely detectable in these 
tissues, consistent with published results (data not shown) (Cheung et al., 2000).
3.2.6 Immunoblot analysis of caveolin and flotillin in skeletal muscle from SHRSP 
and WKY rats.
Recent studies have implicated caveolae and/or lipid rafts as possible components of the 
insulin signalling apparatus. I therefore examined the level of expression of caveolin 
isoforms in muscle tissue from SHRSP and WKY animals, and also the expression of 
flotillin, a protein enriched in membrane rafts and which has been implicated as a 
component of the insulin-signalling cascade. Levels of expression of caveolin-1 and 
flotillin were found to be markedly elevated in the SHRSP animals compared to controls 
(figure 3.7). In EDL muscle, caveolin expression was increased 3.4 ± 0.4-fold (p=0.005) 
and in tibialis by 4.34 + 0.4-fold (^=0.002), Similarly, flotillin levels were also increased 
by 2.9 ± 0.05-fold and 2.7 + 0.12-fold in EDL and tibialis muscles, respectively (p<0.05 
for both).
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Figure 3.6 Immunoblot analysis of SNARE protein levels in skeletal muscle from
SHRSP and WKY rats.
Shown are representative immunoblots (A) in which 20 pg of protein lysates prepared 
from skeletal muscle of male SHRSP or WKY animals were analysed by SDS-PAGE and 
immunoblotting with the antibodies indicated. B presents quantification of 4 experiments 
of this type, with the relative level of expression in SHRSP muscle expressed as a fold of 
that observed in the conesponding WKY muscle (+ S.E.M.). Data from two separate 
experiments is shown for each of EDL and tibialis muscles. Results obtained using 
antibodies specific for eNOS, AMPK and PKB-P are shown to illustrate that the observed 
changes in SNARE protein expression are not a consequence of global increases in the 
expression of proteins implicated in insulin or exercise signal transduction. Details of 
statistically significant differences are not presented on the graph for clarity but are 
included in the text.
Figure 3.6 Immunoblot analysis of SNARE protein levels in skeletal muscle from
SHRSP and WKY rats.
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Figure 3.7 Immunoblot analysis of caveolin and flotillin in skeletal muscle from 
SHRSP and WKY rats.
Shown are representative immunoblots (A) in which 20 pg of protein lysates made from 
skeletal muscle of male SHRSP or WKY animals were analysed by SDS-PAGE and 
immunoblotting with the antibodies indicated. Shown is data from two separate animals 
of each strain; note that the blots presented are deliberately over-exposed in order to show 
the level of caveolin and flotillin present in WKY animals. B presents quantification of 4 
experiments of this type, with the relative level of expression in SHRSP muscles 
expressed as a fold of that observed in the conesponding WKY muscle (+ S.E.M.). 
Statistically significant increases in SHRSP compared to WKY are indicated by: * 
p=0.005, ** p=0.002, f  p<0.05.
Figure 3.7 Immunoblot analysis of caveolin and flotillin in skeletal muscle from
SHRSP and WKY rats.
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3.3 Discussion
Glucose transport in skeletal muscle is stimulated both by insulin and exercise. Insulin- 
stimulated glucose transport is reduced in type 2 diabetes and insulin resistance, but 
several studies have suggested that exercise-stimulated glucose transport is unaffected in 
these states (Hughes et al., 1993); (Kennedy et al., 1999); (Wojtaszewski et al., 2000a); 
(Houmard et al., 1995). Understanding the molecular basis for defective insulin action is 
of fundamental importance, given the greatly increased incidence of cardiovascular 
disease in individuals with type 2 diabetes (Yip et al., 1998); (Laakso, 1999). This study 
has examined the ability of insulin and AICAR (an activator of AMPK) to modulate 
glucose transport in skeletal muscle from SHRSP animals compared to the normotensive, 
insulin-sensitive WKY strain. I have shown that muscle from the SHRSP exhibits 
blunted insulin-stimulated glucose transport (figure 3.1), in agreement with the previous 
observation that adipocytes from these animals also exhibit defective insulin action 
(Collison et al., 2000).
AMPK is activated in response to exercise in both human and rodent muscle (Hayashi et 
al., 1998); (Kurth-Kraczek et al., 1999). AMPK has, therefore, been suggested to play a 
crucial role in exercise-stimulated glucose transport based upon studies showing that 
treatment of muscle with AICAR can activate glucose transport by a mechanism similar 
to that induced by exercise (Hayashi et al., 1998); (Kurth-Kraczek et al., 1999). 
Strikingly, AICAR is able to activate glucose transport to a similar extent in muscle from 
both SHRSP and WKY strains (Figure 3.1), suggesting that the insulin resistance 
observed in the SHRSP is confined to an insulin-specific step in the activation of glucose 
transport. This step is not expression of the major insulin-responsive glucose transporter, 
Glut-4, as levels of expression of this protein were found to be similar in all muscles 
examined (EDL, tibialis and FDB) (Figure 3.2).
In an attempt to identify possible sites of lesion in the insulin signalling cascade, the 
levels of expression and subcellular localisation of several key proteins implicated in 
insulin-stimulated glucose transport were examined, specifically IRS-1, IRS-2 and PI3K 
(Figures 3.3A/B) (White and Kahn, 1994); (White, 1997); (Inoue et al., 1998). The 
subcellular distribution of IRS-1 and IRS-2 is modulated by insulin (Inoue et al., 1998).
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The association of IRS-1 with a cytoskeletal ‘scaffold’ adjacent to the plasma membrane 
has been suggested to be a fundamental aspect of insulin signalling in adipocytes (Clark 
et a l , 1998); (Clark et a l, 2000). In response to insulin treatment, IRS-1 is released from 
this scaffold and appears to behave as a soluble protein, moving from the particulate to 
the cytosolic fraction upon subcellular analysis (Clark et a l ,  1998). In an effort to 
address whether 1RS proteins were cytosolic or particulate in muscle, we subjected 
muscle homogenates to subcellular fractionation. Analysis of the subcellular distribution 
of IRS-1 and IRS-2 revealed that these molecules were associated with both heavy and 
light membrane fractions, with some immunoreactivity evident in the cytosolic fraction 
(Figure 3.3A). However, comparison of these fractions from SHRSP and WKY strains 
revealed no differences in either total level of expression or subcellular distribution 
(Figure 3.3B). Hence, it would appear unlikely that the primary defect in insulin action in 
the SHRSP lies at the level of expression or localisation of these proteins. Similarly, 
levels of expression of AMPKa2 (the major isofoim in skeletal muscle (Cheung et a l, 
2000), both PKB/cAKT and eNOS were similar between the two groups (Figure 3.6).
In an effort to address whether the extent of activation of downstream signalling 
molecules differed between the two strains, we assayed PKB/cAKT activity in both 
soleus and EDL muscles from SHRSP and WKY animals. As shown in Figure 3.4, no 
difference in either basal or insulin-stimulated PKB activity was observed between these 
strains. These data suggest that the defect in insulin action observed in the insulin- 
resistant SHRSP is not a consequence of defective activation of this important kinase.
Insulin-stimulated Glut-4 translocation represents a highly regulated vectorial delivery of 
defined intracellular cargo to the plasma membrane. The fidelity of this response is 
mediated, at least in part, by SNARE proteins (reviewed in (Rea and James, 1997) and 
(Pessin et a l, 1999)). To examine potential defects in the translocation of Glut-4, total 
cellular expression of the SNARE proteins, syntaxin 4 and VAMP2, were quantified. 
GST-fusion proteins for each of these SNARE proteins inhibit insulin-stimulated Glut-4 
translocation in muscle and fat cells, arguing cogently for a crucial functional role of 
these proteins in insulin action (Millar et a l, 1999); (Tellam et a l, 1997); (Martin et a l, 
1998); (Volchuk et a l, 1996); (Oison et a l, 1997); (Cheatham et a l ,  1996). Moreover, in 
the insulin resistant and diabetic ZDF rat VAMP2 and syntaxin 4 SNARE protein
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expression is significantly up regulated compared with lean animals (Maier et ah, 2000). 
Similar data was observed here, VAMP2 expression was doubled in both EDL and tibialis 
muscle from SHRSP compared to WKY (p<0.01 for both muscles), and syntaxin 4 levels 
were also increased. Such data suggest that up-regulation of SNARE proteins may be 
evident in a range of insulin resistant models. However, further work will be required to 
determine whether these changes are causal or adaptive.
One other major difference between these two strains was identified in this study. 
Specifically, the expression of caveolin-1 and flotillin were markedly elevated in muscle 
from the insulin resistant SHRSP compared to WKY animals (Figure 3.7A/B). Caveolin 
is the major structural protein of caveolae, flask-like invaginations of the cell surface 
(Smart et al., 1999). Caveolae have been implicated in the spatial organisation of 
intracellular signalling cascades, and several studies have reported localisation of insulin 
receptors to these structures (Baumann et ah, 2000); (Mastick et al., 1995); (Mastick and 
Saltiel, 1997); (Gustavsson et al., 1999). Caveolin expression is induced upon 
differentiation of adipocytes (Scherer et al., 1994), and insulin stimulates tyrosine 
phosphorylation of caveolin in fat cells (Mastick and Saltiel, 1997). More recently, the 
localisation of insulin-regulated CAP proteins to caveolae has argued strongly for an 
important (but as yet undefined) role for caveolae in insulin signal transduction (Baumann 
et al., 2000); (Saltiel, 1996). The over-expression of caveolin observed in skeletal muscle 
of the SHRSP strain may therefore be an important contributory factor to the insulin 
resistance observed in these animals. Whether increased expression of caveolin could 
result in the sequestration of important insulin signalling components in an inactive 
environment or act as an inhibitor of down-stream effects remains to be determined. 
Strikingly, the lipid raft associated protein, flotillin is also markedly over-expressed in 
SHRSP muscles compared to WKY. Flotillin has been proposed to localise a protein 
complex of CAP-Cbl proteins to lipid rafts in adipocytes which may play a crucial role in 
propagation of the insulin signal, at least in adipocytes (Baumann et al., 2000), The fact 
that both caveolin and flotillin are over-expressed in muscle from the SHRSP suggests 
that over expression of caveolae-associated proteins may act to blunt the ability of insulin 
receptors to signal to proximal molecules in the insulin signalling cascade. Further 
studies will be required to test this hypothesis in a systematic fashion.
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In summary, the data presented here shows that skeletal muscle of SHRSP exhibits 
reduced insulin-stimulated glucose transport compared to WKY isogenic controls. The 
response to activation of AMPK by AICAR treatment was, however, indistinguishable 
between the two strains, suggesting that the defect in insulin action lies on a specific arm 
of the machinery or signalling cascade activated by insulin. Furthermore, the SHRSP, 
like the insulin resistant ZDF rat, exhibits elevated VAMP2 and syntaxin 4 expression in 
skeletal muscle, suggesting that this defect may be common to a range of rodent models 
of insulin resistance. Finally, I report for the first time that caveolin and flotillin are over­
expressed in the insulin resistant muscle tissue. This result may be of considerable 
importance, given the proposed central role of caveolae in the organisation of the insulin 
signalling system.
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Chapter 4.
Establishment of skeletal muscle cell cultures from 
WKY and SHRSP rats and a comparison of the 
effects of insulin and AICAR on deGlc transport
in these cultures.
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4.1 Introduction
Skeletal muscle is the major site for insulin-stimulated glucose uptake facilitated by the 
glucose transporter 4 (Glut-4), DeFronzo et al and Katz et al highlighted the dominant 
role of skeletal muscle in whole body glucose disposal and its apparent pathophysiology 
in type 2 diabetes (DeFronzo et al., 1981); (Katz et al., 1983); (DeFronzo et a l, 1985). 
Study of glucose uptake by intact muscle is prone to problems, such as uneven exposure 
of muscle cells to substrate and agonist. In addition, intact muscle will be composed of 
other tissues such as nerves, connective tissue, endothelial cells and fat, all of which add 
further ambiguity to results (Yaffe and Saxel, 1977). Use of cultured skeletal muscle 
cells offers the chance of isolating a relatively pure population of cells, which can be 
manipulated more easily, with greater scope for experimental analysis under better- 
defined conditions. This culture system though is not without its fair share of criticism 
and problems. Present methodologies for growth and differentiation of such cells do not 
fully recapitulate in situ conditions such as innervation (Smith and Lawrence, Jr., 1984); 
(CodeiTe et a l, 1992), perfusion (Cieland et a l, 1998) and coordinated contraction (Ploug 
and Ralston, 1998) all of which have been shown in animal studies to have dramatic 
effects on skeletal muscle glucose disposal In defence, it seems clear that such systems, 
while not a perfect model of a working muscle, can begin to dissect out environmental 
effects from genetic ones, moreover by using both in situ and in vitro methodologies a 
greater understanding of this interplay can be achieved.
4.1.1 Skeletal muscle cell cultures
Rinaldini and Konigsberg were the first to culture skeletal muscle cells by isolating 
satellite cells from mature muscle (Konigsberg, 1979). Nowadays, skeletal muscle cell 
culture systems are widely used as experimental systems in many areas of research, from 
the study of the highly regulated process of myogenesis to the study of muscle disease 
states such as the muscular dystrophies and metabolic derangements that characterise 
insulin resistance (Comelison and Wold, 1997); (Yeaman et a l, 2001).
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4.1.2 Regulators of myogenesis
Skeletal muscle develops from pluripotent mesodermal cells (reviewed in (Arnold and 
Winter, 1998); (Ordahl and Williams, 1998)). These cells give rise to embryonic 
myogenic cells, which in turn produce the myoblast pool that terminally differentiate and 
fuse to become myotubes (Arnold and Winter, 1998). These events are in part regulated 
by a group of transcription factors known as the muscle determining factors (MDFs). In 
mammals, there are four MDFs - (myoD, myf5, MRF4 and myogenin) (Weintraub, 1993). 
MyoD and myf5 expression in embryonic myogenic cells provoke differentiation of these 
cells into multiple myoblasts through mitotic expansion (Comelison et al., 2000). In later 
stages of myoblast diversification and subsequent differentiation to form fused 
multinucleated myotubes, myogenin, MRF4 and other structural muscle proteins such as 
desmin and muscle-cadherin are expressed (Comelison and Wold, 1997). A small 
minority of embryonic myogenic cells are mitotic all y quiescent and associate closely with 
the newly fornied myotubes eventually residing between the basal lamina and 
sarcolemma of mature myofibres. These precursor cells are called satellite cells and do 
not express the four MDFs (Comelison and Wold, 1997); (Ordahl et al., 2000). By taking 
advantage of the ability of satellite cells to proliferate along myogenic lines and 
differentiate into myotubes, the study of muscle cell biology has increased our 
understanding of the developmental and cellular processes of muscle.
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Figure 4.1 Molecular regulation of myogenesis.
(A) Targeted inactivation o f  the M DFs has defined two groups o f  factors. The primary
MDFs, MyoD and Myf-5, are required at the determination step for commitment o f the
progenitor cell to the myogenic lineage. The committed cells (myoblasts) can proliferate
and further differentiate into myotubes under the action o f  the secondary MDFs,
myogenin and MRF4. Adapated from  Sabourin and Rudnicki, 2000. (B) Phase image o f
m yohbre with satellite cells arrowed. Reproduced from Com elison and Wold, 1997. (C) Upon
activation, quiescent satellite cells (indicated by arrow), first express Myf-5 and MyoD
before co-expressing both and progressing through the developmental program to the
differentiated m ultinucleated myotube. In the absence o f  M yoD or expression o f Myf-5
alone, satellite cells appear to exhibit a propensity for self-renewal rather than
progression through the differentiation program (yellow arrow). Reproduced from  Sabourin 
and Rudnicki, 2000.
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4.1.3 Role of skeletal muscle in carbohydrate metabolism
As mentioned eaiiier skeletal muscle by virtue of its considerable contribution to total 
body mass (approximately 35-45%) is responsible for a large part (approximately 80%) of 
the post-prandial glucose uptake (DeFronzo et ah, 1981). In general, this glucose has two 
fates, it can be stored as glycogen through the process of glycogen synthesis or it can be 
used via the glycolytic pathway to produce energy. These aie dynamic opposing 
processes and which one takes precedence is controlled to a large extent by the 
continually shifting cellular energy demand (Salway, 1994). Therefore, at times when the 
cellular energy demand is high as is the case during exercise, the glycolytic pathway will 
be dominant, as will pathways like glycogenolysis, which liberate glucose from 
intracellular glycogen stores. In contrast, at rest when energy demands are low glucose 
will be stored, thus storage pathways like glycogenesis are dominant (Salway, 1994). In 
addition, during times where glucose is not available and glycogen stores are depleted as 
in the extreme case of starvation alternative sources of energy must be found. An 
example of this is the de novo synthesis of glucose in the liver and kidneys from protein 
and other non-carbohydrate precursors by a process called gluconeogenesis. Usually the 
protein comes from muscle breakdown itself. This however is not advantageous since 
muscle protein is functionally important for survival. The preferred alternative energy 
source is fatty acids derived from fats, which produces energy via a process called 
|3-oxidation. Fats, stored as triglycerides are a very good store of energy and by the 
action of lipases, fatty acids are liberated in a process called lipolysis (Salway, 1994). 
The opposite scenario to starvation would be that of excess food (carbohydrate) intake 
surplus to physical requirement. Under such conditions glycogen storage in muscle and 
liver are saturated and the process of lipogenesis favours a shift to storage as fats. 
Therefore, skeletal muscle in addition to its known structural and mechanical functions 
has an important role in the regulation of the organism’s energy homeostasis.
4.1.4 Cultured skeletal muscle cells: a model for the study of insulin resistance.
A number of studies have shown that skeletal muscles from type 2 diabetic patients are 
insulin resistant and show a marked reduction in insulin-stimulated glucose transport 
(Dohm et al., 1988); (Andreasson et al., 1991); (Krook et al., 1998). In addition, skeletal 
muscle cells cultured from type 2 diabetic patients and non-diabetic relatives of type 2 
diabetic families were found to be insulin resistant (Henry et al., 1995); (Jackson et al.,
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2000). Such data strongly supports the view that inheritable factors predispose such 
individuals to peripheral insulin resistance and NIDDM at the cellular level in the absence 
of circulating factors. This maintenance, by cultured skeletal muscle cells, of the 
metabolic and biochemical properties of skeletal muscle further highlights the usefulness 
of this system in studying diseases such as insulin resistance.
4.1.5 Aims and objectives.
It is possible that the insulin resistance observed in the SHRSP may be secondary to 
changes in physiology, such as altered blood flow to the muscle beds by defective 
vasodilatation in response to insulin, or by changes in circulating factors which regulate 
peripheral insulin sensitivity. By way of addressing this, the objectives of this chapter 
were to:
(i) detail the methodology for the isolation and growth of muscle satellite cells
from SHRSP and WKY animals.
(ii) provide evidence that these cells are of myogenic origin and possess the
insulin sensitive facilitative glucose transporter Glut-4.
(iii) develop methodology for the measurement of deOlc transport stimulated by 
insulin and other agents.
(iv) examine the effect of various growth conditions and differentiation time
periods on insulin-stimulated deOlc uptake.
(v) measure, under optimal conditions established above, the effect of insulin and
AICAR on deGlc transport in the presence and absence of wortmannin in 
skeletal muscle cells derived from SHRSP and WKY rats.
In summary, this chapter details the methodological development and characterisation of 
skeletal muscle cell cultures from the insulin-sensitive WKY rat and the insulin-resistant 
SHRSP rat within the context of insulin- and non-insulin- mediated glucose transport.
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4.2 Method development and Results
4.2.1 Isolation of myoblast cell cultures.
Primary skeletal muscle cultures were grown from satellite cells isolated from dissociated 
muscle tissue by methods adapted from (Yasin et al., 1977); (Konigsberg, 1979); (Blau 
and Webster, 1981); (Sarabia et al., 1990) and Yeaman S.J., University of Newcastle, UK, 
personal communication), Male 12-week-old rats were sacrificed by CO2 overdose and 
the extensor digitorum longus (EDL) muscle was dissected and cleaned of connective 
tissue. All subsequent procedures were performed under sterile conditions. The muscles 
from one rat were washed twice in sterile PBS (room temperature) and minced finely with 
sterile scissors in a petri dish to aid enzymatic dissociation of satellite cells. The minced 
muscle was transferred to a foil-sealed 25ml sterile conical flask containing a sterile 
magnetic stirring bar. The muscle was enzymatically dissociated at 37°C by three 10- 
minute rounds of mixing with 10ml of 300Units/ml Collagenase (Type lA ) made up in 
0.25% w/v trypsin on a magnetic stiner set to 300 revolutions per minute. After each 
round the mixture was triturated 10 times using a sterile 12ml pipette and particulate 
matter was allowed to settle for 5 minutes. The supernatant containing the liberated cells 
from each round was carefully removed to a 50ml coming tube, taking care not to disturb 
the pellet of undigested tissue, neutralised with 2ml of 100% FBS and centrifuged at 1000 
X g for 5 min. The resulting pellet containing the liberated cells was resuspended in 4 ml 
of growth medium (Hams-FlO, 20% FBS, 1% Chick Embryo extract, lOOU/ml 
penicillin/streptomycin, 1% L-glutamine) warmed to 37°C and pre-equilibrated in a tissue 
culture incubator set to a 5% CO2 humidified atmosphere. The resuspended cells were 
pre-plated on a non-coated 75cm^ tissue culture flask at 37°C in a 5% CO2 humidified 
atmosphere for two hours. This step removes any contaminating fibroblast cells owing to 
the ability of fibroblast cells to bind more tenaciously to non-coated plasticware than 
muscle cells. Following this purification step the media containing unbound cells was 
transferred to 25cm^ collagen-coated flasks as collagen coated substrata greatly benefit 
the growth of skeletal muscle cells (Hauschka and Konigsberg, 1966).
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4.2.2 Maintenance of rat skeletal muscle cell cultures.
Cells were fed every third day with growth medium (4.2.1) and passaged once 50% 
confluent. Cells were seeded onto collagen-coated plasticware at 1.2x10^ cells per 6 well 
plate or 4x10^ cells per 75cm^ flask. Cells were differentiated when 70-80% confluent by 
replacing growth medium with differentiation medium (a-M EM , 2% FBS, 1% L- 
glutamine, 100 U/ml penicillin/streptomycin). Cells were used between six and eight 
days post differentiation.
4.2.3 Preparation of cultures prior to use.
Between six and eight days post differentiation when cultures had reached confluence and 
fused, differentiation medium was replaced with serum free a-M EM  supplemented with 
lOOU/ml penicillin/streptomycin and 1% L-glutamine for 24 hours prior to use.
4.2.4 Whole cell indirect immunofluorescence of cultured cells.
In order to ascertain whether these cultured cells were indeed myogenic, whole-cell 
indirect immunofluorescence was performed as outlined in section 2.3.14. MyoD and 
myogenin are exclusively expressed in myogenic cells and as such are considered muscle 
cell specific markers (Comelison et al., 2000). These two transcription factors are 
localised in the nuclei where they are involved in the regulation of muscle cell 
development. The representative fluorescence microscope images illustrated in figure 4.2 
clearly show positive fluorescence within the nuclei of these cells, indicating the presence 
of both MyoD and Myogenin in these putative muscle cells. It is noteworthy that these 
cells refeiTed to as myotubes are highly elongated and multinucleated, a common feature 
of fused muscle cells. Positive staining of skeletal muscle a-actin and desmin, gold- 
standard skeletal muscle-specific structural proteins, are also seen in these cultured cells 
confirming that these are cultured skeletal muscle cells (data not shown).
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Figure 4.2 Immunofluorescence detection of myogenic markers in skeletal muscle 
cell cultures from WKY and SHRSP rats.
Shown are representative fields of differentiated myotubes from SHRSP and WKY 
strains, stained with antibodies against Myogenin or Myo D. Note the presence of 
multinucleated cells, characteristic of myotubes.
Figure 4.2 Immunofluorescence detection of myogenic markers in skeletal muscle 
cell cultures from WKY and SHRSP rats.
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4.2.5 Insulin-stimulated uptake and metabolism of 2-deoxy-D-glucose by cultured 
skeletal muscle cells.
In order to utilise these cultured muscle cells in a comparative analysis of glucose 
transport in WKY and SHRSP animals, it was important to establish an optimised 
methodology for the measurement of glucose uptake. A number of groups have 
examined glucose transport in cultured skeletal muscle and adipocyte cells (Klip et al., 
1984); (Sarabia et al., 1990); (Gould et al., 1994); (Blair et al., 1999). Using adaptations 
of these methods, coupled transport and phosphorylation of glucose was measured using 
the D-glucose analogue 2-deoxy-D-glucose (deGlc). DeGlc is transported into the cell by 
glucose transporters and is phosphorylated by hexokinase but cannot be further 
metabolised. In addition, phosphorylation of deGlc prevents exit from the cell and 
maintains a low concentration of deGlc that maintains unidirectional uptake 
uncomplicated by efflux, allowing simple kinetic measurements. Radiolabelled deGlc 
allows the quantitative measurement of cell accumulation via liquid scintillation 
spectrophotometry. In principle under conditions where transport of deGlc is not rate 
limiting, carrier-mediated transport is related to the amount of cell-associated 
radioactivity in the absence of any non-specific binding of radiolabelled deGlc to the cell 
surface.
In order to determine conditions where deGlc transport was not rate limiting, serum 
starved cultured myotubes (4.2.2-4.2.3) were washed two times in 3 ml of Krebs Ringer 
Hepes buffer pH7.4 and incubated for 30 min at 37°C in the presence or absence of 1(tM 
insulin. Uptake was initiated by addition of 10|liM  deGlc (lp,Ci/ml) for 3-15 min. 
Specific carrier mediated deGlc uptake was determined by calculating the cell associated 
radioactivity in the presence of lQ|aM cytochalasin B. Cytochalasin B blocks carrier 
mediated transport and hence indicates non-carrier mediated but cell associated 
radioactivity. DeGlc uptake was stopped by rapidly washing the tissue culture plates with 
three changes of ice cold PBS. Cells were lysed in 1ml of 1% Tx-100. The lysate was 
transferred to scintillation tubes and cell associated radioactivity was determined by liquid 
scintillation spectrophotometry.
As shown in figure 4.3, deGlc uptake by WKY skeletal muscle cultures is linear up to 15 
minutes in both the presence and absence of IpM  insulin, with a significant increase in
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deGlc uptake over basal seen at 5, 10 and 15 minutes. This data clearly shows that from 3 
to 15 minutes insulin-mediated deGlc transport is not rate limiting with respect to this 
concentration of lOjUiM of deGlc. Interestingly, in the absence of insulin, deGlc is 
transported into the cell but this non-insulin- yet time-dependent increase is not rate 
limiting up to 15 minutes. This basal uptake may be the result of Glut-1 activity that is 
present at the cell surface in muscle cells (Klip and Paquet, 1990); (Gaster et al., 2000). In 
summary, it is noteworthy that a 30-minute stimulation of insulin significantly increased 
deGlc uptake over basal transport after 5 ,10  and 15 minutes incubation with deGlc. This 
increase over basal transport gave a better signal to noise ratio at the later time points of 
10 and 15 minutes. All subsequent experiments utilised a 10-minute incubation time with 
deGlc. In comparison, deGlc uptake by the skeletal muscle L6 cell line is linear up to 30 
minutes in both the presence and absence of IpM  insulin, with a significant increase in 
deGlc uptake over basal seen at the time points indicated (figure 4.4). However, the 
amount of glucose transported by L6 cells is approximately half that of WKY skeletal 
muscle cells at all corresponding time points studied (figure 4.4).
In order to determine optimal agonist treatment timings for maximal effects on a 10- 
minute deGlc uptake, increasing incubation times of IfiM insulin, 500pM AICAR and 
500p.M arsenite were examined. Arsenite is a metabolic poison and has been shown to 
increase glucose transport in muscle cells independently of PI3K activity (McDowell et 
al., 1997). Insulin caused a time-dependent increase in deGlc uptake, with significant 
maximal effects on deGlc uptake being observed by 20-30 minutes (figure 4.5). The 
magnitude and time courses are similar to those observed by others in response to insulin 
(Jackson et al., 2000); (Ciaraldi et al., 1995). Arsenite and AICAR also showed a time- 
dependent increase in deGlc uptake (figure 4.6), with significant effects on deGlc uptake 
being observed by 5 and 20 minutes, respectively. Both compounds showed maximal 
stimulation of deGlc transport by 30 minutes (figure 4.6). Therefore a 30-minute 
incubation with agonists, prior to a 10-minute deGlc uptake, was used in all subsequent 
experiments. Insulin also gave a time-dependent increase in deGlc uptake, with maximal 
effects on deGlc transport observed by 30 minutes in L6 cells (figure 4.7).
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Figure 4.3 Time course analysis of deGlc uptake by WKY skeletal muscle 
cultures.
The effects of increasing incubation times (3-15 mins) of lOpM deGlc on uptake 
(pmol/min/well) by semm starved differentiated WKY skeletal muscle cells incubated for 
30 mins in the presence (• )  or absence (o) of IfxM insulin are shown. Data are the means 
± S.E.M. from four separate experiments. Within each experiment, determinations were 
performed in triplicate. Methods used for treatment and uptake measurements are 
described in 4.2.5. * indicates a significant increase in response to insulin in WKY
cultures at 5 mins, p=0.02. ** indicates a significant increase in response to insulin in 
WKY cultures at 10 mins, p=0.01. *** indicates a significant increase in response to 
insulin in WKY cultures at 15 mins,/?=0.001.
Figure 4.3 
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Figure 4.4 Time course analysis of deGlc uptake by L6 muscle cells.
Shown are the effects of increasing incubation times (3-60 mins) of lOjuiM deGlc on 
uptake (pmol/min/well) by serum starved differentiated L6 skeletal muscle cells 
incubated for 30 mins in the presence (■) or absence (□) of IjnM insulin. Data are the 
means + S.E.M. from three independent experiments. Within each experiment, 
determinations were performed in triplicate. Methods used for treatment and uptake 
measurements are described in 4.2.5. *, ***, **** indicates a significant increase in
response to insulin over corresponding basal at 5, 10, 20, 30 mins, p=0.005, p=0.01, 
/?=0.0006, p=0.0001, respectively.
Figure 4.4 Time course analysis of deGlc uptake by L6 cells.
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Figure 4.5 Time course analysis of insulin-mediated deGlc uptake by WKY
skeletal muscle cultures.
Shown are the effects of increasing insulin (IpM ) incubation times (as indicated) on a 10 
min deGlc uptake (pmol/min/well) by serum starved differentiated WKY skeletal muscle 
cells. Data are the means ± S.E.M. from four independent experiments. Within each 
experiment, determinations were perfoimed in triplicate. Methods used for treatment and 
uptake measurements are described in 4.2.5. * indicates a significant increase in response 
to a 20 min insulin stimulation in WKY cultures, p=0.01. ** indicates a significant 
increase in response to a 30 min insulin stimulation in WKY cultures, p=0.003.
Figure 4.5 Time course analysis of insulin-mediated deGlc uptake by WKY
skeletal muscle cultures.
II
i l
Q
9
8
* *
7
6
5
4
3
2
1
0
100 20 30 40
Time (minutes)
89
Figure 4.6 Time course analysis of AICAR- and arsenite-mediated deGlc uptake
by WKY skeletal muscle cultures.
Shown are the effects of increasing AICAR (500p,M) and arsenite (500|LiM) incubation 
times on a 10 min deGlc uptake (pmol/min/well) in serum starved differentiated WKY 
skeletal muscle cells. Data are the means ±  S.E.M. from four independent experiments. 
Within each experiment, detemiinations were performed in triplicate. Methods used for 
treatment and uptake measurements are described in 4.2.5. ** indicate a significant 
increase in response to arsenite over coiTesponding basal at 5, 10, 20, 30, 60 min, 
p<0.005. t ,  t t  indicate a significant increase in response to a AICAR over corresponding 
basal at 20, 30 and 60 min, p=0.05 and p=0.01, respectively.
Figure 4.6 Time course analysis of AICAR- and arsenite-mediated deGlc uptake
by WKY skeletal muscle cultures.
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Figure 4,7 Time course analysis of insulin-mediated deGlc uptake by L6 muscle
cultures.
Shown are the effects of increasing insulin (l|iiM) incubation times (as indicated) on 
deGlc uptake (pmol/min/well) by serum starved differentiated L6 skeletal muscle cells. 
Data are the means + S.E.M. from three independent experiments. Within each 
experiment, determinations were performed in triplicate. Methods used for treatment and 
uptake measurements are described in 4.2.5. * indicates a significant increase in response 
to insulin in L6 cultures at 30 min compared to 0 min.
Figure 4.7 Time course analysis of insulin-mediated deGlc uptake by L6 muscle
cultures.
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4.2.6 Assessment of growth media on insulin-stimulated deGlc uptake.
A number of variations on the growth and differentiation conditions have been reported to 
contribute to overall cellular health and responsiveness of skeletal muscle cells. Of 
particular interest here are the semi-defined serum-free media of Allen and colleagues and 
that of Ham and colleagues, which support the growth and proliferation or cultured rat 
and human skeletal muscle cells, respectively (Allen et ah, 1985); (Ham et ak, 1988). 
Both of these media do not require chick-embryo-extract (CEE). Allen et al and Ham et 
al found that their media gave better growth results in comparison to the widely used CEE 
containing growth medium described in 4.2.1. Both these media have in common the 
requirement of a cocktail of various growth factors and supplements, which within their 
respective systems are shown to be beneficial in the growth of those muscle cells. I have 
taken supplements common to both recipes to replace the requirement for CEE in the 
present growth medium. This medium will be termed CEE-free growth medium and 
contains Ham’s-FlO nutrient medium, 20% FBS, 1% penicillin/streptomycin, 1% L- 
glutamine, 500 mg/1 BSA fraction (V), 500mg/l Pederson fetuin, 1 |aM  dexamethasone, 1 
nM insulin.
Growth of skeletal muscle cells requires a two-step media change (Konigsberg, 1979). 
The first is optimised for the proliferation of cells whilst minimising differentiation and is 
therefore termed growth medium. The second is optimised for fusion of the cultured 
unicellular myoblast to the multinucleated syncytial myotube and is termed differentiation 
medium (Konigsberg, 1979). Some groups routinely use DMEM nutrient based 
differentiation medium, whereas others use a-M EM  nutrient medium.
In order to examine the effect variations in cell growth and differentiation conditions have 
on deGlc transport, cells were grown in CEE containing or CEE-free growth media, and 
fed as described in 4.2.2. Cells were differentiated once 70-80% confluent as described in 
4.2.2. Cells grown in CEE-free growth medium were differentiated as described in 4.2.2 
using a-M EM  based nutrient medium. Cells grown in the CEE containing growth 
medium were differentiated using either a-M EM  based nutrient medium described in 
4.2.2 or DMEM based nutrient medium. Media changes and all other supplements such 
as antibiotics and serum were maintained as described in 4.2.2. Figure 4.8 shows that of 
all the variations tested, cells grown in CEE-free growth medium (C) gave the best
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response to l|LtM insulin (2.5 ± 0.21 fold increase over basal), a significant p<0.05 
increase over the previously used CEE containing growth media (A), which also gave a 
significant 1.57 + 0.06, p=0.0007, fold increase over basal in response to insulin. 
However, substitution of a-MEM- for DMEM-based nutrient differentiation media (B) 
abolishes insulin-stimulated glucose transport in cultured myotubes, showing no 
significant increase in deGlc transport compared to basal transport. In this system, the 
present experiment suggests that cells grown in CEE-free growth media perform better 
with respect to insulin-stimulated glucose transport in contrast to cells grown in CEE 
containing growth media or differentiated using DMEM based nutrient media. Cells 
grown in CEE-free growth media retained, morphologically, all the characteristics of 
muscle cells previously seen (see figure 4.2). All subsequent experiments were 
performed using CEE-free growth media and a-MEM differentiation media.
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Figure 4.8 The effects of various grovrth and differentiation media on insulin- 
stimulated deGlc uptake by WKY skeletal muscle cultures.
The effects of various media manoeuvres on insulin-stimulated deGlc uptake in cultured 
WKY skeletal muscle cells using methods described in 4.2.5 for treatment and 
measurement of uptake are shown. Data presented are the means + S.E.M. from three 
independent determinations. (A) represents cells grown in CEE supplemented growth 
media defined in 4.2.1 and differentiated in a-M EM  defined in 4.2.2. * indicates a
significant increase over basal transport in response to insulin, p=0.0007. (B) represents 
cells grown in CEE supplemented growth media defined in 4.2.1 and differentiated in 
DMEM defined in 4.2.2. t  indicates no significant difference over basal transport in 
response to insulin. (C) represents cells grown in CEE-free growth media described in
4.2.6 and differentiated in a-M EM  defined in 4.2.2. ** indicates a significant difference 
in magnitude of the insulin response between C and A, p=0.04, and also that the insulin 
response is significantly increased over basal, p=0.002.
Figure 4.8 The effects of various growth and differentiation media on insulin-
stimulated deGlc uptake by WKY skeletal muscle cultures.
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4.2.7 Influence of differentiation time-period on insulin-stimulated deGlc uptake.
Achieving adequate insulin responsiveness is critical to the use of cultured muscle cells to 
study defects in deGlc transport. This will be influenced by the time post-differentiation 
when the cells are assayed. For example in the C2 skeletal muscle cell line, Ploug and 
colleagues observed maturation of Glut-4 enriched compartments residing intracellularly 
as cells are differentiated from day 0 to day 6 (Ploug et al., 1998). Glut-4 reached 
maximal levels of staining by day 6. Such studies prompted an examination of the impact 
of time post differentiation on insulin-stimulated deGlc uptake in these cells. Myoblasts 
grown in CEE-free growth media (4.2.6) were differentiated for 0-16 days. Insulin- 
stimulated deGlc uptake was performed on cells fused for the number of days indicated in 
figure 4.9. The insulin-stimulated fold increase over basal deGlc transport reached 
significance in all 4 and 6 day differentiated cells, p<0.05. In addition, a significant 
increase in the magnitude of the insulin response was seen in 4 and 6 day differentiated 
cells compared to undifferentiated and 16 day differentiated cells, p<0.05. It should be 
noted that the unstimulated (basal) rate of deGlc transport was not significantly different 
between all time points (3.7 + 0.32 pmol/min/well). Moreover, in 4 and 6 day 
differentiated cells, significant reductions in the insulin to basal ratio were observed in 
cultures derived from SHRSP animals with respect to WKY cultures (see 4.2.8 and figure 
4.9). All subsequent deGlc uptake measurements were performed on cells that had been 
differentiated for 6 days in conjunction with all the prior modifications.
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Figure 4.9 Influence of differentiation time period on insulin-stimulated glucose
uptake.
Cells were grown in CEE-free growth media described in 4.2.6 and differentiated using 
media described in 4.2.2. Cells not differentiated and on the days indicated after addition 
of differentiation media were acutely insulin-stimulated (IpiM insulin for 30min) and a 10 
min deGlc transport assay was perfoimed as outlined in 4.2.5. Results shown are the 
means ± S.E.M. of 3 separate experiments. * indicates a significant fold-increase over 
basal p=0.001. indicates a significant fold-increase over basal p=0.005, and also 
indicates a significant fold-increase over con'esponding SHRSP fold stimulation, t  
indicates a significant fold-increase over basal p=0.02. f t  indicates a significant fold- 
increase over basal /?=0.02.
Figure 4.9 Influence of dllïerentiation time period on insuiin-stimulated glucose
uptake.
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4.2.8 Dose-dependent effect of insulin on deGlc uptake in skeletal muscle cells from
WKY and SHRSP animals.
Using methods outlined in 2.3.15 under optimised conditions of growth and 
differentiation (4.2.6, 4.2.7) skeletal muscle cells were treated with insulin doses ranging 
from InM  to lp,M. A dose-dependent increase in deGlc uptake was observed in all 
skeletal muscle cells as illustrated in figure 4.10. I observed both a decreased maximal 
rate of insulin-stimulated deGlc uptake and a rightward shift of the dose-response curve in 
myotubes from SHRSP compared to WKY rats (figure 4.10). Such data suggest that 
while all skeletal muscle cells respond to insulin in a time and dose-dependent manner, 
SHRSP skeletal muscle cells are insulin resistant and exhibit a diminished ability of 
insulin to stimulate deGlc uptake compared with WKY muscle cells. The time- and dose- 
dependent increase in glucose transport observed in WKY and SHRSP skeletal muscle 
cells is indicative of a Glut-4 mediated event. The insulin-regulated glucose transporter, 
Glut-4, is responsible for the bulk of both insulin- and contraction-mediated glucose 
transport by skeletal muscle (Ploug et al., 1998); (Gaster et al., 2000). Both WKY and 
SHRSP cultured skeletal muscle cells lysates express the insulin-regulated glucose 
transporter, Glut-4. In agreement with results seen in whole muscle from these animals 
(chapter 3) there were no significant differences in total Glut-4 levels between WKY and 
SHRSP skeletal muscle cells as seen in the representative immunoblot of figure 4.11.
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Figure 4.10 The effect of increasing insulin concentrations on deGlc uptake by 
WKY and SHRSP skeletal muscle cultures.
A typical dose response curve for insulin in cultured myoblasts from SHRSP or WKY 
strains. Serum starved myoblast were washed two times in KRH buffer then incubated in 
ICRH for 30 min in the presence or absence of the indicated concentration of insulin. 
Each point is the mean of triplicate deteiTninations and is corrected for the non-specific 
association of deGlc uptake with the cells. Data from a representative experiment is 
shown, expressed as a fold increase relative to Basal WKY-derived cultures. A 
significant difference between SHRSP and WKY points is illustrated by * p=0.05 and ** 
/?=0.01. The experiment was repeated three times with similar results. The basal rates of 
transport were not significantly different between WKY- and SHRSP- derived cultures.
Figure 4.11 Immunoblot analysis of Glut4 levels in skeletal muscle cultures from 
SHRSP and WKY animals.
Shown is a representative immunoblot in which 20 ag/lane of muscle lysate, made from 
SHRSP and WKY EDL muscles, were analysed by SDS-PAGE/immunoblotting with an 
antibody specific for Glut-4. Quantification of Glut4 protein levels in these muscles from 
six different animals revealed no significant differences between the two strains (data not 
shown).
Figure 4.10 The effect of increasing insulin concentrations on deGlc uptake by
WKY and SHRSP skeletal muscle cultures.
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Figure 4.11 Immunoblot analysis of Glut-4 levels in skeletal muscle cultures from 
SHRSP and WKY animals.
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4.2.9 Ability of insulin and AICAR to stimulate deGlc uptake in WKY and SHRSP 
skeletal muscle cells.
Stimulation of skeletal muscle cells with 1|liM insulin or 500p,M AICAR demonstrates 
that muscle cell cultures from SHRSP skeletal muscle exhibit blunted insulin-stimulated 
deGlc uptake compared to WKY, but the response to AICAR was similar between the 
two cultures (figure 4.12). This is consistent with data on intact muscle (see chapter 3). 
Moreover, it is noteworthy that similar experimental results were obtained from cultures 
between passage 5-8 (data not shown), indicating a stably maintained trait. In addition, 
and consistent with data from intact muscle, treatment with lOOnM wortmannin two 
minutes prior to agonist completely blocked insulin-stimulated deGlc uptake but was 
without effect on AICAR-stimulated deGlc uptake (figure 4.12).
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Figure 4.12 DeGlc uptake in skeletal muscle cultures - the effects of insulin,
AICAR and wortmannin.
Shown are the effects of a 30 min incubation with either 1 insulin or 500 p-M AICAR 
on deGlc uptake. The effect of pre-treatment of the cells with 100 nM wortmannin on 
these stimulations is also shown. The data are presented as mean ± S.E.M. from 3 
separate experiments, expressed as a fold increase over the basal WKY rate. * indicates a 
significant increase in transport in response to insulin, p=0.01. ** indicates a reduction in 
insulin-stimulated glucose transport compared to WKY strain, p=0.04. t  indicates a 
significant increase in response to AICAR in WKY cultures, /?=0.05. t t  indicates no 
significant difference in the magnitude of the AICAR response between the WKY and 
SHRSP strains, and also that the AICAR response in SHRSP cultures is significantly 
increased over basal, p=0.05. Wortmannin inhibited insulin-stimulated deGlc uptake 
significantly in both WKY and SHRSP cultures (p=0.01 in both) and had no significant 
effect on AICAR stimulated deGlc transport.
Figure 4.12 DeGlc uptake in skeletal muscle cultures - the effects of insulin,
AICAR and wortmannin.
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4.3 Discussion
This chapter expands upon the findings in chapter three by assessing insulin- and AICAR- 
stimulated glucose transport in cultured skeletal muscle cells isolated from WKY and 
SHRSP extensor digitorum longus muscle. Using established cell culture techniques, 
skeletal muscle satellite cells were isolated and cultured. Once differentiated these cells 
possessed the muscle determining factors myoD and myogenin and were morphologically 
distinct from myoblasts in that they were multinucleated and highly elongated indicative 
of myotubes (figure 4.2). In addition, these myotubes expressed the insulin regulated 
glucose transporter, Glut-4 (figure 4.11).
In order to assess glucose transport, the development of adequate methods is necessary so 
as to achieve reproducible and significant results within skeletal muscle cells. As 
previously shown in chapter three and reported by (Sarabia et al., 1990); (Jackson et al., 
2000) skeletal muscle cells give a modest but characteristic two- to four-fold increase of 
insulin-stimulated glucose uptake. As documented here, both growth media composition 
and differentiation timings were important factors that significantly affected insulin- 
stimulated glucose uptake in the present system (figure 4.8). After methodical alteration 
of growth and differentiation media in the present system, I have found that the 
replacement of chick-embryo-extract (CEE) with the supplements common to the semi­
defined human and rat skeletal muscle cell growth media of Ham et al and Allen et al 
respectively, in conjunction with the ot-MEM based differentiation media, gave better 
insulin-stimulated glucose uptake responses compared to cells grown in CEE-containing 
growth medium or differentiated in DMEM medium (figure 4.8) (Allen et al., 1985); 
(Ham et al., 1988). Furthermore, both WKY and SHRSP muscle cells when 
differentiated for four to six days gave significantly better insulin-stimulated glucose fold 
uptake responses compared to undifferentiated or 16-day differentiated cells (figure 4.9). 
A likely explanation for this lack of an insulin response at early time points maybe due to 
the lack of Glut-4 protein (Guillet-Deniau et al., 1994); (Gaster et al., 2000). Indeed 
Ralston et al has shown that Glut-4 is virtually undetectable in C2 myoblasts but is highly 
expressed and intracellularly located in three-day-old C2 myotubes (Ralston and Ploug, 
1996). The decreased insulin-stimulated glucose transport seen in 16 days-old myotubes
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may be due to an age-related effect. In addition, agonist and deGlc incubation times were 
optimised for this culture system.
The development of this skeletal muscle cell culture system permits the comparison of 
insulin- and AICAR-stimulated glucose transport between SHRSP and WKY cells 
without the confusion of physiological factors such as altered blood flow or circulating 
paracrine factors. As discussed earlier in 1.5.1 and chapter three, AICAR is able to 
activate AMPK, an important mediator of the effects of exercise on glucose transport 
(Corton et al., 1994); (Goodyear, 2000). Consequently, the use of AICAR provides the 
opportunity to study the effects of exercise on glucose uptake in vitro. By way of 
optimising deGlc assay conditions, I have determined that these cells display a linear 
uptake of deGlc over 15 minutes in the presence and absence of insulin. In addition, 
these cells gave a time-dependent increase in deGlc uptake in the presence of insulin, 
AICAR and arsenite, with maximal deGlc transport seen at 30 minutes under stimulated 
conditions. Therefore, under the chosen 30-minute agonist stimulation and 10-minute 
deGlc uptake conditions, glucose transport is the rate-limiting step.
The novel and remarkable finding in this study is that the defect observed in insulin- 
stimulated glucose transport in intact muscles from the SHRSP (chapter 3) was also 
observed in cultured myotubes (figure 4.10 and 4.12). Specifically both WKY and 
SHRSP skeletal muscle cells exhibit a time- and dose-dependent response to insulin. 
However, SHRSP skeletal muscle cells show a decreased maximal rate of insulin- 
stimulated deGlc uptake and a rightward shift of the dose-response curve. This 
diminution of insulin sensitivity is evident throughout all passages of cells. Moreover, 
AICAR-stimulated deGlc transport was not significantly different between WKY and 
SHRSP skeletal muscle cells, in agreement with data seen in intact FOB muscle (chapter 
3). Consistent with data on intact muscle, pre-treatment with 100 nM of the PI3K 
inhibitor wortmannin, completely blocked insulin-stimulated deGlc uptake but was 
without effect on AICAR-stimulated deGlc uptake. Such data suggest that AICAR 
stimulates glucose uptake via a wortmannin insensitive/ PI3K-independent pathway.
In conclusion, these data clearly demonstrate that at the level of skeletal muscle cells, the 
SHRSP exhibits a noticeable primary defect in insulin-stimulated deGlc uptake compared
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with WKY rats. This defect is confined to an insulin-specific step in the activation of 
glucose transport since it is not observed in AICAR-stimulated deGlc uptake.
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Chapter 5.
Analysis of glucose transport in skeletal muscle 
from the Zucker diabetic fatty rat -  The effect of 
hyperglycaemia and thiazolidinedione treatment
on glucose transport.
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5.1 Introduction
5.1.1 The Zucker diabetic fatty rat as a model of human type 2 diabetes.
The data presented in chapters three and four have demonstrated that the spontaneously 
hypertensive rat model (SHRSP) is insulin resistant at the level of skeletal muscle, and 
that this insulin resistance is maintained in cultured skeletal muscle cells over several 
passages indicating genetic predisposition. It is now of interest to determine whether the 
sustained insulin resistance observed in the hypertensive SHRSP rat myocytes is common 
to other rat models of insulin resistance.
The Zucker diabetic fatty (ZDF) rat is a model of type 2 diabetes, useful for studies of 
insulin- and non-insulin-stimulated glucose uptake in skeletal muscle in vitro and in situ. 
This model was derived from the genetically obese (fa/fa) Zucker rat characterised by a 
mutation in the leptin receptor (OB-R), which was initially identified in Eli Lilly 
Reseai’ch labs in 1974 (Unger and Orci, 2001). These rats were obese and insulin 
resistant, but did not develop overt diabetes (fasting hyperglycaemia) until a late age. 
Inbreeding of selected pairs with diabetic lineage lead to the establishment of the ZDF rat 
line in 1985 (Peterson et al., 1990). This animal exhibits symptoms of type 2 diabetes and 
cardiovascular disease that are very similar to those seen in humans with type 2 diabetes 
and other obesity-related diseases. Moreover, from a practical point of view, this model 
is particularly convenient, as type 2 diabetes-related pathologies such as fasting 
hyperglycaemia and cardiovascular disease develop rapidly, usually by 14 weeks of age 
in males. The course of the disease begins with the hyperphagic ZDF rat becoming obese 
and insulin-resistant, and develops into the formation of a hyperglycaemic animal that 
exhibits signs of hypo-insulinaemia due to |3-cell decompensation. This progression of 
events is strikingly similar to those seen in human type 2 diabetic patients who, as in the 
case of the rat model, are characterised by hyperinsulinaemic-compensated 
normoglycaemia leading to low blood insulin and hyperglycaemia due to P-cell 
decompensation (Unger and Orci, 2001).
Since a number of studies have shown that chronic hyperglycaemia can impair insulin- 
stimulated glucose uptake and utilisation and exacerbate secondary disease, the 
hyperglycaemia observed in the obese ZDF rat provides a extremely useful model for the
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investigation of glucose transport under this potentially deleterious condition (Rossetti et 
ah, 1987); (Hager et al., 1991); (Davidson et al., 1994a).
5.1.2 Potential molecular defects in hyperglycaemia
The precise mechanism by which hyperglycaemia leads to peripheral insulin resistance is 
not fully understood however it has been demonstrated that diet/drug-induced restoration 
of blood glucose to normal levels improves insulin sensitivity and insulin-stimulated 
glucose uptake in adipocytes or muscle from diabetic rats or Type 2 diabetic humans 
(Henry et al., 1986); (Kahn et al., 1991); (Greenfield et al., 1982); (Kolterman and 
Olefsky, 1984). It is thought that increased biosynthetic activity and production of 
metabolites from the hexosamine pathway, which subsequently impair the function of the 
insulin signalling pathway are associated with the development of insulin resistance 
(Davidson et al., 1994b); (Rossetti, 2000). Studies on skeletal muscle from diabetic 
rodents and humans have shown defects in the insulin signalling pathways at the steps 
involving IRS-1, PI-3K and Glut 4 translocation (Anai et al., 1998); (Heydrick et al.,
1995); (Heydrick et al., 1993); (Folli et al., 1993); (Saad et al., 1992); (Krook et al., 
1998); (Bjomholm et al., 1997); (Goodyear et al., 1995); (Kim et al., 1999); (Friedman et 
al., 1999). These molecules are therefore likely to be involved in the mechanism by 
which restoration of glycaemia improves insulin sensitivity.
Another potential defect in insulin signalling may involve protein kinase B (PKB). 
Defective skeletal muscle PKB activity is observed in human diabetics and the ZDF rat 
(Krook et al., 1998); (Oku et al., 2001). Protein kinase B performs an important role in 
insulin signal transduction, being involved in the regulation of glycogen synthesis and 
implicated in the regulation of glucose transport (Hajduch et al., 2001). Activation of 
endogenous PKB occurs via a two-step process consisting of membrane localisation and 
binding of PIP3 (the product of PI3K activity) and phosphorylation of threonine308 by 
PDKl and serine473 possibly by an as yet undefined PDK2 (Alessi et al., 1997b). To 
address the significance of defects in PKB activity, a novel PKB agonist in development 
at GlaxoSmithkline was used to assess the effect of direct PKB activation on skeletal 
muscle glucose transport.
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5.1.3 Pharmacological management of NIDDM- The thiazolidinediones
The primary goal for all diabetics is to maintain normoglycaemia. Some type 2 diabetics 
can achieve this by diet and exercise, however others require pharmacological 
intervention. In general, marketed drugs either stimulate the pancreas to produce more 
insulin or sensitise tissues such as muscle and fat to the action of insulin. The latter 
recent drugs which re-sensitise the insulin-resistant peripheral glucose storage tissues of 
fat and muscle to the actions of insulin include the thiazolidinediones of which 
Rosiglitazone is an example (Murphy and Holder, 2000). Clinically, Rosiglitazone is able 
to reduce fasting blood glucose and triglycerides. It achieves this by increasing Glut-4 
expression in adipocytes and re-sensitising these cells to the antilipolytic action of insulin 
on the inhibition of hormone sensitive lipase (Young et al., 1995). It has also been shown 
to improve insulin sensitivity with respect to glucose uptake in muscle. At a molecular 
level, thiazolidinediones are high affinity ligands for the transcription factor Peroxisome 
Proliferator Activator Receptor gamma (PPARy) (Muiphy and Holder, 2000). PPARy 
usually act as heterodimers with Retinoid X receptors (RXR) on their cognate response 
elements (Muiphy and Holder, 2000). Interestingly PPARy response elements control 
adipogénie genes, and evidence is accumulating that this transcription factor may also 
regulate muscle specific gene expression.
5.1.4 Aims and objectives.
(i) To compare insulin- and AICAR-stimulated glucose transport and components 
of the insulin-signalling network in isolated skeletal muscle from the diabetic 
ZDF rat model and its normal lean litter-mate.
(ii) To investigate the effect of novel PKB agonists on skeletal muscle glucose 
transport.
(iii) To examine insulin-stimulated glucose transport in cultured skeletal muscle 
cells obtained from ZDF and lean rats.
(iv) To examine the effects of hyperglycaemia on glucose transport in ZDF and 
lean Zucker skeletal muscle cells and the ability of rosiglitazone treatment to 
modulate the effects of hyperglycaemia on glucose transport.
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5.2 Results
5.2.1 The effect of insulin and AICAR on deGlc uptake by flexor digitorum brevis
(FDB) muscles.
ZDF rats are insulin resistant and a model of type 2 diabetes (Peterson et al., 1990). 
Hyperinsulinaemic-euglycaemic clamp studies and glucose transport measurements on 
isolated epididymal fat cells show an impaired insulin response to stimulate glucose 
disposal and glucose transport, respectively, in these animals (Unger and Orci, 2001). As 
the hyperinsulinaemic-euglycaemic clamp suppresses hepatic glucose output, these 
studies indicate that the defects must arise predominantly from impaired skeletal muscle 
glucose disposal (Unger and Orci, 2001). The characteristics of the animals used in this 
study are shown in Table 5.1. Fasting blood glucose levels and body weight were higher 
in the ZDF compared to the lean Zucker animals. In order to compare skeletal muscle 
insulin sensitivity in ZDF rats and lean Zucker rats, FDB muscles were isolated and the 
insulin-stimulated glucose transport was then measured using methods described in 2.3.2. 
Isolated FDB muscles were stimulated with IpM  insulin for 30 minutes prior to 2-deoxy- 
D-glucose uptake measurement. Figure 5.1 shows that maximal insulin-mediated deGlc 
uptake was significantly lower (p=0.002) in FDB muscles from ZDF rats (1.6 ± 0.3-fold) 
compared to lean Zuckers (3.2 ±  0.2-fold). This clearly indicates a diminished ability of 
insulin to stimulate deGlc uptake in isolated skeletal muscle of ZDF rats. These results 
support evidence of muscular insulin resistance in ZDF rats obtained by whole-body 
hyperinsulinaemic-euglycaemic clamp studies.
As described in studies utilising the SHRSP rat model, muscle glucose uptake can also be 
elicited in a non-insulin dependent manner by the AMPK agonist AICAR. To assess the 
effect of AICAR on deGlc transport, lean Zucker and ZDF FDB muscles were treated as 
outlined in section 3.2, Figure 5.1 demonstrates that AICAR stimulates deGlc transport 
in both ZDF (2.8 + 0.08-fold) and lean (2.6 + 0.12-fold) to a similar extent. These results 
are in keeping with those seen in SHRSP versus WKY rats (figure 3.1). Insulin- 
stimulated skeletal muscle deGlc uptake is diminished in both ZDF and SHRSP with 
respect to their lean controls but AICAR elicits deGlc uptake to the same extent in both 
insulin sensitive (WKY and lean Zuckers) and insulin insensitive (SHRSP and ZDF) 
animals.
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Table 5.1 Characteristics of the animal groups.
Lean (n=15) 
Zucker
ZDF(n=15)
Serum glucose Weight
(mmol/L) (g)
5.2 + 1 275 + 11
17 +  3^ 345 + 20^
Shown are the mean body weight and fasted serum glucose of the 12 week-old animals 
used in this study. * indicates a statistical significant difference between the groups, 
p<0.01. Performed in collaboration with Dr. Greg Murphy and Dr. Carolyn Lister, 
Department of Vascular Biology, GlaxoSmithkline, Harlow, UK.
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Figure 5.1 The effect of insulin and AICAR on deGlc uptake in FDB muscle from
ZDF and lean Zucker rats.
Shown are the effects of 30 min incubation with either IjtiM insulin or 500pM AICAR on 
glucose uptake in FDB muscles exposed to deGlc for 10 min. The data are presented as 
mean ± S.E.M. from 3 separate experiments, expressed as a fold increase over the basal 
lean rate. * indicates a significant increase in deGlc transport over basal in response to 
insulin, p = 0 .01 . ** indicates no significant fold-increase in response to insulin with 
respect to basal and a significant difference vs corresponding value in lean Zucker strain, 
p=0.04. t  indicates a significant increase in response to AICAR in lean Zucker muscles, 
p=0.05. t t  indicates no significant difference in the magnitude of the AICAR response 
between the lean Zucker and ZDF strains, and also that the AICAR response in ZDF rats 
is significantly increased over basal, p=0.05. Basal deGlc transport was not significantly 
different between ZDF and lean Zucker rats.
Figure 5.1 The effect of insulin and AICAR on deGlc uptake in FDB muscle from
ZDF and lean Zucker rats.
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5.2.2 Immunoblot analysis of molecules involved in insulin-stimulated glucose 
transport.
Whole skeletal muscle lysates of EDL, soleus, tibialis and gastrocnemius muscles from 
ZDF and lean Zucker rats were prepared and immunoblotted as described (2.3.3, 2.3.8 - 
2.3.10). As shown in figure 5.2A and quantified in figure 5.2B no significant differences 
were detected in total cellular levels of IRS-1 and the p85 subunit of PI3K between ZDF 
and lean Zucker animals. Similarly, there was no noticeable difference in the total 
cellular expression levels of PKB, as detected by an antibody raised to the PKB pleckstrin 
homology domain (figure 5.3A). However, significant differences (p<0.05) are observed 
in the insulin-stimulated S473 phosphorylation of PKB in ZDF rats compared with lean 
Zuckers (figure 5.3B). In addition, insulin-stimulated EDL muscle PKB activity from 
ZDF rats is significantly decreased compared with lean Zuckers as shown in figure 5.4. 
Such data support the view that the insulin resistance observed in ZDF rats with respect to 
the lean Zuckers cannot be due to the altered cellular expression of these key proteins 
involved in glucose transport. However, the diminished activity of PKB is indicative of a 
defect in the insulin-signalling pathway. This result suggests that PKB could be a 
possible target for pharmacological modulation.
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Figure 5.2 Immunoblot analysis of IRS-1 and p85 in various hind limb muscles
from the ZDF and lean Zucker rat.
Representative immunoblots (A) in which 20 & 10 pg of protein lysates made from EDL, 
soleus and tibialis skeletal muscle of male lean Zucker and ZDF rats were analysed by 
SDS-PAGE/immunoblotting with the antibodies specific for the IRS-1 carboxyl terminus 
domain and p85 subunit of PI3K. Data from one animal of each strain is shown. (B) 
represents quantification of 4 experiments of this type from 4 animals from each strain, 
with the relative level of expression in ZDF muscles expressed as a % of that observed in 
the corresponding lean Zucker muscle taken as 100% (means ±  S.E.M.). No significant 
differences in protein expression levels were found in lysates from all muscles studied 
between lean Zucker and ZDF rats.
Figure 5.2 Immunoblot analysis of IRS-1 and p85 in various hind limb muscles
from the ZDF and lean Zucker rat.
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Figure 5.3 Immunoblot analysis of PKB serine-473 phosphorylation in EDL
muscles lysates from ZDF and lean Zucker rats.
EDL muscles from lean Zucker and ZDF rats were incubated with or without 1 pM 
insulin for 30 min and whole muscle lysates prepared as outlined in 2.3.3. Equal amounts 
of protein (10 ng/lane) were subjected to SDS-PAGE/immunoblot analysis using 
antibodies specific for PKB-PH domain and PKB phosphorylated at serine-473. (A) is a 
representative immunoblot for PKB-PH domain. No significant difference was observed 
between basal or insulin-stimulated muscle lysates of lean Zucker and ZDF rats. (B) 
indicates phosphorylated serine-473 PKB levels in EDL muscle lysates in the absence or 
presence of IpM  insulin from ZDF and lean Zucker animals. Insulin causes a significant 
increase (p<0.05, n=3) in serine phosphorylated PKB in lean Zucker muscle lysates only. 
PICB-PH domain is also shown to illustrate that the observed changes in PKB serine-473 
phosphorylation is not a consequence of global changes in PKB expression.
Figure 5.3 Immunoblot analysis of PKB serine-473 phosphorylation in EDL
muscles lysates from ZDF and lean Zucker rats.
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Figure 5.4 Effect of insulin on PKB activity in EDL muscle lysates from ZDF and
lean Zucker rats.
EDL muscles were incubated at 37°C in the presence or absence of 1 pM insulin for 30 
minutes. Muscles lysates were prepared as described in 2.3.3. PKB activity in muscle 
lysates was measured against a peptide substrate based on a motif from GSK3 as outlined 
in 2.3.7. PKB activity is expressed as picomoles of substrate phosphorylated /min/mg 
protein. Shown is data from three experiments (means ± S.E.M.), with each condition 
performed in triplicate in each experiment. * Significantly different (p<0.01) vs 
unstimulated muscle lysates and ZDF muscle lysates. In ZDF muscle lysates insulin did 
not stimulate a significant increase in PKB activity over basal. No significant differences 
in basal activity were observed between lean Zucker and ZDF muscle lysates.
Figure 5.4 Effect of insulin on PKB activity in EDL muscle lysates from ZDF and
lean Zucker rats.
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5.2.3 Effect of pharmacological agonists on in vitro phosphorylation of PKBS473D.
GlaxoSmithkline has identified pharmacological agents able to activate in vitro 
recombinant PKBS473D. PKBS473D is a PKB mutant in which serine (S) in the second 
regulatory phosphorylation site at position 473, is replaced by an aspartic acid (D) 
residue, mimicking the in vivo partially-activating phosphorylation of S473 (Alessi et ah,
1996). This phosphorylation partially reveals the PDKl phosphorylation site at threonine 
(T) 308, which is positioned in the activation loop of the catalytic/kinase domain of PKB. 
Phosphorylation of T308 and S473 fully activates PKB kinase activity toward 
intracellular substrates (Alessi et al., 1996). The pharmacological agents which activate 
PKBS473D are designed to functionally mimic PKB’s PH domain binding of PIP3, which 
is a necessary but not a sufficient step towards the activation of endogenous PKB (Kohn 
et al., 1996b).
Previous screens of GlaxoSmithkline compound bank for pharmacological agents which 
are able to stimulate recombinant PKBS473D kinase activity toward a PKB specific 
substrate peptide sequence has revealed a number of promising leads. Of those, two 
compounds SB456672 and SB437478 were selected as most worthy of further 
investigation and development. In particular, in vitro analyses show these compounds are 
lipophilic and therefore potentially cell permeable, an important prerequisite for drugs 
that must traverse the cell plasma membrane to reach their target. In addition, these 
compounds possess a low binding affinity for serum albumin. Serum albumin is the most 
abundant blood protein and is able to bind and sequester many drugs thus lowering the 
concentration of available drug capable of acting on its target. This lowered ‘biological- 
availability’ limits drug action.
Before investigating the action of these putative PKB agonists on skeletal muscle glucose 
uptake, their effects were examined on recombinant PKB phosphorylation and on their 
ability to activate PKB activity toward a synthetic peptide substrate using systems and 
methods developed within GlaxoSmithkline and described in 2.3.16. Figure 5.5 
illustrates that in the presence of recombinant PDKl and PIP3 vesicles, recombinant 
PKBS473D is phosphorylated on T308 (lanes 3 and 4). This is detected using an 
antibody that specifically recognises the phosphorylated T308 of PKB. This 
phosphorylation is abolished in the presence of 20mM EDTA, which chelates Mg '^^, an
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ion absolutely required for kinase activity (lanes 1 and 2). In addition, removal of either 
PIP3 vesicles (lanes 5-6) or recombinant PDKl (lanes 7-8) effectively abolishes PKB 
T308 phosphorylation.
It should be noted that in the absence of PIP3 (lanes 5-6), there is a slight phosphorylation 
of T308 in recombinant PKBS473D. This low-level phosphorylation of T308 could be 
due to the more accessible nature of the PDKl phosphorylation site in the partially 
primed, recombinant PKBS473D protein, compared to the native enzyme. However, in 
the absence of PDKl there is no detectable phosphorylation of recombinant PKBS473D 
on T308 (lanes 7-8), indicating that T308 phosphorylation is absolutely dependent on 
PDKl in this in vitro system.
In the presence of PDKl but absence of PIP3 vesicles both SB456672 and SB437478 
restore T308 phosphorylation of PKBS473D (lanes 11-12). Indeed, SB437478 was 
shown to elicit T308 phosphorylation in the absence of both PD K l and PIP3 vesicles 
(lanes 9-10). This phosphorylation is further enhanced by addition of PDKl (lanes 11- 
12). These data show that both putative PKB agonists facilitate PDKl-dependent but 
PfP3-independent phosphorylation of T308 in recombinant PKBS473D. This indicates 
that these compounds can substitute PIP3 function in exposing the PDKl phosphorylation 
site of PKB. Moreover, SB437478 but not SB456672 can elicit PDKl-independent 
PKBS473D T308 phosphorylation. Perhaps the simplest interpretation of this result is 
that this implies a further level of pharmacological interaction with PKB enabling PKB 
auto-phosphorylation.
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Figure 5.5 Effect of PKB agonist SB456672 and SB437478 on the in vitro 
threonine308 phosphorylation of recombinant S473D-PKBa.
The effects of PIP3 vesicles, PDKl and PKB agonists on in vitro recombinant S473D- 
PKBa threonine308 phosphorylation were independently assessed. Shown is a 
representative immunoblot of two separate experiments carried out as described in 2.3.16 
and run in duplicate. lOpl of each reaction mixture was resolved by SDS- 
PAGE/immunoblotting and probed with an antibody that specifically recognises 
phosphorylated threonine-308 in PKB a. As indicated, lanes 1-2 represent the effect of 20 
mM EDTA on Thr-308 phosphorylation status in the presence of PIP3 vesicles and PDKl 
and are labelled ‘kinase dead’. Lanes 3-4 represent PKBS473D Thr-308 phosphorylation 
in the presence of purified recombinant PDKl and PIP3 vesicles and are labelled ‘fully 
active’. Lanes 5-6 and 7-8 represent the effect of removal of PIP3 vesicles or recombinant 
PDKl on PKBS473D Thr-phosphorylation respectively, and are therefore labelled ‘PIP3- 
independent’ or ‘PDKl-independent’ respectively. Lanes 9-10 represents the effect of 
either SB456672 (upper panel) or SB437478 (lower panel) on thr-308 PKBS473D 
phosphorylation in the absence of recombinant PDKl and PIP3 vesicles. Lanes 11-12 
represents the effect of compounds [abbreviated CPD in figure] (SB456672 upper panel 
and SB437478 lower panel) on Thr-308 PKBS473D phosphorylation in the presence of 
recombinant PDKL PIP3 in the presence of compounds gave similar results to that seen 
in lanes 9-10 (data not shown). Experiments were repeated once more with similar 
results.
Figure 5.5 Effect of PKB agonist SB456672 and SB437478 on the in vitro 
phosphoryiation of recombinant S473D-PKB.
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5.2.4 Effect of SB456672 and SB437478 on in vitro PKBS473D-dependent 
phosphorylation of PKB peptide substrate.
As shown above in 5.2.3, SB456672 and SB437478 both elicit T308 phosphorylation of 
recombinant PKB by a PIPs-independent but PDKl-dependent mechanism. However, 
such data does not directly establish the effect of these putative agonists on PKB activity. 
To examine this, the ability of recombinant PKBS473D to phosphorylate a synthetic 
peptide substrate (KRPRAATF) was measured after being treated as described in 5.2.3. 
For a full description of methods, refer to 2.3.16. As shown in figure 5.6 SB437478 and 
SB456672 in the absence and presence of PIP3 vesicles significantly increased 
PKBS473D activity compared to vehicle. These data demonstrate that increased T308 
phosphorylation directly correlates with increased activity toward a specific peptide 
substrate.
5.2.5 The effect of PKB agonist on deGlc uptake.
As described earlier, SB456672 was able to reconstitute in vitro PDKl-dependent 
phosphorylation of T308 on PKBS473D in the absence of PIP3 vesicles. This compound 
was also able to stimulate in vitro PKB activity toward a peptide substrate. In addition, 
its lipophilicity and low serum albumin binding profile make it a good candidate for in 
situ analysis of a putative PKB agonist effect on glucose transport in skeletal muscle 
(GlaxoSmithkline data). Therefore, the effect of SB456672 on deGlc uptake in lean 
Zucker and ZDF rat muscles was assessed. Figure 5.7 shows that acute stimulation with 
lOpM SB456672 for 30 min did not significantly stimulate deGlc uptake over basal 
values in lean Zucker or ZDF rat muscles.
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Figure 5.6 Effects of putative PKB agonists on S473D-PKBa-dependent 
phosphorylation of substrate peptide.
Recombinant S473D-PKBa protein was pre-incubated at 30°C for 60 min with 
recombinant PDKl and ATP in the presence or absence of 10 pM PKB agonist (open bar) 
or PIP3 vesicles, recombinant PDKl and ATP in the presence or absence of 10 pM PKB 
agonist (closed bar). In vitro PKB activity was subsequently measured against a peptide 
substrate based on a motif from GSK-3. Methods used are outlined in 2.3.16. Values are 
the mean ± S.E.M. from three separate experiments each carried out in triplicate. 
§indicates a statistically significant increase in S473DPKBa activity in the presence of 
PIP3 vesicles compared with no PIP3 vesicles (p<0.0001). ^indicates a significant 
increase vs conesponding vehicle value, and also indicates no significant difference in 
activity vs vehicle activity in the presence of PIP3 vesicles (p<0.001). **indicates a
significant increase vs corresponding vehicle value (p<0 .000001), and corresponding 
SB437438 value in the absence of PIP3 vesicles (p<0.0001). findicates a significant 
increase in activity compared to conesponding vehicle activity (p=0 .01), and also 
indicates a significant decrease compared to SB437438 value in the absence of PIP3 
vesicles (/?<0 .001). tfindicates a significant increase compared to corresponding vehicle 
activity (/;=0.03) and also indicates a significant increase vs conesponding SB456672 
value in the absence of PIP3 vesicles (p<0.01).
Figure 5.6 Effects of putative PKB agonists on S473D-PKBa-dependent 
phosphorylation of substrate peptide.
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Figure 5.7 The effect of PKB agonist SB456672 on deGlc uptake in FOB muscle
from lean Zucker and ZDF muscle.
The effects of acute stimulation of 30 min incubation with SB456672 on a 10 min deGlc 
uptake in lean Zucker and ZDF FDB muscles are shown. The data are presented as mean 
± S.E.M. from 3 separate experiments, expressed as a fold increase over the basal lean 
rate. SB456672 did not significantly increase deGlc fold uptake over basal in ZDF or 
lean Zucker rats. Basal deGlc transport was not significantly different between ZDF and 
lean Zucker rats.
Figure 5.7 The effect of PKB agonist SB456672 on deGlc uptake in FDB muscle
from lean Zucker and ZDF muscle.
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5.2.6 Immunoblot analysis of c-Cbl, flotillin and caveolin expression in lean Zucker
and ZDF muscles.
As discussed in 1.4 there is evidence that insulin via the insulin receptor co-stimulates an 
alternative PI3K-independent pathway required for the stimulation of glucose transport. 
This proposed pathway thus far includes CAP/c-Cbl/C3G/TC-10, all of which localise to 
plasma membrane domains involved in cell signalling known as caveolae (Baumann et 
al., 2000); (Chiang et al., 2001); (Watson et al., 2001). Caveolae are a subset of lipid rafts 
consisting of membranous invaginations enriched in the structural protein caveolin. 
Caveolin forms homo-oligomers and hetero-oligomers with another structural protein 
named flotillin (Galbiati et al., 2001). As previously shown in figure 3.7, both caveolin 
and flotillin are significantly overexpressed in the insulin-resistant SHRSP with respect to 
the WKY rat. This may contribute to impaired insulin-dependent glucose uptake in that 
animal. In order to investigate whether expression of these proteins is also increased in 
ZDF relative to lean Zuckers, immunoblot analysis of EDL, soleus and tibialis muscle 
lysates were performed. As shown in figure 5.8 A/B no significant differences were 
detected in total cellular expression of c-Cbl, caveolin-1 and flotillin from ZDF or lean 
Zucker skeletal muscle lysates. Therefore, it is unlikely that the impairment of insulin- 
dependent glucose uptake in this animal model is due to altered expression of caveolin, 
flotillin-1 or c-Cbl.
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Figure 5.8 Immunoblot analysis of c-Cbl, flotillin and caveolin-1 expression in
lean Zucker and ZDF muscle.
Shown are representative immunoblots (A) in which 20 & 10 pg of protein lysates from 
EDL, soleus and tibialis skeletal muscle of male lean Zucker or ZDF rats were analysed 
by SDS-PAGE/immunoblotting with the antibodies specific for c-Cbl, flotillin and 
caveolin-1. Data from one animal of each strain is shown; note that the blots presented 
are deliberately over-exposed in order to show the level of c-Cbl and caveolin present in 
muscles with weaker signals. (B) represents quantification of 4 experiments of this type 
from 4 animals from each strain, with the relative level of expression in ZDF muscles 
expressed as a % of that observed in the conesponding lean Zucker muscle taken as 100% 
(means + S.E.M.). No significant change in c-Cbl, flotillin or caveolin-1 protein 
expression levels were observed between lean Zucker or ZDF muscles.
Figure 5.8 Immunoblot analysis of c-Cbl, flotillin and caveolin-1 expression in
lean Zucker and ZDF muscle.
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5.2.7 The effect of insulin on deGlc transport in EDL and soleus skeletal muscle
cell cultures from ZDF and lean Zucker rats.
As shown in chapter 4 an impairment of deGlc transport in the skeletal muscle from the 
insulin resistant SHRSP rat persists in cells cultured from SHRSP muscle. To investigate 
whether this is also observed in ZDF and lean Zuckers rats, primary skeletal muscle cells 
were isolated and cultured from EDL and soleus muscles as previously described in 4.2.1 
and modified in 4.2.6. The immunoblot analysis in figure 5.9 illustrates that these cells 
contain the myogenic marker myogenin. They also express Glut-4 (data not shown). As 
shown previously in figure 5.1 skeletal muscle from the insulin resistant ZDF animals 
exhibit a marked impairment of insulin-stimulated deGlc transport compared with the 
insulin-sensitive lean Zuckers. Acute insulin treatment (1 pM  for 30 min) significantly 
increased deGlc transport in EDL (2.70 + 0.4-fold over basal; p<0.05) and in soleus (2.5 
± 0.3-fold over basal; p<0.05) skeletal muscle cells from lean Zuckers (figure 5.10). The 
mean basal transport rate was 2.4 + 0.01 pmol/min/well and was not significantly 
different in both lean Zucker and ZDF rat. Acute insulin stimulation of ZDF EDL and 
soleus skeletal muscle cell cultures failed to significantly increase deGlc uptake over 
basal (figure 5.10).
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Figure 5.9 Immunoblot analysis of Myogenin expression in lean Zucker and ZDF
skeletal muscle cultures.
A representative immunoblot is shown in which 10 pg of protein lysates made from four 
different differentiated (day 4) skeletal muscle cell cultures from lean Zucker or ZDF rats 
were analysed by SDS-PAGE/immunoblotting with an antibody specific for myogenin. 
The experiment was repeated twice with similar results.
Figure 5.10 The effect of insulin on deGlc uptake in skeletal muscle cultures from 
lean Zuckers and ZDF rats.
The effects of acute insulin stimulation (1 pM for 30 min) on a 10 min deGlc uptake in 
EDL and soleus skeletal muscle cells cultured from 12 week old lean Zucker and ZDF 
rats are shown. Using methods described in 4.2.1-4.2.3 with optimisations defined in 
4.2.6-4.2.7 cells were isolated and cultured. DeGlc uptake was measured as outlined in 
2.3.15. This graph represents data obtained from cells between passages 5-8, The data 
are presented as mean + S.E.M. from 4 separate experiments, expressed as a fold increase 
over the basal rate. Basal rates of transport were not significantly different between lean 
Zucker and ZDF rat. * indicates a significant fold-increase in deGlc transport in response 
to insulin, p=0.01. ** indicates a significant fold-increase in deGlc transport in response 
to insulin, p=0.04. Acute insulin stimulation failed to significantly increase deGlc 
transport above basal levels in ZDF muscle cells cultures.
Figure 5.9 Immunoblot analysis of Myogenin expression in lean Zucker and ZDF
skeletal muscle cultures.
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Figure 5.10 The effect of insulin on deGlc uptake in skeletal muscle cultures from 
lean Zuckers and ZDF rats.
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5.2.8 The effect of hyperglycaemia on insulin-stimulated deGlc transport in EDL
skeletal muscle cell cultures isolated from ZDF and lean Zucker rats.
The diabetic ZDF rat displays fasting hyperglycaemia associated with dyslipidaemia and 
obesity (Unger and Orci, 2001). As observed in figures 5.1 and 5.10, the insulin 
resistance seen in ZDF muscle is maintained in cultured muscle cells implying a genetic 
predisposition to skeletal muscle insulin resistance. To examine the effect of 
hyperglycaemia on insulin-stimulated deGlc transport, cells were grown in chick embryo 
extract (CEE)-free growth medium as described in 4.2.6 and differentiated in a-MEM 
differentiation medium with a final D-glucose concentration of 5mM or 30mM. Cells 
were fed every 24 hours for 5 days with this medium and serum starved for 24 hours in 
serum-free medium containing 5mM or 30mM D-glucose, prior to measurement of 
insulin-stimulated deGlc uptake. The assay for insulin-stimulated deGlc uptake was 
performed as described in 4.2.5. In cells cultured under normoglycaemic conditions, 
acute insulin treatment (IpM  for 30 min) increased deGlc uptake in lean Zucker cultures 
from 2.2 + 0.09 to 6.1 ±  0.4 pmol/min/well (j9<0 .001), but failed to significantly stimulate 
deGlc uptake in ZDF cultures (figure 5.11). In contrast, in cells cultured under 
hyperglycaemic conditions (30mM D-glucose) acute insulin treatment failed to 
significantly stimulate glucose transport above basal in either lean Zucker or ZDF muscle 
cultures. Basal transport levels did not significantly change between lean Zucker or ZDF 
cultures in the presence of 5 or 30 mM D-glucose.
125
Figure 5.11 The effect of hyperglycaemia on insulin-stimulated deGlc uptake in
skeletal muscle cultures from lean Zucker and ZDF rats.
Muscle cultures were grown using media outlined in 4.2.6 and differentiated with a- 
MEM differentiation medium outlined in 4.2.2 supplemented with or without 25mM D- 
glucose, giving a final D-glucose concentration of 30 mM or 5 mM, respectively. Cells 
were fed every 24 hours for 5 days with this differentiation medium and serum starved for 
24 hours in serum-free medium containing 30 mM or 5 mM D-glucose, prior to 
measurement of insulin-stimulated deGlc uptake. Cells were incubated in the presence or 
absence of 1 pM insulin for 20 min prior to a 10 min deGlc uptake assay (insulin 
stimulation was maintained throughout uptake assay) that was performed as described in 
4.2.5. Basal transport levels were not significantly different between lean Zucker or ZDF 
cultures in the presence of 5 or 30 mM D-glucose. ^indicates a statistically significant 
increase in deGlc transport in lean Zucker muscle cultures (p<0,001). Acute insulin 
stimulation failed to significantly increase deGlc transport above basal levels in ZDF 
muscle cells cultured under 5 or 30 mM D-glucose, and lean Zuckers muscle cells 
cultured under 30mM D-glucose. The results shown are obtained from two independent 
ZDF and lean Zucker skeletal muscle cultures and are the mean + S.E.M. from 3 separate 
experiments on each.
Figure 5.11 The effect of hyperglycaemia on insulin-stimulated deGlc uptake in
skeletal muscle cultures from lean Zucker and ZDF rats.
1
0  average basal 
■  lean Zucker 
mZDF
basal Ins 
[5mM Glc]
Ins
[30mM Glc]
126
5.2.9 The effect of chronic Rosigiitazone treatment on insulin-stimulated deGlc 
transport in muscle cells chronically treated with low (5mM) and high 
(30mM) D-glucose.
Cells differentiated for 5 days (as in 5.2.9) in the presence of 5mM or 30 mM D-glucose 
were treated with 1 pM Rosigiitazone over the last 3 days of differentiation essentially as 
(Park et al., 1998b). Prior to deGlc assay (described in 4.2.5), cells were incubated in 
serum-free media containing 5 or 30 mM D-glucose with IpM  Rosigiitazone for 24 
hours. Under normoglycaemic conditions, cells chronically treated with IpM  
rosigiitazone, basal glucose transport drug (basal=4.9 ±  0.4 pmol/min/well; figure 5.12) 
was significantly increased (p<0 .001) approximately 2-fold compared to cells, which 
were not exposed to the drug (basal=2.2 + 0.09 pmol/min/well; figure 5.11). In these lean 
Zucker skeletal muscle cells, acute insulin stimulation (1 pM  for 30 min), gave a similar 
fold increase from this elevated basal value (from 4.9 ± 0.42 to 10.6 ± 0.4 pmol/min/well 
(p<0.001)) but did not significantly increase deGlc uptake in ZDF cultures (figure 5.12). 
However, chronic exposure of the cells to hyperglycaemic conditions (30mM glucose) 
abrogated insulin-dependent glucose uptake whether or not the cells had been treated with 
Rosigiitazone, but did not abolish the increased basal deGlc uptake elicited by treatment 
with the drug. Therefore, the amelioration of hyperglycaemia induced by 
thiazolidinediones (Park et al., 1998a); (Park et al., 1998b) appears to be independent of 
enhanced insulin sensitivity in this in vitro muscle system, but rather a consequence of a 
direct effect of the drug on basal glucose uptake.
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Figure 5.12 The effects of chronic Rosigiitazone treatment on insulin-stimulated 
deGlc uptake in skeletal muscle cultures chronically treated with 5 mM and 30 mM 
D-glucose.
Cells differentiated for 5 days (as in figure 5.11) in the presence of 5mM or 30 mM D- 
glucose were chronically treated with 1 pM Rosigiitazone over the last 3 days of 
differentiation. Prior to acute insulin stimulation (IpM  insulin for 30 min) and 10 min 
deGlc uptake assay (described in 4.2.5), cells were incubated in serum-free media 
containing 5 or 30mM D-glucose with IpM  Rosigiitazone for 24 hours. Basal transport 
levels did not significantly change between lean Zucker or ZDF cultures in the presence 
of 5 or 30 mM D-glucose. f t  indicates that basal deGlc transport in Rosigiitazone treated 
cells is significantly elevated compared to untreated cells (figure 5.11); (p<0.01). 
findicates a significant increase in glucose transport rates compared to non-drug treated 
cells (Figure 5.12); (p<0.01). ^indicates a statistically significant increase in deGlc 
transport in lean Zucker cultures; (p<0.001).. Acute insulin stimulation failed to 
significantly increase deGlc transport over basal transport rates in ZDF muscle cells 
chronically treated with 5 or 30mM D-glucose and IpM  Rosigiitazone. Lean Zucker 
muscle cells chronically treated with 30mM D-glucose and IpM  Rosigiitazone also failed 
to significantly respond to insulin. The results shown are obtained from two independent 
ZDF and lean Zucker skeletal muscle cultures and are the mean + S.E.M. from 3 separate 
experiments on each.
Figure 5.12 The effects of chronic Rosigiitazone treatment on insulin-stimulated 
deGlc uptake in skeletal muscle cultures chronically treated with 5mM and 30mM 
D-glucose.
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5.3 Discussion
This study was designed to extend the findings of the previous chapters, so as to test the 
hypothesis that the major cause of insulin resistance in the ZDF rat is a consequence of 
impaired insulin-dependent glucose uptake in skeletal muscle. I have shown that in the 
flexor digitorum brevis (FDB) muscle of the ZDF rat there is a marked decrease in the 
magnitude of insulin-stimulated deGlc transport with respect to the lean Zucker control 
muscles (see figure 5.1). Moreover, this diminished insulin response is also maintained in 
skeletal muscle cells cultured from extensor digitorum brevis (EDL) and soleus muscles, 
and persists in these cells throughout all passages (figure 5.10). These results strongly 
suggest that the defect in ZDF rats is due to a genetic predisposition, and is not due to an 
acute physiological change such as altered blood flow to the muscle or paracrine effects.
Given the importance of skeletal muscle in the post-prandial disposal of blood glucose, 
such a defect will greatly contribute to the overall diabetic phenotype of the ZDF rat. A 
number of studies on rats have suggested that while insulin-stimulated glucose transport 
is impaired in NIDDM and insulin-resistant states, exercise-stimulated glucose transport 
is unaffected (Goodyear et al., 1988); (Brozinick, Jr. et al., 1992); (King et al., 1993); 
(Brozinick, Jr. et al., 1994). As discussed earlier in 1.5.1 and chapter three, AMPK is 
implicated as a crucial mediator of the effects of exercise on glucose transport (Hayashi et 
al., 1998); (Fujii et al., 2000). Consequently, AICAR, which is able to activate AMPK, 
significantly increased glucose transport to a similar extent in both ZDF and lean Zucker 
animals (see figure 5.1). This result is in agreement with that of chapter three and 
suggests that the insulin resistance observed in the ZDF rat like the SHRSP rat is confined 
to an insulin-dependent event in the activation of glucose transport.
To further analyse this insulin-specific defect, I have examined the levels of expression of 
key proteins involved in the insulin-signalling transduction cascade namely, IRS-1, PI3K, 
caveolin-1, flotillin and c-Cbl. No significant difference was found in the expression 
levels of these proteins in EDL, soleus or tibialis muscles between ZDF and lean Zucker 
rats (see figure 5.2 and 5.8). The lack of significant difference in caveolin-1 and flotillin 
levels is in contrast to the observed increase in expression of these molecules seen in the 
insulin-resistant SHRSP rat (chapter three). However the similar protein expression levels
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of PI3K and IRS-1 in lean Zucker and ZDF rats is in agreement with the analysis of these 
protein levels in WKY and SHRSP. These data may suggest that the caveolae-associated 
molecules do not influence the observed insulin resistance seen in the ZDF rat skeletal 
muscle. On the other hand, while PKB cellular expression is unchanged in EDL muscle 
in both ZDF and lean Zucker rats (see figure 5.3 A), the insulin-stimulated activity of PKB 
in the EDL muscle lysates from ZDF rats is markedly diminished compared to lean 
Zuckers (see figure 5.4). I have also found that the insulin-dependent phosphorylation of 
the PKB serine 473 residue is reduced in ZDF rats compared to lean Zuckers (see figure 
5.3B). Hence, defective insulin-dependent activation of PKB appears to underlie the 
diminished insulin-stimulated deGlc uptake. These observations aie consistent with 
studies involving overexpression of constitutively active PKB, which leads to a 
significant increase in glycogen and protein synthesis and also glucose transport (Hajduch 
et al., 1998); (Kohn et al., 1996a); (Ueki et al., 1998); (Foran et al., 1999) all of which 
suggests PKB plays an important role in insulin-stimulated glucose uptake. However, 
overexpression of a putative dominant negative mutant of PKB was reported to inhibit 
protein synthesis but did not affect glucose transport (Kitamura et al., 1998), possibly due 
to some endogenous PKB activity remaining. Thus a mandatory role for PKB in insulin 
action on glucose transport has been implied but remains controversial. Nevertheless, the 
observed defect in insulin action on glucose transport may be partly due to the defective 
PKB activity and/or elements upstream of this kinase. Pharmacological activation of 
PKB may therefore be of potential therapeutic utility in the treatment of diabetes.
PKB agonists may have positive effects on responses further downstream, similar to those 
seen when constitutively active PKB is overexpressed in cells. In trying to address this, 
GlaxoSmithKline has isolated two compounds able to specifically activate PKB in vitro, 
SB456672 and SB437478. These compounds are thought to act by functionally 
mimicking PIP3 binding to PKB, exposing the PDKl/2 phosphorylation sites. I have 
confirmed that both compounds are able to stimulate PDKl-dependent but PIP3- 
independent, threonine-308 phosphorylation of recombinant PKBS473D (see figure 5.5). 
Intriguingly, SB437478 could also stimulate PKBS473D threonine-308 phosphorylation 
independently of PD K l, probably by allowing PKB autophosphorylation although 
activation of a contaminating kinase by this compound cannot be excluded (see figure 
5.5). In addition, both compounds are able to significantly stimulate PKBS473D kinase 
activity in vitro (see figure 5.6).
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In an effort to address whether PKB agonists in isolation could stimulate glucose 
transport, I treated FDB muscles from ZDF and lean Zucker rats with SB456672. As 
shown in figure 5.7, a small but non-significant enhancement in deGlc uptake was 
observed in muscle from each animal model. Both SB456672 and SB437478 are highly 
specific for PKB and allow activation of PKB in vitro of the compounds isolated from the 
in vitro screen. These compounds were characterised as lipophilic and as possessing low 
serum protein binding activity (GlaxoSmithkline data). However, in recent subsequent 
experiments no activation of PKB in response to these agents was observed in the Chang 
liver cell line, until the cells were ruptured by freeze thawing (GlaxoSmithkline data). 
This implies that these compounds lacked sufficient cell penetrance to support activation 
of endogenous PKB, therefore, unfortunately, cannot be used at this time to unanimously 
demonstrate the absolute requirement for PKB activation in insulin-dependent stimulation 
of glucose transport. Accordingly, the priority in developing these compounds as drugs 
would be to demonstrate that they are capable of supporting phosphorylation and 
therefore activation of endogenous PKB in cells. A demonstration of this will be essential 
in providing evidence for a direct co-relation between PKB activation and increase in 
deGlc uptake.
There has been increasing evidence that whole-body hyperglycaemia induces insulin 
resistance in muscle (Rossetti et al., 1987); (Rossetti, 2000). In an attempt to determine 
whether glucose acts directly on the muscle cell to impair insulin action I evaluated the 
effect of normo- and hyper-glycaemia on deGlc transport in cultured lean/ZDF muscle 
cells. Figure 5.11, demonstrates that in cells derived from lean Zucker, (30mM) D- 
glucose administration caused the glucose uptake efficiency to fall to levels similar to that 
observed in cells derived from the ZDF. This finding agrees with data showing that 
hyperglycaemia directly inhibits insulin-stimulated glucose utilisation and glucose 
transport in rat skeletal muscle (Richter et al., 1988); (Kurowski et al., 1999). No such 
decrease was observed in glucose uptake in ZDF skeletal muscle cells. However, it was 
suggested that the decrease in skeletal muscle glucose utilisation during hyperglycaemia 
is directly linked to inhibition of PKB (Kurowski et al., 1999); (Oku et al., 2001). As 
ZDF rats display ineffective activation of PKB activity by insulin (see figure 5.3 and 5.4), 
this finding could explain why hyperglycaemia fails to have a further effect on the 
glucose uptake in ZDF muscles. In agreement with these observations, recent data 
(Nawano et al., 2000) have shown that while hyperglycaemia can induce further insulin
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resistance in adipose and hepatic tissue, it does not appreciably worsen the insulin 
resistant skeletal muscle of the ZDF rat.
As demonstrated in figure 5.11 the 3-fold insulin-dependent stimulation of deGlc uptake 
in cells derived from lean Zucker rats was abolished by hyperglycaemic conditions 
(30mM D-glucose for 6 days). No insulin-dependent stimulation was detectable (above 
basal) in cells derived from ZDF animals, and this was unaffected by hyperglycaemia, 
indicating that the ZDF-derived cells are already insulin-insensitive.
In order to assess the reversibility of the hyperglycaemic-induced insulin-resistance in 
lean Zucker muscle cells, I used Rosiglitazone, a member of the thiazolidinedione class of 
compounds known to reduce hyperglycaemia, hyperinsulinaemia and 
hypertriglyceridaemia (Park et al., 1998b). Chronic Rosiglitazone treatment (l|aM for 3 
days) caused an approximate 2.5-fold elevation in basal glucose transport (figure 5.12). 
The fold-stimulation elicited by insulin in these cells was not significantly altered 
(approximately 2.2-fold in the presence of Rosiglitazone vs 2.8-fold in the absence of 
Rosiglitazone). However, hyperglycaemic treatment abolished the insulin-dependent 
stimulation of glucose uptake. Again, no insulin-dependent glucose uptake was observed 
in cells from ZDF muscle (figure 5.12), and this was not further affected by 
hyperglycaemia.
Rosiglitazone treatment neither restored the insulin response in hyperglycaemic lean 
Zucker cells nor in ZDF cells. However, in all cases Rosiglitazone treatment significantly 
elevated basal glucose uptake rates. This suggests that the whole-body insulin-sensitising 
effects of the thiazolidinedione drugs are in part mediated in their enhancement of insulin- 
independent glucose uptake in skeletal muscle. These findings are in agreement with 
those reported in muscle cultures derived from diabetic patients (Park et al., 1998a). They 
found that treatment of human skeletal muscle cultures from obese Type 2 diabetic 
patients with Troglitazone was followed by a 2-fold increase in mRNA and protein 
expression of Glut-1 (the basal glucose transporter) but not Glut-4.
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Chapter 6 
Overview and conclusions.
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6.1 General conclusions
Skeletal muscle plays a crucial role in the insulin-mediated post-prandial disposal of 
blood glucose. In addition, it is a highly specialised tissue that is well adapted to respond 
to the continually shifting, and at times disproportionate, energy demands required during 
exercise/contraction. To this extent, skeletal muscle is able to take up glucose in response 
to both the anabolic stimulus of insulin and the catabolic action of exercise. Insulin 
resistance, which manifests itself as a reduction in insulin’s ability to stimulate glucose 
uptake, is of major pathogenic importance in several prevalent human disorders, including 
type 2 diabetes, hypertension and obesity. Interestingly, there is strong evidence to 
suggest that in these insulin-resistant individuals exercise stimulated glucose uptake is 
unaffected. It is therefore the purpose of much cuiTent research to make a distinction 
between the two individual mechanisms by which insulin and exercise elicit their action 
on skeletal muscle glucose uptake.
In an effort to explore these two mechanisms, I have examined insulin- and AICAR- 
stimulated glucose uptake in isolated skeletal muscle and cultured myocytes from the 
insulin-resistant hypertensive rat SHRSP and the obese type II diabetic ZDF rat. The 
insulin- and AICAR-stimulated deGlc uptake pattern from these two disease models was 
compared to that from their normal equivalent, WKY and lean Zucker rat respectively. 
AICAR has been used as an exercise-effect substitute due to its ability to activate AMPK, 
a molecule that is acutely activated during exercise in both human and rodent muscle. 
Present findings indicate that AMPK serves as a “cellular energy sensor” that inhibits 
non-essential ATP consuming biosynthetic pathways, thereby conserving ATP for more 
immediate cellular functions involved with survival such as muscle contraction. In 
addition, treatment of muscle with AICAR has been shown to activate glucose transport 
by a similar mechanism to exercise.
The results from deGlc transport experiments, reported in chapters three and four show 
that the SHRSP rat displays a blunted insulin-stimulated glucose transport at the level of 
skeletal muscle when compared to the normotensive WKY rat. This is in agreement with 
the previous observation by (Collison et al., 2000), who found that isolated adipocytes 
from the SHRSP were also markedly insulin resistant, displaying defective insulin- 
stimulated glucose transport and suppression of lipolysis. Taken together, such data
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indicates that the SHRSP displays a marked insulin-resistance in fat and muscle, key 
insulin-sensitive peripheral tissues responsible for the disposal of the majority of the post­
prandial blood glucose. However, AICAR-stimulated glucose transport was unaffected in 
skeletal muscle, suggesting that the defect responsible for the observed insulin resistance 
is confined to an insulin-specific step in the activation of glucose transport. By examining 
the overtly diabetic rat model, the Zucker diabetic fatty (ZDF) rat, some key similarities 
were found. Importantly, a marked decrease in skeletal muscle insulin-stimulated glucose 
transport is observed in the ZDF rat compared with the insulin-sensitive lean Zucker rat. 
In addition, AICAR is able to activate glucose transport to a similar extent in both ZDF 
and lean Zucker rats. The profile of insulin-stimulated glucose transport is maintained in 
vitro, in cultured skeletal muscle cells from ZDF and lean Zucker rats. Taken together 
these results suggest that like the SHRSP, the ZDF rat has a defect in the insulin- 
stimulated glucose transport in skeletal muscle and that in situ this insulin-resistance is 
also restricted to an insulin-specific step in the activation of glucose transport. These 
results are in agreement with current findings showing that exercise-stimulated glucose 
transport is unimpaired in insulin-resistant individuals and that insulin and exercise 
stimuli contribute to glucose uptake through two distinct pathways.
Following this initial characterisation, I focussed on examining possible causes of the 
observed skeletal muscle insulin resistance. Analysis of the expression levels of key 
proteins involved in insulin signalling and insulin-stimulated glucose transport starting 
with the insulin-responsive glucose transporter, Glut-4 were performed. On comparing 
SHRSP and WKY rats, no difference was found in the total cellular levels of this 
transporter and therefore decreased Glut-4 expression cannot explain the defect in 
SHRSP. Similar data were reported from a similar study on ZDF animals (Maier et al., 
2000).
In addition, the expression or cellular localisation of other molecules such as 1RS-1/2 and 
PI3K is unchanged between SHRSP and WKY. PKB expression and activity was also 
unaffected. In the ZDF and lean Zucker rat, expression of IRS-1, PI3K and PKB was 
found to be similar between the two animal types. However, PKB activity in conjunction 
with PKB ser473 phosphorylation was markedly decreased in ZDF skeletal muscle 
compared with lean Zucker skeletal muscle. This implies that the genetic defect in ZDF
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rats is upstream of PKB. This result would support claims that PKB is potential 
pharmacological target in treatment of insulin resistance (Cohen, 1999); (Alessi, 2001).
Intriguingly, the total cellular expression levels of caveolin and flotillin are increased in 
the skeletal muscle from SHRSP compared to WKY. These proteins are important in 
insulin signal transduction and compartmentalisation. Caveolin is a structural protein and 
a key component of small flask-like invaginations of the plasma membrane called 
caveolae. Caveolae are important mediators of insulin receptor signalling. Indeed, the 
insulin receptor has been found to localise to caveolae and overexpression of caveolin 
enhances insulin receptor tyrosine kinase phosphorylation of IRS-1. Therefore, increased 
expression of caveolin positively modulates signalling through the insulin receptor. In 
this respect the observation of increased levels of caveolin in SHRSP compared to WKY 
skeletal muscle may be a consequence of defective insulin signalling, and so perhaps a 
means of compensation by the skeletal muscle cells by overexpressing an element that 
may enhance insulin action. Furthermore, insulin stimulation leads to the 
phosphorylation of caveolin and expression of caveolin increases as 3T3-L1 fibroblasts 
are differentiated into insulin-sensitive adipocytes. However, it cannot be ruled out that 
overexpression of caveolin seen here could result in a sequestration of important insulin 
signalling molecules in an inactive environment, thereby acting as an inhibitor of further 
downstream events resulting in decreased glucose transport. Intriguingly, the lipid raft 
protein flotillin is also markedly overexpressed in SHRSP muscle compared with WKY. 
Flotillin is able to form heterodimers with caveolin and has been proposed to localise the 
insulin receptor phosphorylated c-Cbl via the c-Cbl-associated protein (CAP) to caveolae. 
Recent studies suggest that CAP-c-Cbl localisation to caveolae is critical for insulin- 
stimulated glucose transport. Therefore, the closely associated caveolae molecules, 
flotillin and caveolin positively modulate insulin action. This close association may 
indicate a dual regulation of these proteins, in that overexpression of one may force or co- 
ordinately regulate the overexpression of the other. In preliminary experiments using 
real-time quantification of messenger RNA for caveolin and flotillin, I have found a two­
fold increase in both flotillin and caveolin mRNA in SHRSP skeletal muscle compared 
with WKY. Although this data did not satisfy the criteria for inclusion in chapter three, it 
does potentially indicate that the regulation of flotillin and caveolin overexpression in 
SHRSP occurs at the level of mRNA and may not be due to decreased degradation of 
these proteins. However, further study is required to test whether the overexpression of
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caveolin and flotillin act to blunt insulin-stimulated glucose transport. In contrast to the 
SHRSP model, in ZDF skeletal muscle lysates there was no significant increase in the 
lipid raft associated proteins c-Cbl, caveolin-1 or flotillin total cellular protein expression 
compared with that observed in normal lean Zuckers. These data may suggest that these 
molecules do not influence the observed insulin resistance seen in the ZDF rat skeletal 
muscle.
The SNARE proteins VAMP2 and syntaxin-4 were also markedly overexpressed in 
SHRSP skeletal muscle compared to WKY rats. These proteins are crucial in mediating 
insulin-stimulated Glut-4 vesicle translocation. They are also found to be overexpressed 
in other rat models of insulin resistance. Previous work from our laboratory has 
illustrated increased expression of the SNAREs VAMP2, cellubrevin and syntaxin-4 in 
ZDF muscles (Maier et al., 2000). However, like flotillin and caveolin further analysis is 
required to determine whether their overexpression is causal or adaptive to the observed 
skeletal muscle insulin resistance.
It is possible that the insulin resistance observed in the SHRSP and ZDF animals may be 
secondary to changes in physiology, such as altered blood flow to the muscle beds by 
defective vasodilatation in response to insulin, or by changes in circulating factors which 
regulate peripheral insulin sensitivity. In order to investigate this possibility, myotubes 
from SHRSP and ZDF animals were cultured through eight passages and were subjected 
to deGlc uptake assays in the presence of insulin. SHRSP myotubes were also tested for 
their ability to transport deGlc in the presence of AICAR. The first important finding is 
that the impaired insulin stimulation of glucose uptake is maintained in cultured myotubes 
from both SHRSP and ZDF rats. Moreover, AICAR-stimulated glucose transport in 
SHRSP myotubes is also unimpaired compared with WKY myotubes in agreement with 
the in situ data. Taken together these data suggest that the observed skeletal muscle 
insulin resistance constitutes a hereditary trait, characteristic to ZDF and SHRSP and is 
not due to altered blood flow or circulating factors. In addition, the observation that the 
AMPK-activator AICAR can stimulate glucose uptake in both SHRSP and WKY 
myotubes to the same extent further support the suggestion that the insulin resistance is 
confined to an insulin specific step in the activation of glucose transport. Moreover, in 
agreement with previous reports, AICAR-stimulated glucose transport, like exercise, is 
insensitive to the PI3K inhibitor wortmannin. In contrast, insulin-stimulated glucose
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transport is completely abrogated by wortmannin. These data strongly indicate that like 
exercise, AICAR- stimulated glucose transport occurs via a PI3K-independent pathway.
Since the diabetic ZDF rat displays fasting hyperglycaemia associated with dyslipidaemia 
and obesity, the effect of hyperglycaemia on insulin-stimulated deGlc transport was also 
tested. The results showed that in the lean Zucker but not in the ZDF rat, hyperglycaemia 
inhibited insulin-stimulated glucose utilisation and glucose transport in agreement with 
other studies (Richter et al., 1988); (Kurowski et al., 1999). Since it has been shown that 
ZDF rats are characterised by low levels of PKB activity in response to insulin, this 
finding suggests that the decrease in skeletal muscle glucose utilisation during 
hyperglycaemia could be directly linked to inhibition of PKB. This may explain why 
hyperglycaemia fails to have a further effect on the glucose uptake in ZDF muscles, as 
illustrated in 5.11.
It might be speculated that pharmacological agents in the form of PKB agonists would 
have positive effects on responses further downstream, similar to those seen when 
constitutively active PKB is overexpressed in cells. I tested the ability of novel agonists 
SB456672 and SB437478 to influence downstream events, and I verified that these 
compounds can achieve PDKl-dependent but PIPa-independent, threonine-308 
phosphorylation and significant increases in activity of recombinant PKBS473D in a 
microtitre plate assay. Intriguingly, SB437478 could also stimulate PKBS473D 
threonine-308 phosphorylation independently of PD K l, probably by allowing PKB 
autophosphorylation although activation of a contaminating kinase by this compound 
cannot be excluded.
I then treated FDB muscles from ZDF and lean Zucker rats with SB456672 in an effort to 
address whether PKB agonists in isolation could stimulate glucose transport. However, 
the muscles were unresponsive to this drug, as was indicated by the non-significant 
increase in deGlc uptake, probably due to insufficient cell penetrance of this compound. 
New cell permeable agonists need to be developed with proven ability to specifically 
phosphorylate and therefore activate endogenous PKB. Such compounds could assist in 
further studies aimed at providing evidence for a direct co-relation between PKB 
activation and increase in deGlc uptake.
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Type 2 diabetes mellitus is commonly managed with diet and exercise but in some cases 
pharmacological intervention is required. In general, these pharmacological compounds 
either stimulate the pancreas to produce more insulin or sensitise tissues such as muscle 
and fat to the action of insulin. The latter group of compounds able to re-sensitise the 
insulin-insensitive peripheral glucose storage tissues of fat and muscle to the actions of 
insulin is known as the thiazolidinediones. Rosiglitazone, an example of a 
thiazolidinedione, is able to reduce fasting blood glucose and triglycerides by increasing 
Glut-4 expression and re-sensitising fat cells to the action of insulin on the inhibition of 
hormone sensitive lipase. Rosiglitazone was used in the skeletal muscle cell cultures 
from ZDF and lean Zucker rats in order to assess the ability of this drug to ameliorate the 
defect in glucose transport observed in this system. Rosiglitazone was found to 
significantly increase the basal glucose uptake in skeletal muscle cells by approximately 
two-fold but had no further effect on insulin-stimulated glucose transport in lean or ZDF 
muscle cells cultured under normoglycaemic or hyperglycaemic conditions. This suggests 
that the whole-body insulin-sensitising effects of the thiazolidinedione drugs are in part 
mediated in their enhancement of insulin-independent glucose uptake in skeletal muscle. 
These findings are in agreement with those reported in muscle cultures derived from 
diabetic patients (Park et al., 1998a). They found that treatment of human skeletal muscle 
cultures from obese Type 2 diabetic patients with Troglitazone was followed by a 2-fold 
increase in mRNA and protein expression of Glut-1 (the basal glucose transporter) but not 
Glut-4.
6.2 Concluding remarks and suggestions for the future.
In summary, the findings of this thesis show that hypertensive SHRSP and type 2 diabetic 
ZDF rat models display a marked skeletal muscle insulin resistance. Furthermore, this 
insulin resistance is maintained in cultured skeletal muscle cells. Using these skeletal 
muscle systems, this study aimed at identifying intermediate molecules that could 
potentially be pait of a defective step in the impaired insulin-stimulated deGlc uptake 
pathway, and it also aimed at the assessment of novel therapeutic agents such as PKB 
agonists. Using this system the possibility of two distinct pathways between insulin and 
exercise-mediated glucose uptake was investigated.
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The conclusions drawn from these studies are the following:
Firstly, the data suggests that the ZDF and SHRSP models used in this project owe their 
skeletal muscle insulin-resistance phenotype to genetic make up rather than secondary 
pathophysiological effects. In addition, in the lean Zucker animal, hyperglycaemia, a 
characteristic of the ZDF rat was found from in vitro experiments to be a 
contributing/determining factor to the insulin-stimulated deGlc uptake defect.
Moreover, in support of accumulating data this system provided evidence for a distinction 
between insulin- and exercise-mediated deGlc transport pathways. In particular the data 
suggests that apart from the insulin-mediated pathway, AICAR through a PI3K- 
independent pathway can also significantly activate deGlc transport in skeletal muscle.
It would be interesting to pursue the analysis of the overexpression of caveolin and 
flotillin. Such analysis may indicate whether or not the overexpression of these 
molecules is primary or secondary to the defective insulin-stimulated glucose transport 
seen in SHRSP rats. In addition, it may also be of interest to examine the effect of insulin 
on the caveolae association of important signalling molecules, such as c-Cbl, in SHRSP 
and WKY animals.
Finally, assessment of lead compounds from the GlaxoSmithkline PKB activator screen 
lead to the conclusion that these particular compounds are unsuitable as therapeutic 
candidates and are not effective in experimental practice as endogenous biochemical 
component activators. There is therefore immediate need for the development of new cell- 
penetrant agents that will assist in the investigation of the specific components that 
comprise the insulin- and the exercise- stimulated glucose uptake pathway. Only by the 
complete identification of the downstream molecules and their roles, can the defective 
steps in insulin signalling pathway, as seen in type 2 diabetes, be completely elucidated in 
order for satisfactory therapy to be achieved.
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